0001493152-19-016811.txt : 20191112 0001493152-19-016811.hdr.sgml : 20191112 20191112063356 ACCESSION NUMBER: 0001493152-19-016811 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYCOR MEDICAL INC CENTRAL INDEX KEY: 0001424768 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203369218 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34932 FILM NUMBER: 191205917 BUSINESS ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY STREET 2: SUITE 320 CITY: BOCA RATON, STATE: FL ZIP: 33487 BUSINESS PHONE: 562.558.2000 MAIL ADDRESS: STREET 1: 951 BROKEN SOUND PARKWAY STREET 2: SUITE 320 CITY: BOCA RATON, STATE: FL ZIP: 33487 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal quarter ended September 30, 2019

[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

	For the transition period from to

VYCOR MEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

Delaware	001-34932	20-3369218
(State of	(Commission	(IRS Employer
Incorporation)	File Number)	Identification No.)

951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (561) 558-2020

Securities registered under Section 12(g) of the Exchange Act:

Common Stock par value $0.0001

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]		Accelerated Filer [ ]
Non-accelerated Filer [ ] (Do not check if a smaller reporting company)		Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [ ] No

There were 24,752,836 shares outstanding of registrant’s common stock, par value $0.0001 per share, as of November 8, 2019.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

TABLE OF CONTENTS

		Page
PART I

Item 1.	Financial Statements	3

	Unaudited Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018	3

	Unaudited Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2019 and 2018.	4

	Unaudited Consolidated Statement of Stockholders’ Deficiency for the three and nine months ended September 30, 2019 and 2018.	5

	Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018.	6

	Notes to Unaudited Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	22

PART II

Item 1.	Legal Proceedings	23

Item 1A.	Risk Factors	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 3.	Defaults Upon Senior Securities	23

Item 4.	Mine Safety Disclosures	23

Item 5.	Other Information	23

Item 6.	Exhibits	23

SIGNATURES		24

PART

ITEM 1. FINANCIAL STATEMENTS

VYCOR MEDICAL, INC.

Consolidated Balance Sheets

(Unaudited)

	September 30,			December 31,
	2019			2018
ASSETS
Current Assets
Cash	$	98,502		$	86,481
Accounts receivable		214,807			257,468
Inventory		226,618			203,122
Prepaid expenses and other current assets		116,046			82,575
Total Current Assets		655,973			629,646

Fixed assets, net		353,746			372,641

Intangible and Other assets:
Patents, net of accumulated amortization		26,320			35,303
Website, net of accumulated amortization		-			187
Other Assets - Long Term		6,100			6,000
Operating lease right-of-use assets		43,586
Total Intangible and Other assets		76,006			41,490
TOTAL ASSETS	$	1,085,725		$	1,043,777

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
Current Liabilities
Accounts payable	$	198,219		$	92,955
Accrued interest: Other		268,666			232,765
Accrued interest: Related party		39,606			24,274
Accrued liabilities - Other		267,573			295,056
Accrued liabilities - Related Party		973,110			648,740
Notes payable: Other		351,058			325,814
Notes payable: Related Party		210,873			193,000
Current operating lease		43,586			-
Total Current Liabilities		2,352,691			1,812,604

STOCKHOLDERS’ DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2019 and December 31, 2018 respectively		27			27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2019 and December 31, 2018, 24,856,170 and 23,244,028 shares issued and 24,752,836 and 23,140,694 outstanding at September 30, 2019 and December 31, 2018 respectively		2,486			2,324
Additional Paid-in Capital		28,173,146			27,771,868
Treasury Stock (103,334 shares of Common Stock as at September 30, 2019 and December 31, 2018 respectively, at cost)		(1,033	)		(1,033	)
Accumulated Deficit		(29,569,267	)		(28,669,686	)
Accumulated Other Comprehensive Income (Loss)		127,675			127,673
Total Stockholders’ Deficiency		(1,266,966	)		(768,827	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	1,085,725		$	1,043,777

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statements of Comprehensive Loss

(Unaudited)

	For the three months ended September 30,						For the nine months ended September 30,
	2019			2018			2019			2018

Revenue	$	346,308		$	456,213		$	1,126,864		$	1,082,979
Cost of Goods Sold		31,527			46,800			106,634			123,130
Gross Profit		314,781			409,413			1,020,230			959,849

Operating expenses:
Depreciation and Amortization		15,115			42,994			45,011			128,326
Selling, general and administrative		491,339			499,143			1,497,016			1,684,445
Total Operating expenses		506,454			542,137			1,542,027			1,812,771
Operating loss		(191,673	)		(132,724	)		(521,797	)		(852,922	)

Other income (expense)
Interest expense: Other		(12,109	)		(12,280	)		(36,074	)		(36,505	)
Interest expense: Related Party		(5,315	)		(5,924	)		(15,331	)		(6,570	)
Loss on foreign currency exchange		(512	)		(1,251	)		(2,009	)		(1,402	)
Total Other Income (expense)		(17,936	)		(19,455	)		(53,414	)		(44,477	)

Loss Before Credit for Income Taxes		(209,609	)		(152,179	)		(575,211	)		(897,399	)
Credit for income taxes		-			-			-			-
Net Loss		(209,609	)		(152,179	)		(575,211	)		(897,399	)
Preferred stock dividends		(162,185	)		(162,185	)		(324,370	)		(324,370	)
Net Loss available to common shareholders		(371,794	)		(314,364	)		(899,581	)		(1,221,769	)
Comprehensive Loss
Foreign Currency Translation Adjustment		7			810			2			33,515
Comprehensive Loss	$	(371,787	)	$	(313,554	)	$	(899,579	)	$	(1,188,254	)

Net Loss Per Share
Basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.04	)	$	(0.06	)

Weighted Average Number of Shares Outstanding – Basic and Diluted		24,222,946			22,221,266			23,689,516			21,258,184

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statement of Stockholders’ Deficiency

(Unaudited)

																			Additional						Accum
	Common Stock				Preferred C				Preferred D				Treasury Stock						Paid-in			Accumulated			OCI
	Number		Amount		Number		Amount		Number		Amount		Number			Amount			Capital			Deficit			(Loss)			Total

Balance at December 31, 2018		23,244,028		2,324		1		0		270,306		27		(103,334	)	$	(1,033	)		27,771,868		$	(28,669,686	)		127,673		$	(768,827	)
Issuance of stock for board and consulting fees		535,714		54																112,446									112,500
Directors deferred compensation granted		-																		21,000									21,000
Accumulated Comprehensive Loss																										(6	)		(6	)
Net loss for period ended March 31, 2019																							(342,483	)					(342,483	)
Balance at March 31, 2019		23,779,742	$	2,378		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	27,905,314		$	(29,012,169	)	$	127,667		$	(977,816	)
Issuance of stock for board and consulting fees		540,714		54																113,385									113,439
Directors deferred compensation granted		-																		21,000									21,000
Foreign currency translation adjustment																										1			1
Net loss for period ended June 30, 2019																							(185,304	)					(185,304	)
Balance at June 30, 2019		24,320,456	$	2,432		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,039,699		$	(29,197,473	)	$	127,668		$	(1,028,680	)
Issuance of stock for board and consulting fees		535,714		54																112,447									112,501
Directors deferred compensation granted		-																		21,000									21,000
Foreign currency translation adjustment																										7			7
Net loss for period ended September 30, 2019																							(371,794	)					(371,794	)
Balance at September 30, 2019		24,856,170	$	2,486		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	28,173,146		$	(29,569,267	)	$	127,675		$	(1,266,966	)

Balance at December 31, 2017		19,925,322		1,993		1		0		270,306		27		(103,334	)		(1,033	)		26,921,574		$	(26,965,960	)		124,841			81,442
Issuance of stock for board and consulting fees		250,000		25																92,475									92,500
Directors deferred compensation granted																				21,000									21,000
Share based compensation issued to management/employees																				4,871									4,871
Accumulated Comprehensive Loss																										(1,162	)		(1,162	)
Net loss for period ended March 31, 2018																							(488,821	)					(488,821	)
Balance at March 31, 2018		20,175,322	$	2,018		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	27,039,920		$	(27,454,781	)	$	123,679		$	(290,172	)
Issuance of stock for board and consulting fees		1,031,125		103																357,397									357,500
Directors deferred compensation granted		-																		21,000									21,000
Issuance of shares and warrants pursuant to offering, net		1,113,936		111																(111	)								-
Share based compensation issued to management/employees																				86,754									86,754
Foreign currency translation adjustment																										3,667			3,667
Net loss for period ended June 30, 2018																							(418,584	)					(418,584	)
Balance at June 30, 2018		22,320,383	$	2,232		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	27,504,960		$	(27,873,365	)	$	127,346		$	(239,833	)
Issuance of stock for board and consulting fees		387,931		39																112,461									112,500
Directors deferred compensation granted		-																		21,000									21,000
Foreign currency translation adjustment																										810			810
Net loss for period ended September 30, 2018																							(314,364	)					(314,364	)
Balance at September 30, 2018		22,708,314	$	2,272		1	$	0		270,306	$	27		(103,334	)	$	(1,033	)	$	27,638,421		$	(28,187,729	)	$	128,156		$	(419,887	)

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

Consolidated Statement of Cash Flows

(Unaudited)

	For the nine months ended September 30,
	2019			2018
Cash flows from operating activities:
Net loss	$	(575,211	)	$	(897,399	)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Amortization of intangible assets		8,983			37,748
Depreciation of fixed assets		43,376			98,455
Inventory provision		9,418			3,139
Stock based compensation		401,440			492,125

Changes in assets and liabilities:
Accounts receivable		42,661			(134,732	)
Inventory		(32,914	)		(7,565	)
Prepaid expenses		58,714			(21,913	)
Security Deposits		-			3,169
Accrued interest - Related Party		15,332			6,570
Accrued interest Other		35,901			35,901
Accounts payable		105,205			(45,575	)
Accrued liabilities Other		(27,483	)		143,945
Cash provided by /(used in) operating activities		85,422			(286,132	)
Cash flows from investing activities:
Purchase of fixed assets		(25,057	)		(56,604	)
Cash used in investing activities		(25,057	)		(56,604	)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party		17,873			193,000
Proceeds from and (repayments of) Notes Payable - Other		(66,941	)		28,473
Cash provided by/(used in) financing activities		(49,068	)		221,473
Effect of exchange rate changes on cash		724			5,180
Net increase (decrease) in cash		12,021			(116,083	)
Cash at beginning of period		86,481			206,213
Cash at end of period	$	98,502		$	90,130

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	0		$	0
Cash paid for income tax	$	0		$	0
Non-Cash Transactions:
Common stock issued to related party for payment of accrued liabilities	$	0		$	225,000

See accompanying notes to consolidated financial statements

VYCOR MEDICAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2019

(Unaudited)

1.	BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2018 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

The unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2019 and 2018, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Ability to continue as a Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $575,211 for the nine months ended September 30, 2019 and has not generated sufficient positive cash flows from operations. As of September 30, 2019 the Company had a working capital deficiency of $473,129, excluding related party liabilities of $1,223,589. As a result these conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

The Company is executing on a plan to achieve revenue growth and a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $268,666, which has a maturity date of December 31, 2019, having been extended on a number of occasions from its initial due date of June 11, 2011. The Company will seek an extension to the note, although it is not known whether the note will be extended or the terms of any extension. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2020 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

2.	SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.

Recent Accounting Pronouncements

The Company adopted Accounting Standards Codification 842, Leases (“ASC 842”) in the first quarter of 2019. As a result the Company updated its significant accounting policies for leases below. Refer to Note 4 for additional information related to the Company’s lease arrangements and the impact of the adoption of ASC 842 on the Company’s unaudited consolidated financial statements.

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Leases

The Company has one leased buildings in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.

The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

	September 30,		September 30,
	2019		2018
Stock options outstanding		700,000		1,380,000
Warrants to purchase common stock		3,717,826		3,717,826
Debentures convertible into common stock		2,707,933		2,479,364
Preferred shares convertible into common stock		1,272,052		1,272,052
Directors Deferred Compensation Plan		1,075,908		685,107
Total		9,473,719		9,534,349

3.	NOTES PAYABLE

Related Parties Notes Payable

Related Party Notes Payable consists of:

	September 30, 2019		December 31, 2018
On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2020 or on demand by the Payee	$	30,000	$	30,000
In March 2019 and between March 2018 and July 2018 the Company issued various promissory notes to Fountainhead Capital Management Limited for $180,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Five notes were extended for another twelve months on their due dates which will be due between March and July 2020 or on demand by the Payee.		180,873		163,000
Total Related Party Notes Payable	$	210,873	$	193,000

Other Notes Payable

Other Notes Payable consists of:

	September 30, 2019		December 31, 2018
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On March 19, 2019, the note was extended to December 31, 2019. See further note below.	$	300,000	$	300,000
Insurance policy finance agreements.		51,058		25,814
Total Notes Payable:	$	351,058	$	325,814

In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $300,000 loan note (the “Note”). Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019. The conversion terms of the Note were reduced to $0.21, the same as the offering price of the 2018 Offering. Conversion of the Note and accrued interest would result in the issuance of 2,707,933 shares of Common Stock as of September 30, 2019. Notwithstanding, EuroAmerican agreed that the Note could not be converted without first offering the Company the right to redeem the Note at principal and accrued interest, and secondly Fountainhead the right to purchase the Note, which cannot be converted prior to such offer and the failure of the Company and Fountainhead to exercise such option in accordance with the amendment terms. In addition, the Company agreed to issue warrants to purchase 2,308,405 shares of Common Stock at $0.27, the same terms as the 2018 Offering, exercisable for three years from January 1, 2018, if and when the conversion option is exercised. The amendment was recognized as a modification, based on the guidance in ASC 470-50.

The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

LEASE

The Company recognized the following related to a lease in its unaudited consolidated balance sheet at September 30, 2019:

	Nine Months Ended September 30,
	2019		2018
Operating Lease Assets
Current portion	$	43,586	$	-
	$	43,586	$	-
Operating Lease Liabilities
Current portion	$	43,586	$	-
	$	43,586	$	-

5.	SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

(a) Business segments

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Revenue:
Vycor Medical	$	301,053	$	399,450	$	988,786	$	930,553
NovaVision	$	45,255	$	56,763	$	138,078	$	152,426
	$	346,308	$	456,213	$	1,126,864	$	1,082,979
Gross Profit
Vycor Medical	$	273,146	$	357,674	$	895,484	$	821,240
NovaVision	$	41,635	$	51,739	$	124,746	$	138,609
	$	314,781	$	409,413	$	1,020,230	$	959,849

	September 30, 2019		December 31, 2018
Total Assets:
Vycor Medical	$	1,022,449	$	981,553
NovaVision		63,276		62,224
Total Assets	$	1,085,725	$	1,043,777

(b) Geographic information

The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
Revenue:
United States	$	320,477	$	425,800	$	1,051,237	$	1,002,923
Europe	$	25,831	$	30,413	$	75,627	$	80,056
	$	346,308	$	456,213	$	1,126,864	$	1,082,979
Gross Profit
United States	$	291,536	$	382,006	$	953,861	$	889,190
Europe	$	23,245	$	27,407	$	66,369	$	70,659
	$	314,781	$	409,413	$	1,020,230	$	959,849

	September 30, 2019		December 31, 2018
Total Assets:
United States	$	1,051,776	$	1,010,067
Europe		33,949		33,710
Total Assets	$	1,085,725	$	1,043,777

6.	EQUITY

Common Stock and Stock Grants

During January to September 2019 and 2018, the Company granted 299,997 and 174,580 shares, respectively, of Common Stock (valued at $63,000 during each period) to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15^th following the termination of their services as a director. As of September 30, 2019 these shares have yet to be issued.

During January to September 2019, under the terms of the Consulting Agreement referred to in note 9, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500. During January to September 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued at December 31, 2017.

During the period ended September 30, 2019 the Company issued 5,000 shares of Common Stock to Robert Anderson for fees of $940 for consultancy.

On April 20, 2018, the Company issued an aggregate of 1,113,936 shares of Company Common Stock on the cashless exercise of an aggregate of Warrants to purchase 3,111,560 shares of Common Stock.

Warrants and Options

The details of the outstanding warrants and options are as follows:

STOCK WARRANTS:

			Weighted average
	Number of shares		exercise price per share
Outstanding at December 31, 2018		3,717,826	$	0.27
Granted		-		-
Exercised		-		-
Cancelled or expired		-		-
Outstanding at September 30, 2019		3,717,826	$	0.27

STOCK OPTIONS:

				Weighted average
	Number of shares			exercise price per share
Outstanding at December 31, 2018		1,380,000		$	0.53
Granted		-			-
Exercised		-			-
Cancelled or expired		(680,000	)		(0.79	)
Outstanding at September 30, 2019		700,000		$	0.28

As of September 30, 2019, the weighted-average remaining contractual life of outstanding warrants and options is 0.36 and 1.71 years, respectively.

7.	SHARE-BASED COMPENSATION

Stock Option Plan

Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option-vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.

For the nine months ended September 30, 2019 and 2018, the Company recognized share-based compensation of $0 and $4,871 respectively, for employee stock options.

Stock appreciation rights may be granted either on a stand-alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2019 there were no awards of any stock appreciation rights.

Non-Employee Stock Compensation

The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

Aggregate stock-based compensation for stock and warrants granted to non-employees for the nine months ended September 30, 2019 and 2018 was $401,440 and $487,254. The expense related to stock not issued during the periods ended September 30, 2019 and 2018 comprise: $63,000, respectively for both periods, related to stock granted but not issued to directors under the Directors Deferred Compensation Plan. As of September 30, 2019, there was $0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

During the nine months ended September 30, 2019 and 2018, options with a value of $0 and $216,582, respectively, were granted to Fountainhead with performance vesting conditions, (see Note 9). The performance conditions of the options granted during 2018 were not met and these options were cancelled.

Stock-based Compensation Valuation Methodology

Stock-based compensation resulting from the issuance of Common Stock is calculated by reference to the valuation of the Stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the expected life of the option or warrant, and the risk-free rate is based on the U.S. Treasury Constant Maturity rate.

The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2019 and 2018:

	Nine Months Ended September 30,
	2019			2018
Risk-free interest rates		-	%		1.72-2.41	%
Expected life		-			1.5-4.0 years
Expected dividends		-	%		0	%
Expected volatility		-	%		102-107	%
Vycor Common Stock fair value	$	-		$	0.20-0.49

8.	COMMITMENTS AND CONTINGENCIES

Lease

The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month. The lease terminates September 30, 2020. The Company’s subsidiary in Germany occupies premises on a short-term lease agreement of EUR1,963 per month (approximately $2,200). Rent expense for the nine months ended September 30, 2019 and 2018 was $73,925 and $74,784 respectively.

Potential German tax liability

In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of a maximum of approximately €630,000 preliminarily reduced to €75,000, with an additional interest charge of €12,000. This assessment is for the 2010 fiscal year and relates to the Company’s acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax of the same for the same period was preliminarily reduced to zero. The Company did not accept this trade tax assessment and appealed against it to the relevant tax authorities with a view to its reduction. The relevant tax authorities agreed to suspend the assessment pending the outcome of certain court hearings and proposed tax legislation, and the Company agreed to make monthly payments on account totaling €75,000 which were completed in October 2016 and fully expensed. At that time the Company appealed against the interest charge of €12,000 which the tax authorities did not accept but also agreed to suspend pending the outcome of the hearings and proposed legislation outlined above. Accordingly, the Company has made no provision for this liability in the nine months ended September 30, 2019 and the year ended December 31, 2018 respectively.

9.	CONSULTING AND OTHER AGREEMENTS

The following agreements were entered into or remained in force during the period ended September 30, 2019:

Consulting Agreement with Fountainhead

In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees of $450,000 are payable to Fountainhead, with an option to receive $5,000 per month in cash and the remainder payable in Company Common Stock issued at the higher of $0.21 and the average price for the 30 days prior to issuance, and deliverable at the end of each fiscal quarter. The Consulting Agreement also contains provisions for Fountainhead to receive a higher proportion of its fees in cash subject to certain future liquidity events and Board approval. Under the terms of the Amended Agreement, Fountainhead provides the executive management team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive no remuneration from the Company.

During the nine months ended September 30, 2019, under the terms of the Amended Agreement, Fountainhead received total fees of $337,500, which were paid through the issuance of 1,607,142 shares of Company Common Stock. During the nine months ended September 30, 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued as at December 31, 2017.

During the nine months ended September 30, 2019 and 2018, options pursuant to the Vycor Medical, Inc. 2018 Stock Option Plan with a value of $0 and $216,582, respectively, were granted to Fountainhead with performance vesting conditions. The performance conditions of the options granted during 2018 were not met and these options were cancelled.

10.

RELATED PARTY TRANSACTIONS

Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2019, 56% of the Company’s Common Stock and 70% of the Company’s Preferred D Stock. Adrian Liddell, Chairman, is a consultant for Fountainhead.

During the nine months ended September 30, 2019, under the terms of the Consulting Agreement referred to in note 9, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500. During the nine months ended September 30, 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued as at December 31, 2017.

During the nine months ended September 30, 2019 and 2018, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,037 was in respect of Fountainhead and $83,386 was in respect of Peter Zachariou.

During the nine months ended September 30, 2019 and 2018 the Company issued unsecured loan notes to Fountainhead for a total of $17,873 and $133,000, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary. During the nine months ended September 30, 2019 and 2018 the Company issued unsecured loan notes to Peter Zachariou for a total of $0 and $30,000, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary. (See Note 3)

11.

CONCENTRATION

Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.

Sales Concentration
	Three months ended						Nine months ended
	September 30,						September 30,
	2019			2018			2019			2018

Number of customers over 10%		1			1			1			3
Percentage of sales		11	%		25	%		10	%		10%, 11 % and 11	%

Accounts Receivable Concentration

	At September 30,			At December 31,
	2019			2018

Number of customers over 10%		1			2
Percentage of accounts receivable		48	%		13% and 40	%

We have two sub-contract manufacturers who both represent over 10% of purchased on an annual basis.

12.

SUBSEQUENT EVENTS

The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the consolidated financial statements were issued and has determined that there were no significant subsequent events or transactions which would require recognition or disclosure in the financial statements.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PLSRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding Vycor Medical, Inc. (the “Company” or “Vycor,” also referred to as “us”, “we” or “our”). Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and (e) our anticipated needs for working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” as well as in this Form 10-Q generally. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise. We intend that all forward-looking statements be subject to the safe harbor provisions of the PSLRA.

1. Organizational History

The Company was formed as a limited liability company under the laws of the State of New York on June 17, 2005 as “Vycor Medical LLC”. On August 14, 2007, we converted into a Delaware corporation and changed our name to “Vycor Medical, Inc.”. The Company’s listing went effective on February 2009 and on November 29, 2010 Vycor completed the acquisition of substantially all of the assets of NovaVision, Inc. (“NovaVision”) and on January 4, 2012 Vycor, through its wholly-owned NovaVision subsidiary, completed the acquisition of all the shares of Sight Science Limited (“Sight Science”).

2. Overview of Business

Vycor is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and operates two distinct business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Both businesses adopt a minimally or non-invasive approach. Both technologies have strong sales growth potential, address large potential markets and have the requisite regulatory approvals. The Company has 64 issued or allowed patents and a further 8 pending. The Company leverages joint resources across the divisions to operate in a cost-efficient manner.

The Company periodically engages in discussions with potential strategic partners for or purchasers of each or both of our operating divisions.

Vycor Medical

Vycor Medical designs, develops and markets medical devices for use in neurosurgery. Vycor Medical’s ViewSite Brain Access System (“VBAS”) is a next generation retraction and access system that was fully commercialized in early 2010 and is the first significant technological change to brain tissue retraction in over 50 years in contrast to significant development in most other neuro-surgical technologies. Vycor Medical is ISO 13485:2016 and MDSAP (Medical Device Single Audit Program) certified, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (Class III) for brain and spine surgeries, and regulatory approvals in a number of other international markkets. Vycor Medical has 26 granted and 8 pending patents

NovaVision

NovaVision provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other brain injury, and has 38 granted patents.

Strategy

The Company is continuing to execute on a plan to achieve revenue growth and a reduction in cash operating losses. For Vycor Medical this plan includes in particular: increasing market penetration in the US through closer cooperation with complementary product manufacturers, broadening of the distribution network and programs to increase penetration in exiting hospitals; increasing international growth in territories where we are not represented or under represented; and continued new product development. The first phase of the modification of the existing VBAS product range to make it more compatible with the most common IGS systems was completed in September 2017 and has been well received by surgeons, resulting in increased hospital penetration and revenues particularly in the US. The second phase of the development of further IGS integration is in process and will then be subject to regulatory clearances and approvals. Upon regulatory approval and product release of this new VBAS the Company intends to conduct a multi-center study tp provide additional clinical data on the product. We will also be exploring with surgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures. For NovaVision, given the company’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the distribution of its broad range of patient and professional products is by partnering with entities that have either direct access to the end users or a desire and financial wherewithal to leverage the NovaVision therapy platform. The Company is in the process of identifying and talking to such partners. Management is determined to reduce the losses it is incurring in this division and is open to a broad range of alternatives which could comprise distribution and marketing partnerships, licensing, merger, sale and/or a significant restructuring of its activities.

Comparison of the Three Months Ended September 30, 2019 to the Three Months Ended September 30, 2018

Revenue and Gross Margin:

	Three months ended
	September 30,
	2019		2018		% Change
Revenue:
Vycor Medical	$	301,053	$	399,450		-25	%
NovaVision	$	45,255	$	56,763		-20	%
	$	346,308	$	456,213		-24	%
Gross Profit
Vycor Medical	$	273,146	$	357,674		-24	%
NovaVision	$	41,635	$	51,739		-20	%
	$	314,781	$	409,413		-23	%

Vycor Medical recorded revenue of $301,053 from the sale of its products for the three months ended September 30, 2019, a decrease of $98,397 over the same period in 2018. The decrease in revenue is primarily due to a large one-time international order in the 2018 period not being repeated. The US continued to experience growth, of 13% compared to the same period in 2018, and other international sales tend to be more lumpy and impacted by timing differences. Gross margin of 91% was recorded for the three months ended September 30, 2019 and 2018. Gross margin is affected by the revenue mix and also by manufacturing validation charges during the 2018 period.

NovaVision recorded revenues of $45,255 for the three months ended September 30, 2019, a decrease of $11,508 over the same period in 2018, as a result of reduced patient volumes in both the US and Europe offset by increased professional revenue in Europe. Gross margin was 92%, compared to 91% for the same period in 2018.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses decreased by $7,806 to $491,339 for the three months ended September 30, 2019 from $499,143 for the same period in 2018. Included within Selling, General and Administrative Expenses are non-cash charges for share based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the three months ended September 30, 2019 and 2018 was $133,500. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $45,139 from $101,900 to $56,761 in 2019; this was a result of commissions paid to an international distributor for a large one-time order in the 2018 period.

The remaining Selling, General and Administrative expenses increased by $37,335 from $263,743 to $301,078 in 2019. The Company is in the process of migrating to a new EU Notified Body for VBAS, with a resultant significant increase in regulatory fees for this migration during the period; patent fees were also higher due to the filing of 8 new patents for VBAS.

An analysis of the change in cash and non-cash G&A is shown in the table below:

	Cash G&A			Non-Cash G&A
Regulatory		56,424			-
Legal, patent, audit/accounting, insurance		25,947			-
Sales, marketing and travel		(8,524	)		-
Board and Management		-			-
Payroll		(33,764	)		-
Other G&A, Premises		(2,750	)		-
		37,333
Commissions		(45,139	)		-
Total change		(7,806	)		-

Interest Expense:

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the three months ended September 30, 2019 was $5,315 compared to $5,294 for 2018. Other Interest income and expense for 2019 decreased by $171 to $12,109 from $12,280 for 2018.

Comparison of the Nine Months Ended September 30, 2019 to the Nine Months Ended September 30, 2018

Revenue and Gross Margin:

	Nine months ended
	September 30,
	2019		2018		% Change
Revenue:
Vycor Medical	$	988,786	$	930,553		6	%
NovaVision	$	138,078	$	152,426		-9	%
	$	1,126,864	$	1,082,979		4	%
Gross Profit
Vycor Medical	$	895,484	$	821,240		9	%
NovaVision	$	124,746	$	138,609		-10	%
	$	1,020,230	$	959,849		6	%

Vycor Medical recorded revenue of $988,786 from the sale of its products for the nine months ended September 30, 2019, an increase of $58,233 over the same period in 2018. Good performance from the US (increase of 43%) and international (up 16%) was offset by two large international orders in the 2018 period which were not repeated during 2019. Gross margin of 91% was recorded for the nine months ended September 30, 2019 compared to 88% for the same period in 2018.

NovaVision recorded revenues of $138,078 for the nine months ended September 30, 2019, a decrease of $14,348 over the same period in 2018, as a result of reduced patient volumes in both the US and Europe primarily in the third quarter, offset by increased professional revenue in Europe. Gross margin of 90%, compared to 91% for the same period in 2018.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses decreased by $187,429 to $1,497,016 for the nine months ended September 30, 2019 from $1,684,445 for the same period in 2018. Included within Selling, General and Administrative Expenses are non-cash charges for share based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the nine months ended September 30, 2019 was $401,440 a decrease of $90,685 over $492,125 in 2018. Also included within Selling, General and Administrative Expenses are Sales Commissions, which decreased by $237 from $187,859 to $187,622.

The remaining Selling, General and Administrative expenses decreased by $96,507 from $1,004,461 to $907,954. The Company is in the process of migrating to a new EU Notified Body for VBAS, with a resultant significant increase in regulatory fees for this migration during the period; patent fees were also higher due to the filing of 8 new patents for VBAS.

An analysis of the change in cash and non-cash G&A is shown in the table below:

	Cash G&A			Non-Cash G&A
Regulatory		91,995			(4,871	)
Legal, patent, audit/accounting, insurance		18,362			-
Sales, marketing and travel		(63,664	)
Board and Management		-			(85,815	)
Payroll		(138,087	)
Other G&A, Premises		(5,112	)
		(96,506	)
Commissions		(237	)		-
Total change		(96,743	)		(90,686	)

Interest Expense:

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the nine months ended September 30, 2019 was $15,331 compared to $6,570 for 2018. Other Interest expense for 2019 decreased by $431 to $36,074 from $36,505 for 2018.

Liquidity

The following table shows cash flow and liquidity data for the periods ended September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018			$ Change
Cash	$	98,502		$	86,481		$	12,021
Accounts receivable, inventory and other current assets	$	557,471		$	543,165		$	14,306
Total current liabilities	$	(2,352,691	)	$	(1,812,604	)	$	(540,087	)
Working capital	$	(1,696,718	)	$	(1,182,958	)	$	(513,760	)
Cash provided by/(used in) financing activities	$	(49,068	)	$	221,473		$	(270,541	)

Operating Activities. Cash provided by/(used in) operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities. The net repayment of normal insurance financing should also be taken into account when considering cash provided by/(used in) operating activities.

The following table shows the principle components of cash provided by/(used in) operating activities during the nine months ended September 30, 2019 and 2018, with a commentary of changes during the periods and known or anticipated future changes:

	September 30, 2019			September 30, 2018			$ Change
Net loss	$	(575,211	)	$	(897,399	)	$	322,188

Adjustments to reconcile net loss to cash used in operating activities:
Amortization and depreciation of assets	$	52,359		$	136,203		$	(83,844	)
Share based compensation		401,440			492,125			(90,685	)
Other		9,418			3,139			6,279
	$	463,217		$	631,467		$	(168,250	)

Net loss adjusted for non-cash items	$	(111,994	)	$	(265,932	)	$	153,938
Changes in working capital
Accounts receivable, accounts payable and accrued liabilities		120,383			(33,193	)		153,576
Inventory		(32,914	)		(7,565	)		(25,349	)
Prepaid expenses and net insurance financing repayments		(8,227	)		6,560			(14,787	)
Accrued interest (not paid in cash)		51,233			42,471			8,762
	$	130,475		$	8,273		$	122,202

Cash used in operating activities, adjusted for net insurance repayments	$	18,481		$	(257,659	)	$	276,140

The adjustments to reconcile net loss to cash of $463,217 in the period have no impact on liquidity. The decrease in net loss (as adjusted for non-cash items) by $153,938 to $111,994 was primarily a result of increased revenues, as well as reduced expenses. There was a decrease in accounts receivable offset by an increase in accounts payable.

The Company is in the process of modifying the VBAS product suite to make it easier to integrate with IGS. The first phase of this project was completed in September 2017 and additional inventory of $108,000 was purchased during the nine months ended September 30, 2019. The Company is progressing the second phase of this project and as a result anticipates purchasing additional new inventory of approximately $40,000.

Investing Activities. Cash used in investing activities for the nine months ended September 30, 2019 was $25,057, which primarily reflected expenditure on the second phase of modifying the VBAS product suite to make it easier to integrate with IGS. The Company anticipates additional expenditures for this second phase, including work to obtain regulatory clearances and approvals, of approximately $100,000.

Financing Activities. During the period ending September 30, 2019 the Company received funds of $17,873 in respect of loans from Fountainhead.

Liquidity and Plan of Operations, Ability to Continue as a Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $575,211 for the nine months ended September 30, 2019 and has not generated cash flows from operations. As of September 30, 2019 the Company had a working capital deficiency of $473,129, excluding related party liabilities of $1,223,589. As a result these conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

As described earlier in this ITEM 2 “Strategy”, the Company is continuing to execute on a plan to achieve revenue growth and a reduction in cash operating losses. For Vycor Medical this plan includes in particular: increasing market penetration in the US through closer cooperation with complementary product manufacturers, broadening of the distribution network and programs to increase penetration in exiting hospitals; increasing international growth in territories where we are not represented or under represented; and continued new product development. The first phase of the modification of the existing VBAS product range to make it more compatible with the most common IGS systems was completed in September 2017 and has been well received by surgeons, resulting in increased hospital penetration and revenues particularly in the US. The second phase of the development of further IGS integration is in process and will then be subject to regulatory clearances and approvals. Upon regulatory approval and product release of this new VBAS the Company intends to conduct a multi-center study tp provide additional clinical data on the product. We will also be exploring with surgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures. For NovaVision, given the company’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the distribution of its broad range of patient and professional products is by partnering with entities that have either direct access to the end users or a desire and financial wherewithal to leverage the NovaVision therapy platform. The Company is in the process of identifying and talking to such partners. Management is determined to reduce the losses it is incurring in this division and is open to a broad range of alternatives which could comprise distribution and marketing partnerships, licensing, merger, sale and/or a significant restructuring of its activities.

However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2020 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $256,568, which has a maturity date of December 31, 2019, having been extended on a number of occasions from its initial due date of June 11, 2011. The Company will seek an extension to the note, although it is not known whether the note will be extended or the terms of any extension. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

Critical Accounting Policies and Estimates

Uses of estimates in the preparation of financial statements

The preparation of unaudited consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ from those estimated. To the extent management’s estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant estimates and assumptions contained in the accompanying unaudited consolidated financial statements include management’s estimate of the allowance for uncollectible accounts receivable, amortization of intangible assets, and the fair values of options and warrant included in the determination of debt discounts and share-based compensation.

A detailed description of our significant accounting policies can be found in our most recent Annual Report on Form 10-K for the year ended December 31, 2018.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable

ITEM 4. CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures

We are required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (also our principal executive officer) and our chief financial officer (also our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

The Company’s management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), have evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and our CFO have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective as of that date to provide reasonable assurance that the information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that information required to be disclosed by the Company in the reports its files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its CEO and its CFO, as appropriate, to allow timely decisions regarding required disclosure. There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

(b) Changes in Internal Controls

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s internal control over financial reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of November 8, 2019, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuance Type	Security	Shares
FHC Management Fees	Common	1,607,142
Robert Anderson	Common	5,000

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None

Index to Exhibits

31.1		Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 8, 2019.

	Vycor Medical, Inc.
	(Registrant)

	By:	/s/ Peter C. Zachariou
		Peter C. Zachariou
		Chief Executive Officer and Director (Principal Executive Officer)

	Date	November 11, 2019

	By:	/s/ Adrian Liddell
		Adrian Liddell
		Chairman of the Board and Director
		(Principal Financial and Accounting Officer)

	Date	November 11, 2019

EX-31.1 2 ex31-1.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Peter Zachariou, certify that:

	1.	I have reviewed this Form 10-Q for the period ended September 30, 2019 of Vycor Medical, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 11, 2019

/s/ Peter Zachariou
Peter C. Zachariou
Principal Executive Officer

EX-31.2 3 ex31-2.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Adrian Liddell, certify that:

	1.	I have reviewed this Form 10-Q for the period ended September 30, 2019 of Vycor Medical, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 11, 2019

/s/ Adrian Liddell
Adrian Liddell
Principal Financial Officer

EX-32.1 4 ex32-1.htm

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Vycor Medical, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The report on Form 10-Q for the period ended September 30, 2019 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 11, 2019

	/s/ Peter Zachariou
	Peter Zachariou
	Principal Executive Officer

A signed original of this written statement required by Section 906 has been provided to VYCOR MEDICAL, INC. and will be retained by VYCOR MEDICAL, INC. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32-2.htm

EXHIBIT 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

Date: November 11, 2019

	/s/ Adrian Liddell
	Adrian Liddell
	Principal Accounting Officer

EX-101.INS 6 vyco-20190930.xml XBRL INSTANCE FILE 0001424768 2019-01-01 2019-09-30 0001424768 2018-09-30 0001424768 2018-12-31 0001424768 2019-09-30 0001424768 2018-01-01 2018-09-30 0001424768 us-gaap:CommonStockMember 2017-12-31 0001424768 VYCO:PreferredCMember 2017-12-31 0001424768 VYCO:PreferredDMember 2017-12-31 0001424768 us-gaap:TreasuryStockMember 2017-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001424768 us-gaap:RetainedEarningsMember 2017-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001424768 us-gaap:CommonStockMember 2018-12-31 0001424768 VYCO:PreferredCMember 2018-12-31 0001424768 VYCO:PreferredDMember 2018-12-31 0001424768 us-gaap:TreasuryStockMember 2018-12-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001424768 us-gaap:RetainedEarningsMember 2018-12-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2018-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2019-01-01 2019-09-30 0001424768 VYCO:StockOptionPlanMember 2019-01-01 2019-09-30 0001424768 VYCO:WarrantsToPurchaseCommonStockMember 2019-01-01 2019-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2019-01-01 2019-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2019-01-01 2019-09-30 0001424768 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-09-30 0001424768 VYCO:StockOptionPlanMember 2018-01-01 2018-09-30 0001424768 VYCO:WarrantsToPurchaseCommonStockMember 2018-01-01 2018-09-30 0001424768 VYCO:DebenturesConvertibleIntoCommonStockMember 2018-01-01 2018-09-30 0001424768 VYCO:PreferredSharesConvertibleToCommonStockMember 2018-01-01 2018-09-30 0001424768 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2018-01-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:WarrantMember 2018-01-31 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2018-12-31 0001424768 VYCO:InsurancePolicyFinanceAgreementsMember 2019-09-30 0001424768 VYCO:PeterZachariouMember 2018-12-31 0001424768 VYCO:PeterZachariouMember 2019-09-30 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2018-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2011-03-25 0001424768 VYCO:EuroAmericanInvestmentCorpMember VYCO:TermNoteMember 2011-03-24 2011-03-25 0001424768 VYCO:VycorMedicalMember 2019-01-01 2019-09-30 0001424768 VYCO:NovaVisionMember 2019-01-01 2019-09-30 0001424768 VYCO:VycorMedicalMember 2018-12-31 0001424768 VYCO:NovaVisionMember 2018-12-31 0001424768 VYCO:VycorMedicalMember 2018-01-01 2018-09-30 0001424768 VYCO:NovaVisionMember 2018-01-01 2018-09-30 0001424768 VYCO:VycorMedicalMember 2019-09-30 0001424768 VYCO:NovaVisionMember 2019-09-30 0001424768 country:US 2019-01-01 2019-09-30 0001424768 srt:EuropeMember 2019-01-01 2019-09-30 0001424768 country:US 2018-12-31 0001424768 srt:EuropeMember 2018-12-31 0001424768 country:US 2018-01-01 2018-09-30 0001424768 srt:EuropeMember 2018-01-01 2018-09-30 0001424768 country:US 2019-09-30 0001424768 srt:EuropeMember 2019-09-30 0001424768 2018-04-19 2018-04-20 0001424768 2018-04-20 0001424768 VYCO:FountainheadMember VYCO:ConsultingAgreementMember 2017-01-01 2017-12-31 0001424768 VYCO:NonemployeeMember 2019-01-01 2019-09-30 0001424768 VYCO:NonemployeeMember 2018-01-01 2018-09-30 0001424768 VYCO:NonemployeeMember 2019-09-30 0001424768 srt:MinimumMember 2018-01-01 2018-09-30 0001424768 srt:MaximumMember 2018-01-01 2018-09-30 0001424768 country:DE 2019-01-01 2019-09-30 0001424768 country:DE 2018-01-01 2018-09-30 0001424768 2012-09-30 0001424768 VYCO:FountainheadConsultingAgreementMember VYCO:MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember 2019-01-01 2019-09-30 0001424768 VYCO:FountainheadConsultingAgreementMember VYCO:MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:DirectorsMember 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:DirectorsMember us-gaap:SeriesDPreferredStockMember 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2019-01-01 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2019-09-30 0001424768 VYCO:PeterZachariouMember 2018-06-24 2018-06-25 0001424768 VYCO:PeterZachariouMember 2018-06-25 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2018-03-01 2018-07-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2018-07-31 0001424768 us-gaap:CommonStockMember 2019-09-30 0001424768 us-gaap:CommonStockMember 2018-09-30 0001424768 VYCO:PreferredCMember 2019-09-30 0001424768 VYCO:PreferredCMember 2018-09-30 0001424768 VYCO:PreferredDMember 2019-09-30 0001424768 VYCO:PreferredDMember 2018-09-30 0001424768 us-gaap:TreasuryStockMember 2019-09-30 0001424768 us-gaap:TreasuryStockMember 2018-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001424768 us-gaap:RetainedEarningsMember 2019-09-30 0001424768 us-gaap:RetainedEarningsMember 2018-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001424768 2017-12-31 0001424768 2018-06-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember 2019-09-30 0001424768 VYCO:EmployeeStockOptionsMember 2019-01-01 2019-09-30 0001424768 VYCO:EmployeeStockOptionsMember 2018-01-01 2018-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2018-01-01 2018-09-30 0001424768 VYCO:PreferredDStockMember 2019-09-30 0001424768 VYCO:PreferredDStockMember 2018-09-30 0001424768 VYCO:FountainheadMember VYCO:ConsultingAgreementMember 2018-01-01 2018-09-30 0001424768 2019-07-01 2019-09-30 0001424768 2018-07-01 2018-09-30 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:ExtendedMaturityMember 2019-03-18 2019-03-19 0001424768 VYCO:VycorMedicalMember 2019-07-01 2019-09-30 0001424768 VYCO:NovaVisionMember 2019-07-01 2019-09-30 0001424768 VYCO:VycorMedicalMember 2018-07-01 2018-09-30 0001424768 VYCO:NovaVisionMember 2018-07-01 2018-09-30 0001424768 country:US 2019-07-01 2019-09-30 0001424768 srt:EuropeMember 2019-07-01 2019-09-30 0001424768 country:US 2018-07-01 2018-09-30 0001424768 srt:EuropeMember 2018-07-01 2018-09-30 0001424768 VYCO:RobertAndersonMember VYCO:ConsultancyMember 2019-01-01 2019-09-30 0001424768 2012-09-29 2012-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001424768 VYCO:CustomerTwoMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001424768 VYCO:CustomerOneMember us-gaap:AccountsReceivableMember 2019-01-01 2019-09-30 0001424768 VYCO:CustomerOneMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0001424768 VYCO:CustomerTwoMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0001424768 VYCO:EuroAmericanInvestmentCorpMember us-gaap:ExtendedMaturityMember 2019-01-01 2019-09-30 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2019-09-30 0001424768 VYCO:FountainheadMember VYCO:UnsecuredLoanMember 2018-09-30 0001424768 VYCO:TwoThousandEighteenStockOptionPlanMember VYCO:FountainheadMember 2018-01-01 2018-09-30 0001424768 VYCO:TwoThousandEighteenStockOptionPlanMember VYCO:FountainheadMember 2019-01-01 2019-09-30 0001424768 2019-11-08 0001424768 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001424768 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001424768 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001424768 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001424768 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001424768 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001424768 us-gaap:CommonStockMember 2019-03-31 0001424768 us-gaap:CommonStockMember 2019-06-30 0001424768 us-gaap:CommonStockMember 2018-03-31 0001424768 us-gaap:CommonStockMember 2018-06-30 0001424768 VYCO:PreferredCMember 2019-01-01 2019-03-31 0001424768 VYCO:PreferredCMember 2019-04-01 2019-06-30 0001424768 VYCO:PreferredCMember 2019-07-01 2019-09-30 0001424768 VYCO:PreferredCMember 2018-01-01 2018-03-31 0001424768 VYCO:PreferredCMember 2018-04-01 2018-06-30 0001424768 VYCO:PreferredCMember 2018-07-01 2018-09-30 0001424768 VYCO:PreferredCMember 2019-03-31 0001424768 VYCO:PreferredCMember 2019-06-30 0001424768 VYCO:PreferredCMember 2018-03-31 0001424768 VYCO:PreferredCMember 2018-06-30 0001424768 VYCO:PreferredDMember 2019-01-01 2019-03-31 0001424768 VYCO:PreferredDMember 2019-04-01 2019-06-30 0001424768 VYCO:PreferredDMember 2019-07-01 2019-09-30 0001424768 VYCO:PreferredDMember 2018-01-01 2018-03-31 0001424768 VYCO:PreferredDMember 2018-04-01 2018-06-30 0001424768 VYCO:PreferredDMember 2018-07-01 2018-09-30 0001424768 VYCO:PreferredDMember 2019-03-31 0001424768 VYCO:PreferredDMember 2019-06-30 0001424768 VYCO:PreferredDMember 2018-03-31 0001424768 VYCO:PreferredDMember 2018-06-30 0001424768 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001424768 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001424768 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001424768 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001424768 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001424768 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001424768 us-gaap:TreasuryStockMember 2019-03-31 0001424768 us-gaap:TreasuryStockMember 2019-06-30 0001424768 us-gaap:TreasuryStockMember 2018-03-31 0001424768 us-gaap:TreasuryStockMember 2018-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001424768 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001424768 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001424768 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001424768 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001424768 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001424768 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001424768 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001424768 us-gaap:RetainedEarningsMember 2019-03-31 0001424768 us-gaap:RetainedEarningsMember 2019-06-30 0001424768 us-gaap:RetainedEarningsMember 2018-03-31 0001424768 us-gaap:RetainedEarningsMember 2018-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001424768 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001424768 2019-01-01 2019-03-31 0001424768 2019-04-01 2019-06-30 0001424768 2018-01-01 2018-03-31 0001424768 2018-04-01 2018-06-30 0001424768 2019-03-31 0001424768 2019-06-30 0001424768 2018-03-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2019-03-01 2019-03-31 0001424768 VYCO:FountainheadCapitalManagementLimitedMember 2019-03-31 0001424768 VYCO:NonemployeeDirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2019-01-01 2019-09-30 0001424768 VYCO:NonemployeeDirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2018-01-01 2018-09-30 0001424768 VYCO:FountainheadMember VYCO:FountainheadConsultingAgreementMember 2019-01-01 2019-09-30 0001424768 VYCO:DirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2019-09-30 0001424768 VYCO:DirectorsMember VYCO:DirectorsDeferredCompensationPlanMember 2018-09-30 0001424768 country:DE VYCO:ShortTermLeaseAgreementMember 2019-01-01 2019-09-30 0001424768 VYCO:PeterZachariouMember VYCO:UnsecuredLoanMember 2019-01-01 2019-09-30 0001424768 VYCO:PeterZachariouMember VYCO:UnsecuredLoanMember 2018-01-01 2018-09-30 0001424768 VYCO:PeterZachariouMember VYCO:UnsecuredLoanMember 2019-09-30 0001424768 VYCO:PeterZachariouMember VYCO:UnsecuredLoanMember 2018-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001424768 VYCO:CustomerOneMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001424768 VYCO:ManufacturerOneMember VYCO:PurchaseMember 2019-01-01 2019-09-30 0001424768 VYCO:ManufacturerTwoMember VYCO:PurchaseMember 2019-01-01 2019-09-30 0001424768 VYCO:FountainheadMember 2019-09-30 0001424768 VYCO:FountainheadMember 2018-09-30 0001424768 VYCO:PeterZachariouMember 2019-09-30 0001424768 VYCO:PeterZachariouMember 2018-09-30 0001424768 us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001424768 us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001424768 us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001424768 us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001424768 us-gaap:SalesRevenueNetMember VYCO:CustomerThreeMember 2018-01-01 2018-09-30 0001424768 us-gaap:AccountsReceivableMember 2019-01-01 2019-09-30 0001424768 us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure VYCO:Number iso4217:EUR 2019 VYCOR MEDICAL INC 10-Q 2019-09-30 false --12-31 Non-accelerated Filer true false false Q3

86481

98502

257468

214807

203122

226618

82575

116046

629646

655973

372641

353746

35303 26320 187 41490 76006

1043777

1085725

981553

62224

1022449

63276

1010067

33710

1051776

33949

92955

198219

232765 268666 24274 39606

295056

267573

648740

973110

193000

210873

30000

163000

180873

325814

351058

300000

25814

51058

300000

1812604

2352691

2324

2486

27771868

28173146

1033

-28669686

-29569267

127673

127675

-419887

-768827

-1266966

1993

-1033

26921574

-26965960

124841

2324

-1033

27771868

-28669686

127673

2486

2272

-1033

28173146

27638421

-29569267

-28187729

127675

128156

81442

-239833

2378

2432

2018

2232

-1033

27905314

28039699

27039920

27504960

-29012169

-29197473

-27454781

-27873365

127667

127668

123679

127346

-977816

-1028680

-290172

1043777

1085725

0.0001

10000000

270307

0.0001

55000000

23244028

24856170

23140694

24752836

103334

1126864

1082979

988786

138078

930553

152426

1051237

75627

1002923

80056

346308

456213

301053

45255

399450

56763

320477

25831

425800

30413

106634

123130

31527

46800

1020230

959849

895484

124746

821240

138609

953861

66369

889190

70659

314781

409413

273146

41635

357674

51739

291536

23245

382006

27407

1542027

1812771

506454

542137

-521797

-852922

-191673

-132724

36074

36505

12109

12280

15331

6570

5315

5924

-53414

-44477

-17936

-19455

575211

897399

209609

152179

-575211

-897399

-209609

-152179

324370

162185

-899581

-1221769

-371794

-314364

-342483

-185304

-371794

-488821

-418584

-314364

-342483

-185304

-488821

-418584

33515

810

3667

810

3667

-899579

-1188254

-371787

-313554

-0.04

-0.06

-0.02

-0.01

23689516

21258184

24222946

22221266

19925322

270306

-103334

23244028

270306

-103334

24856170

22708314

270307

270306

-103334

23779742

24320456

20175322

22320383

270306

-103334

112501 112500 54 54 54 25 103 39 112446 113385 112447 92475 357397 112461 112500 113439 92500 357500 535714 540714 535714 250000 1031125 387931

4871

86754

4871

86754

21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000

8983

37748

43376

98455

401440

492125

5000

-42661

134732

-58714

21913

15332

6570

35901 35901

105205

-45575

-27483

143945

3169

85422

-286132

25057

56604

-25057

-56604

17873

193000

-66941

28473

-49068

221473

Related Party Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2020 or on demand by the Payee</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">30,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">30,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>In March 2019 and between March 2018 and July 2018 the Company issued various promissory notes to Fountainhead Capital Management Limited for $180,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Five notes were extended for another twelve months on their due dates which will be due between March and July 2020 or on demand by the Payee.</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">180,873</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">163,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Related Party Notes Payable</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">210,873</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">193,000</td> <td> </td></tr> </table>   Other Notes Payable   Other Notes Payable consists of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On March 19, 2019, the note was extended to December 31, 2019. See further note below.</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">300,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">300,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Insurance policy finance agreements.</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">51,058</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">25,814</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Notes Payable:</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">351,058</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">325,814</td> <td> </td></tr> </table>

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">301,053</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">399,450</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">988,786</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">930,553</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">45,255</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">56,763</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">138,078</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,426</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346,308</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">456,213</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,126,864</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,082,979</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Vycor Medical</td> <td> </td> <td>$</td> <td style="text-align: right">273,146</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">357,674</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">895,484</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">821,240</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">41,635</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">51,739</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">124,746</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">138,609</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">314,781</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,020,230</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">959,849</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,022,449</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">981,553</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">63,276</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,224</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,085,725</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,043,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">320,477</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">425,800</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,051,237</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,002,923</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">25,831</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">30,413</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">75,627</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,056</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346,308</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">456,213</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,126,864</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,082,979</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">United States</td> <td> </td> <td>$</td> <td style="text-align: right">291,536</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">382,006</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">953,861</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">889,190</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,245</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">27,407</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">66,369</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,659</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">314,781</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,020,230</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">959,849</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,051,776</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,010,067</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">33,949</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">33,710</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,085,725</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,043,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

STOCK WARRANTS:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Outstanding at December 31, 2018</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">3,717,826</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.27</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled or expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding at September 30, 2019</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,717,826</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.27</td> <td> </td></tr> </table>

225000

9418

3139

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif; text-align: justify">5.</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">SEGMENT REPORTING, GEOGRAPHICAL INFORMATION </td></tr> </table>   (a) Business segments   The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">301,053</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">399,450</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">988,786</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">930,553</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">45,255</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">56,763</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">138,078</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">152,426</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346,308</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">456,213</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,126,864</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,082,979</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Vycor Medical</td> <td> </td> <td>$</td> <td style="text-align: right">273,146</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">357,674</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">895,484</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">821,240</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">41,635</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">51,739</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">124,746</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">138,609</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">314,781</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,020,230</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">959,849</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">Vycor Medical</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,022,449</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">981,553</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">NovaVision</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">63,276</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,224</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,085,725</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,043,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>    (b) Geographic information   The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Revenue:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">320,477</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">425,800</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,051,237</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,002,923</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">25,831</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">30,413</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">75,627</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,056</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">346,308</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">456,213</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,126,864</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,082,979</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross Profit</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">United States</td> <td> </td> <td>$</td> <td style="text-align: right">291,536</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">382,006</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">953,861</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">889,190</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">23,245</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">27,407</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">66,369</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">70,659</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">314,781</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,020,230</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">959,849</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total Assets:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt">United States</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,051,776</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1,010,067</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Europe</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">33,949</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">33,710</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,085,725</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,043,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt Calibri, Helvetica, Sans-Serif">8.</td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif">COMMITMENTS AND CONTINGENCIES</td></tr> </table>   Lease   The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $5,700 plus sales tax per month. The lease terminates September 30, 2020. The Company’s subsidiary in Germany occupies premises on a short-term lease agreement of EUR1,963 per month (approximately $2,200). Rent expense for the nine months ended September 30, 2019 and 2018 was $73,925 and $74,784 respectively.   Potential German tax liability   In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of a maximum of approximately €630,000 preliminarily reduced to €75,000, with an additional interest charge of €12,000. This assessment is for the 2010 fiscal year and relates to the Company’s acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax of the same for the same period was preliminarily reduced to zero. The Company did not accept this trade tax assessment and appealed against it to the relevant tax authorities with a view to its reduction. The relevant tax authorities agreed to suspend the assessment pending the outcome of certain court hearings and proposed tax legislation, and the Company agreed to make monthly payments on account totaling €75,000 which were completed in October 2016 and fully expensed. At that time the Company appealed against the interest charge of €12,000 which the tax authorities did not accept but also agreed to suspend pending the outcome of the hearings and proposed legislation outlined above. Accordingly, the Company has made no provision for this liability in the nine months ended September 30, 2019 and the year ended December 31, 2018 respectively.

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">11.</td> <td style="font: 10pt Times New Roman, Times, Serif">CONCENTRATION</td></tr> </table>   Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Sales Concentration</td><td> </td> <td colspan="14"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">Number of customers over 10%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Percentage of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10%, 11 % and 11</td><td style="text-align: left"> %</td></tr> </table>   Accounts Receivable Concentration   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">At September 30,</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Number of customers over 10%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13% and 40</td><td style="text-align: left">%</td></tr> </table>   We have two sub-contract manufacturers who both represent over 10% of purchased on an annual basis.

Principles of Consolidation   The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.

Recent Accounting Pronouncements   The Company adopted Accounting Standards Codification 842, Leases (“ASC 842”) in the first quarter of 2019. As a result the Company updated its significant accounting policies for leases below. Refer to Note 4 for additional information related to the Company’s lease arrangements and the impact of the adoption of ASC 842 on the Company’s unaudited consolidated financial statements.   From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Net Loss Per Share   Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.   The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 59%">Stock options outstanding</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">700,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,380,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants to purchase common stock</td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Debentures convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,707,933</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,479,364</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred shares convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Directors Deferred Compensation Plan</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,075,908</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">685,107</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,473,719</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,534,349</td> <td> </td></tr> </table>

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 59%">Stock options outstanding</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">700,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,380,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants to purchase common stock</td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,717,826</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Debentures convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,707,933</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,479,364</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Preferred shares convertible into common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,272,052</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Directors Deferred Compensation Plan</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,075,908</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">685,107</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,473,719</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,534,349</td> <td> </td></tr> </table>

The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2019 and 2018:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk-free interest rates</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">1.72-2.41</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.5-4.0 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%">Expected dividends</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">-</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">0</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">102-107</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vycor Common Stock fair value</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.20-0.49</td> <td> </td></tr> </table>

6000

6100

Leases   The Company has one leased buildings in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.   The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

The Company recognized the following related to a lease in its unaudited consolidated balance sheet at September 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating Lease Assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%; padding-bottom: 1.5pt; padding-left: 10pt">Current portion</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right">43,586</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,586</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating Lease Liabilities</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Current portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">43,586</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">43,586</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

43586

Yes No false

724

5180

12021

-116083

90130

86481

98502

206213

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt Calibri, Helvetica, Sans-Serif">9.</td> <td style="font: 11pt Calibri, Helvetica, Sans-Serif">CONSULTING AND OTHER AGREEMENTS</td></tr> </table>   The following agreements were entered into or remained in force during the period ended September 30, 2019:   Consulting Agreement with Fountainhead   In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees of $450,000 are payable to Fountainhead, with an option to receive $5,000 per month in cash and the remainder payable in Company Common Stock issued at the higher of $0.21 and the average price for the 30 days prior to issuance, and deliverable at the end of each fiscal quarter. The Consulting Agreement also contains provisions for Fountainhead to receive a higher proportion of its fees in cash subject to certain future liquidity events and Board approval. Under the terms of the Amended Agreement, Fountainhead provides the executive management team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive no remuneration from the Company.   During the nine months ended September 30, 2019, under the terms of the Amended Agreement, Fountainhead received total fees of $337,500, which were paid through the issuance of 1,607,142 shares of Company Common Stock. During the nine months ended September 30, 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued as at December 31, 2017.   During the nine months ended September 30, 2019 and 2018, options pursuant to the Vycor Medical, Inc. 2018 Stock Option Plan with a value of $0 and $216,582, respectively, were granted to Fountainhead with performance vesting conditions. The performance conditions of the options granted during 2018 were not met and these options were cancelled.

STOCK OPTIONS:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">exercise price per share</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Outstanding at December 31, 2018</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">1,380,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.53</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled or expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(680,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.79</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding at September 30, 2019</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">700,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.28</td> <td> </td></tr> </table>

45011

128326

15115

42994

1497016

1684445

491339

499143

2009

1402

512

1251

32914

7565

24752836

-6

-1162

-6

-1162

111 -111 1113936 0001424768 -473129

1223589

300000

268666

2019-12-31

2020-11-30

9473719

9534349

700000

3717826

2707933

1272052

1075908

1380000

3717826

2479364

1272052

685107

300000

Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019.

Due on demand or by their one-year anniversary.

Five notes were extended for another twelve months on their due dates which will be due between March and July 2020

Due on demand or by their one-year anniversary.

Due on demand or by their one-year anniversary

0.21

2707933

2308405

0.27

P3Y

300000

30000

180873

0.16

0.10

2020-06-25

2019-12-31

43586

299997

174580

63000

1113936

1669056

5000

1607142

225000

562500

940

337500

3111560

P4M9D

P1Y8M16D

3717826

0.27 0.27

1380000

700000

680000

0.53

0.28

0.79

401440

487254

4871

63000 63000

216582 0

0.00

0.0172

0.0241

P0Y

P1Y6M

P4Y

0.00

1.02

1.07

0.20 0.49

5700

73925

74784

2200

2020-09-30

630000

75000

12000

450000

0.21

0.56

0.70

324370

226037

83386

17873

133000

30000

0.10

0.25

0.11

0.48

0.13

0.40

0.11

0.10

0.11

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td></tr> </table>   Principles of Consolidation   The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.   Recent Accounting Pronouncements   The Company adopted Accounting Standards Codification 842, Leases (“ASC 842”) in the first quarter of 2019. As a result the Company updated its significant accounting policies for leases below. Refer to Note 4 for additional information related to the Company’s lease arrangements and the impact of the adoption of ASC 842 on the Company’s unaudited consolidated financial statements.   From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.   Leases   The Company has one leased buildings in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.   The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.   Net Loss Per Share   Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.   The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Stock options outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">1,380,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,717,826</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,717,826</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debentures convertible into common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,707,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,479,364</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Preferred shares convertible into common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,272,052</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,272,052</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Directors Deferred Compensation Plan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,075,908</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">685,107</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,473,719</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,534,349</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="font-weight: bold">Sales Concentration</td><td> </td> <td colspan="14"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Nine months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left">Number of customers over 10%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Percentage of sales</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10%, 11 % and 11</td><td style="text-align: left"> %</td></tr> </table>   Accounts Receivable Concentration   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">At September 30,</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">At December 31,</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Number of customers over 10%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13% and 40</td><td style="text-align: left">%</td></tr></table>

1 1 1 3 1 2

EX-101.SCH 7 vyco-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Stockholders' Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Segment Reporting, Geographical Information link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Consulting and Other Agreements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Concentration link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Segment Reporting, Geographical Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes Payable - Summary of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable - Summary of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Segment Reporting, Geographical Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Segment Reporting, Geographical Information - Summary of Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Equity - Schedule of Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity - Schedule of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Consulting and Other Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Concentration (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Concentration - Schedule of Concentration (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vyco-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 vyco-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 vyco-20190930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Preferred C [Member] Preferred D [Member] Treasury Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive (Loss) [Member] Legal Entity [Axis] EuroAmerican Investment Corp. [Member] Antidilutive Securities [Axis] Stock Options Outstanding [Member] Warrants to Purchase Common Stock [Member] Debentures Convertible into Common Stock [Member] Preferred Shares Convertible into Common Stock [Member] Directors Deferred Compensation Plan [Member] Related Party [Axis] Stock Warrants [Member] Short-Term Debt, Type [Axis] Insurance Policy Finance Agreements [Member] Peter Zachariou [Member] Fountainhead Capital Management Limited [Member] Debt Instrument [Axis] Term Note [Member] Business Segments [Axis] Vycor Medical [Member] NovaVision [Member] Geographical [Axis] United States [Member] Europe [Member] Fountainhead [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Consulting Agreement [Member] Non-employee [Member] Range [Axis] Minimum [Member] Maximum [Member] German [Member] Fountainhead Consulting Agreement [Member] Scenario [Axis] March 2017 and Effective April 1, 2017 [Member] Related Party Transaction [Axis] Title of Individual [Axis] Directors [Member] Class of Stock [Axis] Series D Preferred Stock [Member] Unsecured Loan [Member] Employee Stock Options [Member] Customer [Axis] Customer One [Member] Concentration Risk Benchmark [Axis] Sales Revenue [Member] Preferred D Stock [Member] Loan Restructuring Modification [Axis] Extended Maturity [Member] Robert Anderson [Member] Consultancy [Member] Customer Two [Member] Accounts Receivable [Member] Plan Name [Axis] 2018 Stock Option Plan [Member] Non Employee Directors [Member] Directors Deferred Compensation Plan [Member] Germany [Member] Short-Term Lease Agreement [Member] Manufacturer One [Member] Purchase [Member] Manufacturer Two [Member] Customer Three [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable Inventory Prepaid expenses and other current assets Total Current Assets Fixed assets, net Intangible and Other assets: Patents, net of accumulated amortization Website, net of accumulated amortization Other Assets - Long Term Operating lease right-of-use assets Total Intangible and Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current Liabilities Accounts payable Accrued interest: Other Accrued interest: Related party Accrued liabilities - Other Accrued liabilities - Related Party Notes payable: Other Notes payable: Related Party Current operating lease Total Current Liabilities STOCKHOLDERS' DEFICIENCY Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2019 and December 31, 2018 respectively Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2019 and December 31, 2018, 24,856,170 and 23,244,028 shares issued and 24,752,836 and 23,140,694 outstanding at September 30, 2019 and December 31, 2018 respectively Additional Paid-in Capital Treasury Stock (103,334 shares of Common Stock as at September 30, 2019 and December 31, 2018 respectively, at cost) Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders' Deficiency TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenue Cost of Goods Sold Gross Profit Operating expenses: Depreciation and Amortization Selling, general and administrative Total Operating expenses Operating loss Other income (expense) Interest expense: Other Interest expense: Related Party Loss on foreign currency exchange Total Other Income (expense) Loss Before Credit for Income Taxes Credit for income taxes Net Loss Preferred stock dividends Net Loss available to common shareholders Comprehensive Loss Foreign Currency Translation Adjustment Comprehensive Loss Net Loss Per Share Basic and diluted Weighted Average Number of Shares Outstanding - Basic and Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of stock for board and consulting fees Issuance of stock for board and consulting fees, shares Directors deferred compensation granted Accumulated Comprehensive Loss Foreign currency translation adjustment Issuance of shares and warrants pursuant to offering, net Issuance of shares and warrants pursuant to offering, net, shares Share based compensation issued to management/employees Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to cash provided by (used in) operating activities: Amortization of intangible assets Depreciation of fixed assets Inventory provision Stock based compensation Changes in assets and liabilities: Accounts receivable Inventory Prepaid expenses Security Deposits Accrued interest - Related Party Accrued interest Other Accounts payable Accrued liabilities Other Cash provided by /(used in) operating activities Cash flows from investing activities: Purchase of fixed assets Cash used in investing activities Cash flows from financing activities: Proceeds from Notes Payable - Related Party EX-101.PRE 11 vyco-20190930_pre.xml XBRL PRESENTATION FILE XML 12 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

12.

SUBSEQUENT EVENTS

XML 13 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	COMMITMENTS AND CONTINGENCIES

Lease

Potential German tax liability

XML 14 R10.htm IDEA: XBRL DOCUMENT

Lease

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Lease

LEASE

The Company recognized the following related to a lease in its unaudited consolidated balance sheet at September 30, 2019:

	Nine Months Ended September 30,
	2019		2018
Operating Lease Assets
Current portion	$	43,586	$	-
	$	43,586	$	-
Operating Lease Liabilities
Current portion	$	43,586	$	-
	$	43,586	$	-

XML 15 R33.htm IDEA: XBRL DOCUMENT

Segment Reporting, Geographical Information (Details Narrative)	9 Months Ended
	Sep. 30, 2019 Number
Segment Reporting [Abstract]
Number of reportable segments	2

XML 16 R37.htm IDEA: XBRL DOCUMENT

Equity - Schedule of Stock Warrants (Details)	9 Months Ended
Equity - Schedule of Stock Warrants (Details)	Sep. 30, 2019 $ / shares shares
Equity [Abstract]
Number of shares Warrants Outstanding, Beginning Balance \| shares	3,717,826
Number of shares Warrants, Granted \| shares
Number of shares Warrants, Exercised \| shares
Number of shares Warrants, Cancelled or expired \| shares
Number of shares Warrants Outstanding, Ending Balance \| shares	3,717,826
Weighted average exercise price per share Warrants, Outstanding, Beginning Balance \| $ / shares	$ 0.27
Weighted average exercise price per share Warrants, Granted \| $ / shares
Weighted average exercise price per share Warrants, Exercised \| $ / shares
Weighted average exercise price per share Warrants, Cancelled or expired \| $ / shares
Weighted average exercise price per share Warrants, Outstanding, Ending balance \| $ / shares	$ 0.27

XML 17 R9.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Notes Payable

3.	NOTES PAYABLE

Related Parties Notes Payable

Related Party Notes Payable consists of:

	September 30, 2019		December 31, 2018
On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2020 or on demand by the Payee	$	30,000	$	30,000
In March 2019 and between March 2018 and July 2018 the Company issued various promissory notes to Fountainhead Capital Management Limited for $180,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Five notes were extended for another twelve months on their due dates which will be due between March and July 2020 or on demand by the Payee.		180,873		163,000
Total Related Party Notes Payable	$	210,873	$	193,000

Other Notes Payable

Other Notes Payable consists of:

	September 30, 2019		December 31, 2018
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On March 19, 2019, the note was extended to December 31, 2019. See further note below.	$	300,000	$	300,000
Insurance policy finance agreements.		51,058		25,814
Total Notes Payable:	$	351,058	$	325,814

XML 18 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 08, 2019
Document And Entity Information
Entity Registrant Name	VYCOR MEDICAL INC
Entity Central Index Key	0001424768
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,752,836
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

XML 19 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Common Stock [Member]
Balance	$ 2,432	$ 2,378	$ 2,324	$ 2,232	$ 2,018	$ 1,993	$ 2,324	$ 1,993
Balance, shares	24,320,456	23,779,742	23,244,028	22,320,383	20,175,322	19,925,322	23,244,028	19,925,322
Issuance of stock for board and consulting fees	$ 54	$ 54	$ 54	$ 39	$ 103	$ 25
Issuance of stock for board and consulting fees, shares	535,714	540,714	535,714	387,931	1,031,125	250,000
Directors deferred compensation granted
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net					$ 111
Issuance of shares and warrants pursuant to offering, net, shares					1,113,936
Share based compensation issued to management/employees
Net loss
Balance	$ 2,486	$ 2,432	$ 2,378	$ 2,272	$ 2,232	$ 2,018	$ 2,486	$ 2,272
Balance, shares	24,856,170	24,320,456	23,779,742	22,708,314	22,320,383	20,175,322	24,856,170	22,708,314
Preferred C [Member]
Balance	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1	1	1	1	1
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees
Net loss
Balance	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1	1	1	1	1
Preferred D [Member]
Balance	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306	270,306	270,306	270,306	270,306
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees
Net loss
Balance	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,307	270,306	270,306	270,306	270,306	270,306	270,307	270,306
Treasury Stock [Member]
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees
Net loss
Balance	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)	(103,334)
Additional Paid-In Capital [Member]
Balance	$ 28,039,699	$ 27,905,314	$ 27,771,868	$ 27,504,960	$ 27,039,920	$ 26,921,574	$ 27,771,868	$ 26,921,574
Issuance of stock for board and consulting fees	112,447	113,385	112,446	112,461	357,397	92,475
Directors deferred compensation granted	21,000	21,000	21,000	21,000	21,000	21,000
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net					(111)
Share based compensation issued to management/employees					86,754	4,871
Net loss
Balance	28,173,146	28,039,699	27,905,314	27,638,421	27,504,960	27,039,920	28,173,146	27,638,421
Accumulated Deficit [Member]
Balance	(29,197,473)	(29,012,169)	(28,669,686)	(27,873,365)	(27,454,781)	(26,965,960)	(28,669,686)	(26,965,960)
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss
Foreign currency translation adjustment
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees
Net loss	(371,794)	(185,304)	(342,483)	(314,364)	(418,584)	(488,821)
Balance	(29,569,267)	(29,197,473)	(29,012,169)	(28,187,729)	(27,873,365)	(27,454,781)	(29,569,267)	(28,187,729)
Accumulated Other Comprehensive (Loss) [Member]
Balance	127,668	127,667	127,673	127,346	123,679	124,841	127,673	124,841
Issuance of stock for board and consulting fees
Directors deferred compensation granted
Accumulated Comprehensive Loss			(6)			(1,162)
Foreign currency translation adjustment	7	1		810	3,667
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees
Net loss
Balance	127,675	127,668	127,667	128,156	127,346	123,679	127,675	128,156
Balance	(1,028,680)	(977,816)	(768,827)	(239,833)	(290,172)	81,442	(768,827)	81,442
Issuance of stock for board and consulting fees	112,501	113,439	112,500	112,500	357,500	92,500
Directors deferred compensation granted	21,000	21,000	21,000	21,000	21,000	21,000
Accumulated Comprehensive Loss			(6)			(1,162)
Foreign currency translation adjustment	7	1		810	3,667		2	33,515
Issuance of shares and warrants pursuant to offering, net
Share based compensation issued to management/employees					86,754	4,871
Net loss	(371,794)	(185,304)	(342,483)	(314,364)	(418,584)	(488,821)	(899,581)	(1,221,769)
Balance	$ (1,266,966)	$ (1,028,680)	$ (977,816)	$ (419,887)	$ (239,833)	$ (290,172)	$ (1,266,966)	$ (419,887)

XML 20 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 229 276 1 false 55 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://vycormedical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://vycormedical.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://vycormedical.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://vycormedical.com/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Stockholders' Deficiency (Unaudited) Sheet http://vycormedical.com/role/StatementOfStockholdersDeficiency Consolidated Statement of Stockholders' Deficiency (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Cash Flows (Unaudited) Sheet http://vycormedical.com/role/StatementOfCashFlows Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://vycormedical.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Significant Accounting Policies Sheet http://vycormedical.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Notes Payable Notes http://vycormedical.com/role/NotesPayable Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - Lease Sheet http://vycormedical.com/role/Lease Lease Notes 10 false false R11.htm 00000011 - Disclosure - Segment Reporting, Geographical Information Sheet http://vycormedical.com/role/SegmentReportingGeographicalInformation Segment Reporting, Geographical Information Notes 11 false false R12.htm 00000012 - Disclosure - Equity Sheet http://vycormedical.com/role/Equity Equity Notes 12 false false R13.htm 00000013 - Disclosure - Share-Based Compensation Sheet http://vycormedical.com/role/Share-basedCompensation Share-Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://vycormedical.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Consulting and Other Agreements Sheet http://vycormedical.com/role/ConsultingAndOtherAgreements Consulting and Other Agreements Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://vycormedical.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Concentration Sheet http://vycormedical.com/role/Concentration Concentration Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://vycormedical.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://vycormedical.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://vycormedical.com/role/SignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies (Tables) Sheet http://vycormedical.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://vycormedical.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Notes Payable (Tables) Notes http://vycormedical.com/role/NotesPayableTables Notes Payable (Tables) Tables http://vycormedical.com/role/NotesPayable 21 false false R22.htm 00000022 - Disclosure - Leases (Tables) Sheet http://vycormedical.com/role/LeasesTables Leases (Tables) Tables http://vycormedical.com/role/Lease 22 false false R23.htm 00000023 - Disclosure - Segment Reporting, Geographical Information (Tables) Sheet http://vycormedical.com/role/SegmentReportingGeographicalInformationTables Segment Reporting, Geographical Information (Tables) Tables http://vycormedical.com/role/SegmentReportingGeographicalInformation 23 false false R24.htm 00000024 - Disclosure - Equity (Tables) Sheet http://vycormedical.com/role/EquityTables Equity (Tables) Tables http://vycormedical.com/role/Equity 24 false false R25.htm 00000025 - Disclosure - Share-Based Compensation (Tables) Sheet http://vycormedical.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://vycormedical.com/role/Share-basedCompensation 25 false false R26.htm 00000026 - Disclosure - Concentration (Tables) Sheet http://vycormedical.com/role/ConcentrationTables Concentration (Tables) Tables http://vycormedical.com/role/Concentration 26 false false R27.htm 00000027 - Disclosure - Basis of Presentation (Details Narrative) Sheet http://vycormedical.com/role/BasisOfPresentationDetailsNarrative Basis of Presentation (Details Narrative) Details http://vycormedical.com/role/BasisOfPresentation 27 false false R28.htm 00000028 - Disclosure - Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Details) Sheet http://vycormedical.com/role/SignificantAccountingPolicies-ScheduleOfCommonStockNotIncludedInCalculationOfDilutedNetLossPerShareDetails Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Details) Details 28 false false R29.htm 00000029 - Disclosure - Notes Payable (Details Narrative) Notes http://vycormedical.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://vycormedical.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - Notes Payable - Summary of Notes Payable (Details) Notes http://vycormedical.com/role/NotesPayable-SummaryOfNotesPayableDetails Notes Payable - Summary of Notes Payable (Details) Details 30 false false R31.htm 00000031 - Disclosure - Notes Payable - Summary of Notes Payable (Details) (Parenthetical) Notes http://vycormedical.com/role/NotesPayable-SummaryOfNotesPayableDetailsParenthetical Notes Payable - Summary of Notes Payable (Details) (Parenthetical) Details 31 false false R32.htm 00000032 - Disclosure - Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) Sheet http://vycormedical.com/role/Lease-ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) Details 32 false false R33.htm 00000033 - Disclosure - Segment Reporting, Geographical Information (Details Narrative) Sheet http://vycormedical.com/role/SegmentReportingGeographicalInformationDetailsNarrative Segment Reporting, Geographical Information (Details Narrative) Details http://vycormedical.com/role/SegmentReportingGeographicalInformationTables 33 false false R34.htm 00000034 - Disclosure - Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) Sheet http://vycormedical.com/role/SegmentReportingGeographicalInformation-ScheduleOfBusinessSegmentsInformationDetails Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) Details 34 false false R35.htm 00000035 - Disclosure - Segment Reporting, Geographical Information - Summary of Geographic Information (Details) Sheet http://vycormedical.com/role/SegmentReportingGeographicalInformation-SummaryOfGeographicInformationDetails Segment Reporting, Geographical Information - Summary of Geographic Information (Details) Details 35 false false R36.htm 00000036 - Disclosure - Equity (Details Narrative) Sheet http://vycormedical.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://vycormedical.com/role/EquityTables 36 false false R37.htm 00000037 - Disclosure - Equity - Schedule of Stock Warrants (Details) Sheet http://vycormedical.com/role/Equity-ScheduleOfStockWarrantsDetails Equity - Schedule of Stock Warrants (Details) Details 37 false false R38.htm 00000038 - Disclosure - Equity - Schedule of Stock Options (Details) Sheet http://vycormedical.com/role/Equity-ScheduleOfStockOptionsDetails Equity - Schedule of Stock Options (Details) Details 38 false false R39.htm 00000039 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://vycormedical.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://vycormedical.com/role/Share-basedCompensationTables 39 false false R40.htm 00000040 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used in Calculations of Black-Scholes Option Pricing Model (Details) Sheet http://vycormedical.com/role/Share-basedCompensation-ScheduleOfAssumptionsUsedInCalculationsOfBlack-scholesOptionPricingModelDetails Share-Based Compensation - Schedule of Assumptions Used in Calculations of Black-Scholes Option Pricing Model (Details) Details 40 false false R41.htm 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://vycormedical.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://vycormedical.com/role/CommitmentsAndContingencies 41 false false R42.htm 00000042 - Disclosure - Consulting and Other Agreements (Details Narrative) Sheet http://vycormedical.com/role/ConsultingAndOtherAgreementsDetailsNarrative Consulting and Other Agreements (Details Narrative) Details http://vycormedical.com/role/ConsultingAndOtherAgreements 42 false false R43.htm 00000043 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://vycormedical.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://vycormedical.com/role/RelatedPartyTransactions 43 false false R44.htm 00000044 - Disclosure - Concentration (Details Narrative) Sheet http://vycormedical.com/role/ConcentrationDetailsNarrative Concentration (Details Narrative) Details http://vycormedical.com/role/ConcentrationTables 44 false false R45.htm 00000045 - Disclosure - Concentration - Schedule of Concentration (Details) Sheet http://vycormedical.com/role/Concentration-ScheduleOfConcentrationDetails Concentration - Schedule of Concentration (Details) Details 45 false false All Reports Book All Reports vyco-20190930.xml vyco-20190930.xsd vyco-20190930_cal.xml vyco-20190930_def.xml vyco-20190930_lab.xml vyco-20190930_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 21 R43.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
	Apr. 20, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017
Number of common stock issued for fees	1,113,936
Fountainhead [Member]
Accrued dividends		$ 226,037	$ 226,037
Fountainhead [Member] \| Fountainhead Consulting Agreement [Member]
Number of common stock issued for fees		1,607,142
Number of common stock issued for fees, value		$ 337,500
Fountainhead [Member] \| Consulting Agreement [Member]
Number of common stock issued for fees			1,669,056
Number of common stock issued for fees, value			$ 562,500	$ 225,000
Peter Zachariou [Member]
Accrued dividends		83,386	83,386
Preferred D Stock [Member]
Accrued dividends		324,370	324,370
Fountainhead [Member] \| Unsecured Loan [Member]
Unsecured loan notes issued		$ 17,873	$ 133,000
Unsecured loan notes interest rate		10.00%	10.00%
Unsecured loan maturity description		Due on demand or by their one-year anniversary.	Due on demand or by their one-year anniversary.
Fountainhead [Member] \| Directors [Member]
Equity ownership percentage		56.00%
Fountainhead [Member] \| Directors [Member] \| Series D Preferred Stock [Member]
Equity ownership percentage		70.00%
Peter Zachariou [Member] \| Unsecured Loan [Member]
Unsecured loan notes issued		$ 0	$ 30,000
Unsecured loan notes interest rate		10.00%	10.00%
Unsecured loan maturity description		Due on demand or by their one-year anniversary	Due on demand or by their one-year anniversary

XML 22 R26.htm IDEA: XBRL DOCUMENT

Concentration (Tables)

9 Months Ended

Sep. 30, 2019

Risks and Uncertainties [Abstract]

Schedule of Concentration

Sales Concentration
	Three months ended						Nine months ended
	September 30,						September 30,
	2019			2018			2019			2018

Number of customers over 10%		1			1			1			3
Percentage of sales		11	%		25	%		10	%		10%, 11 % and 11	%

Accounts Receivable Concentration

	At September 30,			At December 31,
	2019			2018

Number of customers over 10%		1			2
Percentage of accounts receivable		48	%		13% and 40	%

XML 23 R22.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of Supplemental Balance Sheet Information Related to Leases

The Company recognized the following related to a lease in its unaudited consolidated balance sheet at September 30, 2019:

	Nine Months Ended September 30,
	2019		2018
Operating Lease Assets
Current portion	$	43,586	$	-
	$	43,586	$	-
Operating Lease Liabilities
Current portion	$	43,586	$	-
	$	43,586	$	-

ZIP 24 0001493152-19-016811-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-016811-xbrl.zip M4$L#!!0 ( #HT;$_Z]13"@H( "ZE!P 1 =GEC;RTR,#$Y,#DS,"YX M;6SL?6MSX\:QZ/=;=?\#[A[[E%U%:?$B :X3W])*VHUR=B5%TMHW^9*"@*&( M& 08/*1E?OWMG@%(@$^ >! @QR?'IDA@IJ>[IZ>[IQ]_^K_?)X[P2OS ]MP_ MOY/.Q7<"<4W/LMV7/[_[]GAV\7AY<_-.^+^__N__)< _?_H_9V?")YLXU@?A MRC//;MR1]XMP:TS(!^$S<8EOA)[_B_";X43XC??)=H@O7'J3J4-" C^PF3X( M_7/IF0AG9SG&_8VXEN=_>[B9CSL.P^F']^_?WM[.7>_5>//\/X)ST\LWW*,7 M^2:9C_7;WR_O!%F4AN)0$05)_)OP-T6X^G1[_GT$"[DR0G@&?_Y1OI(D_)?\ M)(H?^H,/HOJ/G!.&1A@%\PG%[[HHJJ(H#MCK?_K^[#OV!_RW ,1P@P_? _O/ M[U)K?%/./?_EO2R*TOO_]_7+HSDF$^/,=H/0<$WR+GG+L=T_UKTG#8?#]_37 MY-&5)W'R9 [E/?[\; 2+D1' +<^O0 *_6N'\A?3#_??LQ\RC]MI'!^Q1.WG4 M(DO/!<0\?_%>W\,/[Y%"9Z)TIDC)XSX9;01Y\!Y^31ZT T^5)6W;^M@3R0M1 M*8/QS^L 09^\3V'!&O?H;^L>:K(?+"OWWX6Q*WL-# M9_ 4\6US_M[NE[(O SX]7KHZ"]KH#.]R W]V7J2Q#_B:]K2:Y'O@X#9]%[\ MZYKY C]GBWFG[]&W- .9_-OY]_;%OXRLD&04BA)AKH)ZBYO_N?=KR!5 M)%56M8'^I_?++R^F>[]VOGBV*7"&9ZU" 5O<#U$<_KI83C+2XK>5UT!VIU[" M=2^FMS*O)-]G $B^C%&Z&<\7P=T(YM [B5LF0,-?%PN83Q'_4C&2)!FW2X>1 M1!=0*Y*ZN4M32!K6R4FQ6--38JV;6R\CUO1]Q)K>@%C3&,/_,]8P_@D*]<1S M'T//_.,KF3P3_V!87R"2O$Q(BK_F/UD S/>I8YMVR& 5+!N>9 9'O* /J",3 M?/_ZWQ' C0:#Y\*?P<5W.WCW:_+8RKK_]'[M%&GPWJ^'K_3^TAH00O$G1.*Y]'[RB1%$_NSTY/>:E9\8 M[2\LRPX!=89S;]C6C7MI3.W0<$Z*"[;BX,3XX8&$ANT2Z]KP7=M]"4Z*$=8O M_L0XX,(THTGD ,*LNW!,?$263\:(TE=RXYK>A)P44^3&QY'SBI-_+IM#1T[UMIF AZ3XU0E2_/ 689,4YQ9ANRS"0]">6X3MM0@/ MP0_<(FR317@0B< MPLY9A ?0$Z\CW[N@@3R&>^.^DB#$)5UZ_K3;W&$1^\,7 M\F(XUQ3>E):X:\7'2O_-042<%]K""RV/C]K-0E0#OYNB&G;O&&ZW^69^=,"X MENU$(9P4C\2,?% S27#]W70BBUB(%#Q,(CB'X+6[4:)VW!/_<6SXY.-L_0 I M/ER+-LY\!9GO=\/W05X&3]Y]Y)MC(R!'Y^ZLGQ5S()$S9D'&O"+/L.+()\&E M!Z>,']K/#NBS<,#HRPZA]X?V[ MF8\;1B=@&'61,;EA='*&41?9E!M&)VH8=8I9N6%TZH91^]AUD5$OG<"E\R( MA<89W /Z9T^@- :&B3P3?)RE?VGQ/62VEH!4?TQ"(?:82[I8)>=,LR?3% $O M9YA-AB1'S[:94)H;-XA\+&%T[\%B9Y]L%_^X>/$).:(3]W'L^>$3\2=@;X1/ MLRE)<60^#!QK@$VVY@?GBLYP1:U%3C:D9Y"0^/\P3- B;2]B2^UK@Z&N2_W! M,3/#NH6?ED!8AP%.\6/>[)^PD)UANV-B6$E2@N$:+U3\?;$G-BAWQ\\'^;%P MY/( 3'3E3.X?NS'^N("\DS^$6N_7"CF=PU,DA M1:06"BM04D,_PEE28&31?%#77LPTQ5Q[2]S<=#S9;U@U]2NKFMIM3EUQ@GR, M MLE0?#(ADO?;JRNF@?+%&2<6^_5^,U&U)\.VRROF3--#LV:2YB#:TP'R%GD MXN%X*;X[&(/O^18<$.V[:=[-.%QL<*99?[YPNZ45$J9A+RTW.@XN'AKN-+#6 MY&1=9O[Y[;&K! _\<$'LS\1[\8WI&'J M$:F(B<(B%5%6L_%T8F3)YJ"D\5O+%M!2.HVV.>PTB^2-5.BJ6-P[AVH51[M% M9A& , ;V;G2!.5$LT#4U]T8J'%0YT_91SI9:V30?+^22R=3Q9J3CQ_O>?+R" M >[**WP[S'FH33S4?B.1\TU+^.;P__&KXY?GKSGL9>%!BN]4A>X1E"7/A\/1H1$PN!74Q]V[ES MR;KGNGV6Y_%+Y<)G-6ZRC.1X-($*P"(I4"JB%C^,/#- MUR=7M@\H\_PCJ=VTP>'3P"T)\NV3'3JPAVY,I2GQ$/%IDV7.A?ND8 7 )I6BVX.(6HA_K?BEF$F3WSCG&I=(;]% MAP1O8@>!Y\^P7M*1*,9MKVJX[-X<%"X0%5.X5M&6@XLXHS28?).A>%TR1$G= M9T;QO=]>;]IG-/V.5)4#W;4>WRX!1O!XH?T;Q?M#['O+RS+Q@L@P[DW;.O& M39P9I\0%6W%P8K* \T-[^>$0\N&!H)N36$DSYY-BA/6+/S&)P#F@31QP$!W! M-*-)1.-&[L(Q\1%9/ADC2E_)C6MZDR/)QLY[/N3%QXE)"LXGW>.3)N1)7+"F MNSEW6B-E KZ[-A5GI!8R4OOJ">QFI$OZ'^+?N60Y=\QP2/" ^9X1N24=+P?) M2M3\R_.3]:;9:04'N[FH"$=?>JX)$/L&\NF#'?SQ%=JWFK2Y$-[;CF/&A "Z?[P>A>JZNIS-G%*W3S M"MUIG+?[9%NX0K0E5TC'?(?+G@*MK9X";4FB=!G/^CYX;HB?E3-)3_@9/@_S MNGD7K>6^AP ;L;X:8>0#AKHMQ>OT A<1VFAC/!"T0DQ$J_ORU;-@H::QL(:2 M1]<3X- N2.2KPH)%275X:4J \Y[8A^V)W8T3:0OC\+;:G&ERJS%*I0SR/:CADN-TSY*UC$%EQJ<0?+$!#YX M@)[PPK6('R0*V]*EC^&:'7<3[GW9LPX[U7@.-WLN5[!^Z).PG>&)M,F+S'IM MRZLQSY>1[Y/#,VX%%(@76HP"\F'-7A[7Q^/ZMK!T:P_*'*&J3V_>R;/T' >< MI;L0!+%)]]LLI2],:G,!BDUBOQK/SA%8$>T7U)NPSA7 W;*:9A]RQN:,7;?$ MSJ2Y'HJQ5Y60DV3L@^LAG+$K4D5X_!J/7SLB%25'1U/>%Z#-?0$.D(##$P=Y MXN J(QXX(RC5?/?:?AEC[]U4VON]8RQ=&:U2K>N/LS]F_(O9OL9(J 6!ZQZY(,[H:74"M1^22C%#0)\/[^ARXKT\E M^TMIP.NAIEAGP%M"M9!UU'U89W"(<&#..BUCG=8&"J=M.GY@M8YU]K6':C^P M]-2!I?,#JYVL4_S TALXL-:%!'+6:1GKM"ST;G%7P@^I-K!+]A9$:: [,C]A MVD?WVNN4$LHW@HOZ-4)4O^J!"%O:" MT%S>4$YHYR:%Y13_-2\H)SBI^8%Y10_)2]H M$@_\Y!,CB/S9Z44$KUGYH;T4W?&'%[-,='REGG[:Q3Z>\ MI9Q]6L@^W?&;T[[=M#^$!GWG/:M MH?U!/:T7EF5C"5W#N3=LZ\9-BO&?$D=LQ<&A_1_=\[YREFHY2W7/(\M9JN4L MU3TO+6>I-K-4)SVWG*5:SE+=\^9REFHY2W7#P\O9J&5L=&"O+^>'5O-#XYY@ MS@_MY8=#>(&[]KN2W!23+%^\8?VOG3/1\R9J'5, MU#VO,&>BUC%1]_S G(G:Q42=]/QR)FH=$W7/U\N9J'5,U WO+F><@S/.@?VY MG -:Q@&->W Y![2) P[AL^47LUI'6:U[?F'.:EUDM4YZCSFK=935 MNN=CYJS645;KAB>:LU='V.O0\<><3[K()\W')7,^Z1R?'"1>F?-)%_GD$![R M@W' B;F'.X[G=OI&USBLNHSG+GEK.H[GEKDJLO9CQW![&..ITTAJRG+H+I)J M59L7Q[2RH?'L)R]R,81B3 PKR70S7..%*IM?[(D-JN21J-!CSP^?B#^Y(L_A MTVQ*4BTX\F/AT!=J2KOTP/6]N3A3M9NIFCK(UEMCZ79_MV#%3J:.-R/DRO:) M&7I^',.5/#'_^BKI%0XV+9#!P!S=>\=PN\U(@1]^>+)#A]R-;ES+?K6MR'!2 M3+090;N9I@@C(R9OC4F:?W-B_M 2<2_+N.D0 \[SG.>KXOE]K>?:>7Z+G$^? MA5E>SYR2GAM$3FB[+QC"!UB8/K));]E$$2[U-^C!::X_3?&^-]-S8;]&.Q\VX$'A/,MY MMDJ'5GT\NTW3P&/+G_WSZCKAV;EQ_H48 3D2E0*5Y_EM\&?BO?C&=&R;B0(= M8^'#U75S"L-6/'-%H:"J?$]"XO_#,,<&C!]EI? W%_@M@EW_Q3MRB9ONC[P& M(=4R-SKO;D!.^=$29Z_!-^?G@NX.SL^L-.<[#G(?39#NHA<:9 MD3/C>F9LR/1:2=.-F>^2_H?X=VX<93J/TWTT'!(\D%?B1N26'($%]M7XE^&+X?V1#@=>B_-#*:SO3@;<8 M8YRE.4MO9^EVVF-;6/JKX48C.$/AU$JQ=:);1#X?KYXS<-D9>[U%8O>#O*H\V&N-P3'8\9X%VL4"MUG-^ MOZ(DBWU1[NO#PV5^'(H=]G/D')-,6(US%+)44>,^FS# U;7=(E*2E^KH<5YJ'R_M*9[Q:88@),8+()[_:@:?*DO8!GDD&2W[*3H&C;1C_<6SX)-@X M18P$^M#>SL9 M^_K;0_X)+&)_N/),&@7XR0Y,P_D[,?Q/\$T@Q'OL@8RV'?/OZ+'PI_=;1DI/ M=DV%S -YL0.0=FZ(V6"Y9T(WEVS:=6.N6R"F_.2>2Q+/ M_I9=%;Z^;MA[*J"NF?@JA+7D,-TX6GJZ"_C5HMAUC)?'[,\#-;X8395EV?B-%N?.=@(*/_H#Z@6 1TP8B!G]^!]#H M U4'_BTT5V4 )CC9!N!0[XMR20!754>PI>/MNB_BY+ZFHH*<9XZR\.3!DRRI MNJCM!\^-^PK?@M" 1_;&AZA(OOF%]- M@'UH2>6+("!A4)(-=."#_@**'#-5!%P>'$G20%0'I:"K!$D#>3A(PU%NQCPK M'_3[0TW).>.][X&M%J%(:]9OG* M/'H0H?47+ MLL)N>*CFGBI$?C'Q_-#^#S75X;%[^&Y_G@" 1"!0KCE* Y1+H P46:P6H-_) M,^@1>Y_-DJ[MA">>HCQ &U#T/; _N+;SYW>H![X3WFM2NHP(<.V\4L!DH]-<5!5-TY8E5_Y)R?B*YK>9Z?E?B87%*V*WY':53NKW5X3SWK/?>J_&;S:Z%7/,/9!E M62V-W3T7+HDPN3JL;/IB*U=D;>4,W@/I<7&6;X\[EBK!]BG!Q\L.<'0!34F. M=2J*)HD5H#CO.ON25@:OR7R!'Q99XS '&\46P+TQ0_6_I XWE(?]_JIYD1U\ M?Q!RB:VA+DO#O# D1R&<6Q;(;^*3(*2B>V\+!S=0?W$BKPR\U\SY5!-],!CL M.7,Z-'/OI:NRIJZ?/SU\&3!R*;'#@;@!#>O 2/B$'=CL^2^V\6P[=FB3LD8- M[ >QG]KXVVUP5 'C7.P7;2([<+_UC2"3BQDB30%.@ELW2B#EFV4JM>G5[:UJ/!/OU]2 M1BER7Y?4I<-ES?AEX,CGR@*E6Z\7CB7F1<7\8D)\L/-<=#0'(5+UTO.G>7>D MV"B\-VX0^89KDGO/L?!K)-"M/?4E44FK%ZKC[S9S/VUQLY@>">A2QK@W? MM=V7('6=<45&&.&Y+P[.9'TP& [2#+E[LFK RX.H,WG8'PSEM->T.'@Y&@=_ M\8+@EH1WHR?C^][L)&N#S 5KL6EK@#H7*R+4_G3E( MKTI@I*8(OSKTOI/GV!;:0-?E&B;/Q?2@@,">'%0_N[9T@Y Z>_(88L.A4AM, M?4559;4OR5M!$.N>7]9RZREU$25S'.0@RUGV-*D+K W'KI,)J*Q>*>LB&K25<-4^+Y2RR#RQP0 MU4#03>!*ZEP;!BN2'%D%M6*=9E_) MH=:#P5(PR9I<'YY:(\U:! IX:?V*(&#%NFD>KNPH[<+.YMXYX :\EKT'-"":!5^-K'/ >FEM-!]M7R< MM02LY1.M/6"U$5O+O%7&MAJ*?46JP;N]S&AE;%11&0Z&-=@PRUQ7!H\ XU"N M\5BL L:^J-9R%[3,C_O9T:(D2X-Z+-5!>2M?&FIJ'?[E91[<"SI-[:N:7LN] M606XTW1-408U6/4KG"KU.$;C?EV M^[89:K"CZYE\MX='$F5]H-=G=.X^"XK=4:4BB2]&8@O+F]A-8YN=87713_/.F::L# M=BTNFP263741A6//M_]#K'P8W0"@)(I+*03;)RL/VBK^&@3M)@BBDAA#Q5S< M&'^?GJ8<0+GQ5"U =U&(/6TLT,5J1U-JK@I JQ1A6T!+^:$;$W(YYJP(S%+B MK1R8E0JV?G]9>FR9J210N3FO6J"J$&:*K*J@F6T!:+WH* !,_GVIZOV!I&W# M3DY@*A-BBJ2*@^'ZI*5%3$3+VX3JRQ&!7[LBIWAT_SET:3%:TKJRI4@$WK#^16KFPM M1^:EER@/Y<[LLT+TTL5,K:[VK&Q-N]CM)2/4@2*V5=XO-YOI_N2<3A4.V+'5MC(2+V!]J@.UR: M[S139%'56GE$KUM4H<-,[NN*U,:5K>7'?.1285%B9S99L6*]HEKQ.7?I!>'= MZ+/G6?1NC_BOMDF"1\_)W?9FNQXX&"@9I]FFV:*F2S=[L)(MRFFZI\0M.791CAOVAGJZ3O?_, MU;FD]&%?U=6:82KF?)#53&N02NFS+Y9D@*HNGMG7T380Z^.E?*?DL ]02'4! M4>A4@S-B4 DZ2G@L='TH#6OCDF(.(7'0KXH["IX^V4C/4C@H=L"(PXQB4^F: M]Y0;\E+V(JOU\4Q.^UF7:?^C>H HA@Y-30?\;('D;HJ]4<%XBEO[*N?UR1@4- M-@7 RBQ[@5'8_-$E6=.DJL$H>M[TQ8':5VM 1J&S!T@B*7N19%'5L0K>..O+ MDC9.9.&4J;X4J58*<0H9Y(B:_(Z?MT, M2M)3)N:EU=8]>S*+,A#3Q^ZZ:?8%I2BS*(.^V*\'E*+,(LE2VJZJ&"N%F$62 MY72.PQZ@;.QRM/?9HZ1=O5MF*PE8408:]+7-F*H0KL+'DR)MYNMJ\57LP!K* MF[?^-KAN/=?+BJSXI6J.+T5-)_MNG*P45(5/,E7-7-W4 U7Q0TT;INV#VG!5 M\'P;JND+V-Q0+8Z_Y";"=B-X*3X?/3?X2$:>'R?'/1G?27#]/?0-S[=LU_!G M-R&9!# ;KL'W'(?.Q[BZ"L[L:Z!9921?;> >&#-%=X<^!%MY> J8*;I#97$X M$$\",X45&VJF'! S,$0LASX2E^Q_L[2I'?4>L^78=Q7.EH.7JUW;+O[8-=LM M":LVE9=$>F:&PM,7-X^7Y&:YZ0MK#\O"J?3J"ZH)2Q)@Z_39E+HK^]6VB&L% M[ 6:%89-KFXF4\.LY+!79%71-F:*;I^_:M@+6](M@KVPZ3V0);W?#M@+'VD5 MPI[9#!>OANU@\[4G+Y67%>?.?S0"VZQ$&NK#85_?) UWPU##$@I+5$D&F3+8 M)%0.LH;"8EG10"RJ;5I"8=&N2*HR:-42EC9#L=JDA123O>%34_ 5JU/:#'PK M%XAM@F])4K2.OGJ*OH7KT#8#W\J-:)O@6[=_SCH\NS9@T*W<\\>%+J=>_:@ M?+=13\Y16OC FG)K(-RH*[<#PFW:*P0VU=M&PXU2<2\N[=0] MPMX5W0^M7[4;[LVZ5HOAWJIWM1ONS3I8N^'>K(^U&.XU\N0(E*^N:5=K=NL1 M*!>-:@^;=A:-Z/1\8K^XEY'O$]>G.0HO&PFA=7&31:!E=$KNXS%HC5IKCO];#7&OD2'-;H/4P MUQC#T2 WMQOB&J,I&N3D=D-<8US# ?FX71#7&&%P0#YN%\0UW_,?0,-H+]0U MW[8?0,MH+]2-W70?@,.[ ']CM\P'X/HNP%_^KK:%C-]JP,O?.[:0U5L->"VW M;=ESX= M(@Q]^SD*V?79O0%3A%)E"=KIB@DEX*EY:<43MR5=ES-%/%N[MKT2NO6R2/L_TUOG"M:YL)PK)?FU%-K6=/A//TP$).Z:N -*=^V,; MI(,F(=W)[=L@E1O&Z7;FW0:IM#>DO\-),H;O+UZ);[R0VPAUCKL1?375-+DT M^V[L*#W0AWTIQ1/[ 53?LK;S^J9E27)?E]+Q*6U;UO:-L;'1MBS+0[7=U-JR MBS8M"_Z1Y$'ER\K5Y5QC?<5S73!O:O<]',I])5VI>F?3\R*@]155E=6^).> MI%X09"T',35129\QE<*1TT&_25(O]V6O!C:]/ =A?P15E/6Z0-M]Y]P40VV" M:/7VL%'^6J9AF_BK2*C1QH-#[P^D=%6WJM!6'C0@J*Y(M6&M3:S?-HCRATML MVXQ:4X@ZL(PH=B'?]!G47MB*%$S;>#YJVE!3*]>PBD2>;A2MV)BW7\.)5!YK MH#?5H9<6B2/=*/4!:THZ$Z5:7FN5C,T9J-C@.=0R'.4/YFR0:CG+$C5]!.6, M%FQ8>VXEMO+'5C9-Q (E^+9G_68X$?GD^1\]P[ZCRWM_*.I9 M1^&*V[@.L7WK*%5M>*FK8"M7MW_F5Q=6MW^.6.M75ZI.V?*Y>5 M+*+2RN7MGU:7#949MF]U-91XKE_NM0W JA,"ZY<^;0.PZ@3%^D5 JP"LH>AS M\[OXT !6G0[9_"X^-(!5IV5MEK[5EM9>>O,:H>R MJK60M)5E+F== 7U-&;:3M-7D.:\P\J"%GN_R-;H/KW.U#,Z:DK6;$V M@[.F M'/+FI$:;X&RTCG2#^E3K06^NFG2#FD[K06^NIG2#2DB[02]:6;K%=^G%4MTE M16WC]5;1&M/#=I*C<%)^7VM@'2S.II$8C0VA/WU8J+3CPG\'E/4M=*]PC4T+ M5<7V+G2OR(W.473?((Y-09*P07=MT8,M=*]XCDU!QJ*"IUQ+5[I7:,>&E2JZ M-E1VN#ER+G0>RKA%=B=Y\L1")0@T(%I+I?+XHUW5O"H#L;Z"V_5AL:*JQ/7A ML&T UM7!N#D,'AK .GO(UK^7VP1D#9<8JJZEDVH*0]H\0?9?JS[0TE6(6K38 MFIR[S1&E97 VWU2M ;YO/>B%'!>=$3S-B!2J@E_9/C%#SP^NR C.[NR3GWW# MW;?ZUG)0OK2PY/+,60F01;-V#@)DJ92 M.JQZ^QV>CVK)Y*ARIQT8GEKR-*K<90>&IY8LC"IWV('YIY8?^:AB>6O(CZMQ?#?-/;=D/=6B+!X2IMMR&.C3& \)46^9"'5KC ?FIAKR$ M0YF;-20='&HI-604',I348.G_5!+J<&1WA;_45>74G,8?QW2Z+!@U1FD7X>4 M."Q8=8;@U[%[#\M;#0?8UZ(JM W2AL/G:SGHVP9IP\'QM1S3K8*T:.A[6RR$ M]@%9].ZW+:IP+4 F=\$7$VQC]1_ZR-WHQ@T-]\5^=LA%$) P3ZSYSAM2?9@N MK+Q]OO+0+1%Y)W2*IJGZON!=$1 ,IKWQGKXHJE1%T5(%7M/#%YVZ*!Z&NMKO MYYLZ?YQ"X?6+DJHNMX78'5.Q;_3';GB&,@VQK@N>-?A)?,6?O,A%?7-,C%0L M\\6+3P@V=&0'4/+P5\,WQT]OWM/8BP+#M1[)*SQ#B N?KT$4F"&<7!=3WW;N M7++NN3P%(*F<*88)."S1^T:N"/OOC0MG*RXL>" FL5^Q9UX5?'.FRH-!*DXG MS[Q5P5J4IR1%U12Y:ECO?3(U;.OZ.]*B&ISV=2W=!V77G%7 6!27LC24E"I! MO(K(D_= J.YW;\!)D"O=:C?-^\IVDJ^9MS)@BR)UT$]WYBD$*]5"EM\ =@9U MV(*S%%22(*0J=15(5?K#>=GG/'-6 F1A]6)/('=+AWMC5I7XE,2^+/;SB*1X MTDJ@+(K*,U!0M&JAI"B/R?#%-IYMQZYJRY_)H%=NE4T;)J\4ZL*'DZH,U:TX MWAOJ1V)&OAW.0+/T GMOTV)7F/!^$Q?>UM)@N U+RW,N0WE+PDLC&-_[WJMM M$>OC[%N @N!N2GR#ZGFHL57&BWI?3;?=R3]YM6 7WO"R/I"42@ 'B8!:<_#D M79C_CL!,AC'@K7!V[X!5? %:,GP[Q4>JP+?<%_NI-F3Y)Z\6[*+X[@\&Z<;1 M^X.]@4XW[BL<';1JS^]WHU@M)E>K5V6 P5*5-,*Z?MRI8"UM4 MNKJ9U/E W<#'GVS7<,WJ=[\Z% ?ZSEVT9O9JX2Z,:%G*8'I_N!_-,;$BAV!# M:L\/GX@_06Y_ @ _.I[Y1UXL__K?3OC+5 C"F4/^_&YB^"^V^T$0I^&[_WX) M?\$?WT_II_^2E/A?Z1=&,,L'08+GA2=[ DBZ)6_"@S_2+, MA_Y%0+C.#,=^@3__%8&8&\WH;/'6%>C>%2BW"2DN#^P ]#AO]*%9J/[;F$Q_ M^2]I(&[$1L@@)(X33 TD&]*:_CTU+"OY.PN;!+!=PFS/OMT3_D*<5Q+:I@%P M&6YP%@/W9EOA&-@B#T!^9^"_SQGIU7<8 M2V#*Q$B2*)+T"I%$/_J%>!68'M;_XH-Y;R'C>_X'X;\N+Z^O/WU:Q\;)8/&V M&<@_ED?-G2O\-7*)(/<90@0PA 5T?AON3+!I,J4P!>D*'SU_)KA49H6><$^ M,L(_#'-L^+87"2//%WX U@.UY5QX@C'8D\_$\ 4[=@4)1@A@_2B NBT8KAM- MX-^68/A$F,9"T'/I_/"28\-#W@B^(<(,!X'Q1_8K$2QC%L!LCN.]@>"ACUO$ M@5\ .GC^#>S3D+CPW00'1[#B\UUXGM&G0> 2LH!1>#," 7B.N' ^T><-^!K] M9.$;2BUA N@,!!7)S;>Q'9*-AW^9E=^X M KV)I*WVS'@:72[[,4 M2"%_FR ^KU@1RJO4%)8BQ;2DBC9XS%>'4A:/"Y<#I8"T/*1.67JI3QX*JRV6 M;9.;3CZ7D;"6%\'$S1_!NV&JA=MDJ;4[]S0)(@UKV_[OJ2\F\]6AO$(US9O8 MZBQ88564+*SU%GG(ZIEW#0JXGY#[";F?D/L)#^ GC*U=YBB4UMFX!E#%GS"W M6NP0I%X#M'&O(]^[F,!XIN$*[/:7VHN7GC\]%WYBN-)E6?PE_>3\:^F7GYG% MNY@!K=X@:_8.ELU>=.ZAO9CV<0))\:>Q@88SV)!SFQ2L1D. -Y]CH]@TC< & M<7LNS%L&LPB'S#-8DPA5/)G DC>K%-!"/): BXTVD; OM23^SK;;1<.X=*.-UT M2>V >E*1RREC%GW@7J:ZG1I*>_?JB1*DOAV_[&5:[UW8'$R5RJC;$<:U)>R+ MO. !^D"FF+OJOMRX8%),:$+>QUG\8Z>CP9Y2!I1'@[T)FC-"^.8)SU%@NR0( MA( M-/A @?EM9H)9]958*(1[\;W8R#.C@ 3LTNO5-DE C2^7@!T%ZLD+\6>_ M4(OGUGLU?K/1I%GS*GTZ92@&A''$APO8.,Q &S7="(+QGG$/2$\FC8!]0DM MIE#PHI 92O3R$B?Q,;$S BQ3$.# ">A]Z@@#,W#,D!X,!LNB1LB( 7/$*#P& M9YF\&[:F?&7)&S&P<^E'U9S"&E/)4>8>I$$]'J2SP/X/8;R1=10]C8'1A:_L MYOJ:N@ R'K;"?B..5OQP"\*O#5C=0QDNXU>NFFPU^5,WDFTO=W([.?X J"ON M9.:HXUS7':X[G&=A>?T/3(^LVFE0E&LVV(05SL0AYY WX.S;Z&!?J\N5F&<]\+&JG0!EG*R-$66OMQ3 MY:+JQX$<'3NMJF6XY$K89;]12MS+U\(P>U^_K]@ ZJ"GB&5W,B=-#:11X>R3 MI;)G'R=-#:21>I(\Z.F#O-$IG#B-$D?4Y=Y0&]9,G/H-R+PK_DQ#1>YIJ$C. M1>?EEJ)K+:A>H:W,'=)>^0*O4&"G=PMXPJ?:FG*65-%4Z5 MJCVILMK3G@EF GZU))EN&DJ;(X.5Z+B@F=@?"B,B+[&+LA:_!SJ$%1?+\[[.DS^VS:"7 M"@-'?53NJ865GN,.K2^'TZ$N\=#Z;MX\'*A8US*N!DI/UH[?2=H6;,L]62X; M<=9JWV>IC9O6R6HVC4_,WX !=?V>)I>].^3.H'J(HRH]3=-J)LX:P5!+&;4B M9=$V5U>+2R#0%JC7W\'@=0WG,@I@I<0/+ESKB^>^?+%?B<7DQKI[KIE0L&: M9>=U((1[]P[GE.+UR8X"K;P^62==M-R[W8U*44>'.LYU'>"ZBBQ[7I_L.*]+ M..1'?T55MCY9QBXL**VZ<)U2LIJ6+/;4PFZ8X[Z@*H=1%3L '$GWHW9@%"OH M23U9X5Q:*4Y%N3>4^45J%B_,9W@0>^ HG:RUI.'5R5I-'%Z= MC+O\.>0G"GG3ZFE#;OY"B*E!9I=PJPRE7E_AU<3J+(\;%(ME9 E+:QE5 M-+$WZ/.Z9-P/E%_/YG7)VDH:7I>LM:3A=ERSD:845CL*+AG4=D;QH M6 H9O&A8^R%ORL2JJ&C8L6=DE"X:AM7U"U.*@C@Z!^F7W" M5P(M*6*E*+UA:1.A_>[+]F!;D\K:RJUV2RYO6IF7#&N#*X"7#&LW<8ZI9%C5 MM;XV5Q5[#.'GL>< ;8+K?T=V.+OU0O*[X?N&&P9W_@.2(>ATT;"YM8H?(OSP M^'1W^3_"[QW3X_,<(WF@#T? ,1:G' 2P'8)LSW[=D_X"W%>"9Y; )?A M!F<->^$JMYA3#J"#6>W+,"0_)X]4QRQ+WBK*HK\3W)O$VLBTS8%B ",8+V0M M),VX+)KFN6*Z<[/4N(VH@](;M8 S@K'AQWZ<"ABC.;H50[\4T[ M(,+4MTVZ;YY]X?T<]BF0CV)N"7'=B$Z,SY2!O-GSDQMC=U$8A(:+)YQ@A,)Z M[WMAGXU\"#_8H)"7*C>&T![6>KI\'"[!W,O>UU?8KX<*XGGAY.P&_8<;'1&E MU_T9[818!VG=C4^9A9T=:$E'L?3ZSYK2B[R.3V#.NIQU.R5Q+PT7S7YB"5AZ M_/O4]BOGX4Y<#+1^.W L=NY06+(V-@1--;31UOCE*QVR%=9(HYLNWTU';2;( M@4A2P#0IM'EKZ952[#IBY5X#7[\)@HA84MZK"B%R;?;0M\>K=X)%3'MB. 'Z MTW\54S"FABXZK9Z:5L\QK2SW13'GW#?N*W%#SY_][H/&<>6]N54L?*A*^F+^ MU3GV@Z(H'A1)&1:!XHH\AU=V8#I>$/E-=;HI=#-3[75+Z$US^.%D=?K]%Z' MG="VB[3RKD^%M<@IXM3"-/K0- M&_S^N?5W2A6D>)P ELKG;QS2PJWEBLT5_AJY1)#[#"&T 5[29<^F6B?VOYO M1U"^!)?*K- 3[@E01OB'88X-W_8BV@KO!V ]4%W/!>S4QYY\)H8OV$A%$H1H M54OBCP)>-A:#GTOGA)<>FE]CP#1%F. B,/[)?B6 9,VR\ MYSC>&QKJ^+A%'/@%H(/GWT ]#(D+WTUP< 0+!L?F?,+SC#X- I>0!8S"FQ$( MP'.$]@7#YPWX>@RSAV\HM82)1_N& 6C8 ]"*$ 1X#7"00IPL(H#>?-[T7 7U MG,IN*9NT;NN^YJ2,M2=,_(ZSU22H2&[6YW._<86OAF^.Z:E*1=8S =E 4E_K M].N_1LYLHQ!]I7(R6"M,/\%"0L-VQ\2P0&F:VAC&_=5PC1=")=<7>T+SHJB0 ME72QIVM*-Z3L)QR, ?D&T.44M/"M[<]%;8"T!3R_V8X#2Z7?9RF00OXV07S> MI .W4B=LO126<[)%LNVR4UWFCY^66KMSCU-@DC# MVK;_Z7@.[ZAN<-+^PC4HX'Y"[B?D?D+N)SR GS"V=IFC4%IGXQI %7_"W&JQ M0Y!Z#=#&Q8("%Q,8SS1< 6]S@Y#:BY>>/ST7?F*XTF59_"7]Y/QKZ9>?F<6[ MF &MWB!K]@Z6S5YT[J&]F/9Q DGQI[&!AC/8D'.;%*Q&0W"3_!G!,TTCL$'< MG@OSU4M#MFEZ=/FK_D-8Z#+O#,\!C8"/R*?2/ 8=#.N\YBAW#&[S2G'/X.$] M@R?L&@PB'T-RA2F<2N9,&-DN_=-X\0GUW07"Y+#+8 ,"_ C/C9&XT .X &FD*?C$ !NXM_.J>07"XF2T]#KT1-TX\8<9D% M^>9%C@63!Y$3PK?T:;1LJ48';\L]3=1Z0T5AZ?D4<."4"8Q-@[01./@JXV*A M0+"UP\3( 4F.22_+"I298,ECL&/G8)H4(B JWGLRO.$M"P[C12%HFSZ /<=% MFG/Q,Y4S@$0* ^ 4F#6%@1!QYYKV%,[2=>A@5G) 8%K+F67OJ-.C"],(+&,C M(/.Q>_&%+2QK&70*"LSK^?AF$,%3%'PZ%[X_,FPG\N<439:#/VB6Q/=ZV=EB6GC,L0%\SE(0,JN5 ML9-O3Q7[&[DAI-RKI;B7\3OCX80S%AS;2Y9$W:CH0 G' B]F8>-YGN3N:2* M=V%/L$=L)XX)X]?4YDHP$LPQ9;$-.$<&!0$WL0]4?G'M_Z /!^ 3)IYECX M M&6J>8;E6$C7P$MD,MX#IB\=+0=7$L[YXWC97=.7S;C%6!V!'N"T_7V)JND:..?I%,AXV% MO/NEDS*:@O3Q^O/7Z]LGX>'Z_N[AZ>;V'B_B\WEQ=?A)O;3W;NYNA1QKJE_S;94(H_/^9/PL?(P"$%!! *<[W9#!T4OO%2'M@?RCL66H MY[UYPO,R2CY08'Z;@2XA?"46;N5$KQEY9A20@$69O=HHW/&P=@GH6:6JA9>VO?D^RTT7H+PJ\-6-W#^UPFD*-J MLC7=CX:W\BF#NN:Z]QP=ZCC7=8#K]A"F-?6,BDN:5WU+5Y1K>&\H#OEA(:]H M2^;MQZ6JY?IQ9QHJDG/1>;FE*%=Q!S2'_#2<_@T[^@LAI@:9 MO;\\EC6E)ZF'ZE+1/GPH?:TWT,IGDAT+/O1AOZ?J'!]S?,A23U:[4,Z..[B[ MY!U2I=Y X0[NEE&E+_4TI:RIPJE2M2=55GM:;IV%DZ7!>X>!6/=N:=J"X-Z@ M.AW<$NQD72K),IPT=3BXQ6%/Y0[N-I)&ZHFRV).5HL%AG#@-$&?8'_9T]0#N M[2-)U\TY!<]@K&Z4@Z6 5%"!ER,2/Y0OTGM@=;R">[8Y,EA-O N:B?VA,"+R M$KLH:_%[H$-8<;$\[^L\^6/;#'JI,'#41^6>6ECI.>[0^G(X'>H2#ZWOYLU# MA0.6X:"!TI.UXW>2M@7;\. MN3.H'N*H2D_3M)J)LT8P5.P.6I[\0'7+?GK^6?A,O!??F(YM4[#=D>=/:,FP M9N$XU/JWU6U[6> EJ=S&BI5A^;)O+FV;^AC2-[!@&9;XN=R84+'562_E3 M[A0\G"^+ES4["K3RLF:=].QRIW@W"DP='>HXUW6 ZRIR"/"R9L=YR\(A/_J; MK;)ES3)V84%IU85;F))%N&2QIQ;VWASWO58YC*K8J>M(NI2V Z-8>$_JR0KG MTDIQ*LJ]H-WXOFE*R]JUE;2\*)FK24-+VK6:N+PHF;YX70218Z/18ZV JI47K_;\>-# MUX<]:7C:1T*QM5-%ZJLB=J"VCRF#04P:\S%S+J**)O4&? MES/C?J#\>C8O9]96TO!R9JTE#2]GUF+B\')F(4\KK' 47FNLZXCDM<92R."U MQMH/>5,F5D6UQHX](Z-TK3$LRE^XL-%Q1[N7QJDD]L1!'1D$]=/*O-)8&UP!O-)8NXG3EDIC&=_)W&2!CWYG]]^WCQ='-WFV-E.?:6SH2_M]/E\*3-[5-09/T'BW%E]3[(_#LA#H%$!#\9638 MOO!J.!$1O)'@,=P9;X9O!0)\PD %_?/$-X.PH *$C&&[R[-2W42P)$\\B MSKF U079@_2UU/!V(/C$]%Y<.'4LP0-I,P>"#77VBN#!4%-8L&+'7UFP 9_NP9CZ6$9@ \ M^SLF7D)QBU'E;)DJ6(QQB2SX'@4A2P]D 8J^Z=0!@8C'$IT39S( %-] ;>/, MP2)Q ((=U%+&L7V;[E/,5BXN?.+1ZGADM3H>NR] 4!#EZ/3.;LT4$0)4-F*R MIOD"*?"#2$GV@]K3-0E>"J;$#.U7XLQZ:W@CWEFG0@IV "# C)MAC*J @?P M\DQXCB438)78@'HF?V+N!:3"B%["NP*@$F0'J';_BER3CO0&[PB&X^!/4\,/ MD1JTABH.E47W?)YH+@FF!YQ)IW.!'/,#\!Q!F0^S/ OL ML/A@6S<5!94>X6P_A>/4*4]GM0 ,,_3\@!881G'I6XMS+MZU](B"PVUQPO7B M8QI^G1 #K3P&AI$\+3#:Z;(L_A(_@4<\U5_F/TF_Y%%\OON-40_7,H%PI<=C7+"M\& M+6&N%6%H<]E?S[Z[(B/AHFZ0/*6J;KE4& M*/#SBNNH#2#J1,K-U"D=N:DME2$G6@=!>E_&U*2HB-4'IE+@%VYL;N&N.2D5 M\6K!1#N8>*&8+13V1,XQ77!A-R=:N2P->GU=[BTIYE2G2VVJ3U[DAH;MCHEA ML;'24CN1N"".+9O.QV#Y*0"5Y]:#/3W\F>V<]%N+I[.R;[&;X_W#MB33,D,X M$QF',(-TOC[\V<1Q'8=8S;'&C@N@YGEF!T 9SU,L9"^7+?G?@$O8'OU*PK%G MP2@OLU-35!\W'4.P4R*'\CO37^.3'P4LY6M@YEBK9-H^: RFX9@1DW//:#B# MB"7X:*R,O,[Q'6\$]N*2-RN9@%GA\1D$Z@1"LI"QB:K(5*<4V &,7P7-H>P M<6GQH!FI/+?/UZI,FPY>!D:L]L;2/X9J1C(8O)$ ^K?CZ5E]>:$D+2'"= MB0N)01'2-Q<^OEZL&>.W'_%&ZNS1''L.*NUK%.5>(FWF*"^H)C(S)J,J"C6H MB5LB(9KHU&:Z)AT/EC39.'I7MHPJ&TQ$*)IXC]-7MS* M+G.N9MJC'?QQ-L(6)-A<9V5=W\X? 2B?$F,&PLVE!IWPU0CA@(85XDLGHHU1 MJ>0YP!+4MDZQ#M5 HH"Q3R+P\1?FM!OEW3Q[62P?VH;]?=('\MQC-IT_L"EX MO,HPX+K;XQ2_SZVZ;TZE,5>M(5=-20C%R;578L=IX*5XHD:EO%I1*D;NI3_, M#W(;<0GZ&SV<:ZE^5#[#HVIC MS&UIT*_3ZO3QL4*A;=2^'*ERNZ!_IIZ+PHP8?GD!6?_AL!3&.! WI]@4YV[+ MQB@DU]HS^4H^1(J15B@!J/(MD3_CJ?*SI@T)7H-ZL%^R2\ZIGU(+O].)GU5< MY=J)\)N4N@M;^K52G$?7;S/3\[!W.PIE>!VN4 ;:^@IG=T"$[CCOQ7!;/ MQ//GW[]"AT^W3S>WGZ]O+F^O' M'"LYZ'X]=% T?K#QPQ<"6Y@"8<^Q%!R/T -)/7P1% M476-Q;#\?O\D?*%WB<*7\_MSEIAAX'UU@+$.+DL=F$Y][SN-!XAOKG_H]S11 M%*9.% B!@3>:H?$=8QO8O26[R*;0TUMLVT57],HUIBRR!^/E)G''DO9+0(.' M;% 6< H_)19EO"#W)-%\>=SX0%?22(^)8^/^@Z^- #9,0'<$LO57X\4BSY'_(EQB M* <-1J%TH&$K$P-V1C19V?Y)XH R4'\9 ->+HDBA6$QD.PB!%9DL."SUO-9G M4%0 M>-"W&V<,.E3XQ!%WZQ!*$T<".QV'9]"*&O,0)L^?@-Q8(+XGW+CFN7#A N V MY>,EY((=.?7P HX%^C"LTC V8[*0*O2/."(,Y<5&)/Z'^%Y&5@J6;=&@6,,T M01#!:)@#,2=A"IHDEP6H2$!2 U.\&!@3)=AA@A.8E;QB7 ]]-0I!DL*BR")V MV :6AF=M&K4-0"&F&#@;7Z72ET6E1R#P8B 2U,:PX?=),)87A:8WH90W07\U M:$I;Y(?"&"@)#['X)^#$J8>A-E1@D!<[8+$VBUB]!$$+ ";&'['LCD^O:6PW MT @^T\0(9Q:SCK"L\&LUSUDD M=P04/DQW.GMJI5ACCM-V?V.UF'6Y;)O&)BVH:^'LR0<[Q:#;BANFVPW3G95F M-QIZ&ZM:2F)I^[,&J!ZNOUP\75\)]QC0PVW8QUX6>6@"=\4+8 M<]GT&"J8O3<0BSVTS=;D2PG]P8_IK,%UZDC&_XQ23A-_7((I\_R]GV1N7;&7 M0!I;O@T*UA?;LF ?]X3+L6'[%*NH0*$\P4P&(U96THLX$9-DC]RJ7BIK#LW, M%)^X25[(Q=SFG-,$]2:7AI<+P^S)&"?F2;V!J/4D56;1^<%*&DGH41@RK(9D M&Q'V\ ^*HO7ZJ!_G7U6<)%9@1?-4OS7P#X;8%GLS_,)FV/L#&6''SVS[_"#+ M3.T:PZ//A% 5S8]H%@G3E\*5AUZ G*AHU8&PWT;B2U),,Y:D?1%=ZBCY8?5Q8$M/'3]/MI]9Z8E-H M=N<2K]FG$1@E)M84$!S/8!(I6+LWC3B!%]E!TGJZIC#"20K+2J8@9!1KYNY; MC/I,:$91;,O AC58>@F,*,%9AJ/AF6IA.I K6&2"WV!V\RRNB>"YY"RVX%V8 MP@\,?Y86;Q2$8IG=!3"RK"\L(T6<:Q _, ](-HFV*73\]$@8(FBBK?+S.ANE M@)6Q>GE&"S;X[ +.#OXH:YG48&C,S8+\5SA;K9%]QELV5\1SN6^[>XQ4_F9* MDDI;,DV">WEW>WE]"Z9-.RH&G@$#4'-Y_D62OI#^CA7IW>'MWA\WV5,H@X4J MCZ3R:]V=;MZ",Y0%]'PE%DW-#%#T4%#0D^F2R$=I]D)_LPA+PHTS0+\]8G+> MA#EBF66()\/8"Z8V' ,!\S=2F>X:S(?MH+0&.%[&6.TF].WGB%J3;V-J 821 M[U(($GU^/E9K:A8TR+B+LR M^Y?/AFPRT3KQGSDFB@&<-PAMFX>*>G#>"$8$ MX>,.JYW^2&]$,^?GDAC;)[E*4K=$[!8/$=IGV3OFWXZ5?3,B5T;;F#OV-,;\ MI[1&6 F(K5C;[;*R6]72JDS"W*/N_A:X%X7QRS:-*HCPN<*9S/MQ;8N$U:2GO-*#;[8/-,NHJG[&.&:M( MP/%?GG^21;4G*WI/[O=_SG&#KRQW;$/' E-K(ZH98- /F*C>A%ZK8FTL2?QQ MXZ:I(/5T S@YY,_S["^@UB6)%,+R!HS:SU-J)5D7F8>&/FZ=U%OZX\6!GX<=G2B0. M_]B;0YGK'TD2V&VFM+F^S.[5"LM8S-6!S2GG+N_.S4TUP#KQ%=P%"W]FMR(/ M-&^ >N97G=<;KN9J65J!(H.=OCXH5+1NE]U8H@+>WB8PG>%B*=*Q-J#;C(%T M2%J=". >3NZEXEZJMOA33L:#TU\V_8[ @[/LE#HE2W[SVN6.6?);;8FLB1_G M^@5Q@BRU(MIEL*F;9? )&)S*C\7L330UU30'='22]'5C]&SP'Y=P2O7;_R_NRDN41/N8V)GH_?/CY>_^W; M]>V3S01NNE8_G@J M)8)6T&#;,BF,\&PXM+%3,"8D;JZ3A/C.^S/%G2JI)46+\HQL%U["FA!!"%_0 M_' *"*T@$*>>X.0(JD58?1Q,%!RS?D6IQKH!X, >P49"5EI %R\ 4^C3\,=U M"KS(L9)&XTF[HGF#+]J<-!%02;#S.HBK3I;?*//6I)W$N 28[^&3.6M(/C96 M_,:W =M3)TF53*V7@G:2E6^>:$.';_RP-3!45!J.P"B.N;@7*IVPN.:9X M8R[?OR,#&X^Q6B79"F#GPH7C"%C0Q[>3XCMGYB(UE&*REY$NO:04R B12-4N MFIP;%ZQ)A"UK1+Y@Z/-ULF#;%E\6!\!3\1T%*"CWON?"1Y/Q 'OS*$4$WL2 MH%^L7,@N_;3EQ#R)V?*FN(]2:'H,@4UIZ]A+SZ)'Y_SHTU6Y)]"J@X'P4U) M019_N7B\%."W^3?2+S\O#D8_"(5X(^'>0P:BW7"-N!ED)JTTFC*!A3LD?70; M"_BFR*UV7+<.\TI9B;^DU]P#9ERC]D%3.E66>9JNDD5[J,;-*#-MK=<5AHCK MX&';MQ?&-_.B.38\O4C2I@+42EK%C808)4D7N'5C%Y#5QY_(3>?]M-+3WH71 MTK3/;F&$QEAHA"S95_@T1^!:KO[HP7]0\V-MT(/X!R$@(7WR&;B>Q$W8)\:, M"6HXD1)Z;R0H V)9># E\=K'/9ZQ=)H6A>G!\ MF6/J<'-#9YYYO0,KF/Y,1TV*6QF862V\1,!E>(#BMEA4P2*C$4N]9@JY/4_B M&T7H 1#>;#CLL"S6*C)PIZ9@@6'G:T[498I*NHCXM?EPSV1QA,;5T1;L/_58 M0;E>+"@"ULF1L(.>;433",;""#8^:B6$PN50-&3Z&"_.S:)GX?)9>FWX+E;U MNB<^+:)\E$?G+5AJ7[!Z*:Q2H,L\WN1\/S\<>/5L!WJ,P+N3IJTXNN@G5KH6(M%%KL8)-89;"\?7>WNXDHH M]5: ->.HP,*M9BVJ6[ "B.?"E>U$B1ZY ^87 !C>9CL?P3-@3UKX/HJ!Z;RZ M:'9^NI6I;9T'$AB)@K)I-#SW[(!6+@%#A/6JQ7./_4I[-B/N:'M6\IWXIAVP M0,,M79!=>IQBA8?X))XF-5@H*,&\)!1[*K1Q!HL\A^?"(XJH.:PT:SE&1PP1 M;;'\G5I,%I,W"^$9>PV>*:E9W4E0<5:)<$[!N/7BP=%A2MORTI)'Z,^@-@$M M]Q?K)0ES" ESI%&?16@LM1D1:#',@,I"&-0THH L>O;&Z$AC-3WL1MS&OIIU M^!46N$5\+A "+]MG"2Y/1)7)]KIE?F-:#Q4.WI =NG-.8XPYK_R4:>9,-YQ! M?5FA$%OK\R;+J4ZY^*+%=O\:IN,M;H^AQ>TB;*76SI]UM:L]\>7O<8O?0LX[ M?%=:WJWW&+KU+@='#2OH0?>840M3ZDS!B\HC[,NHB:S._%Z(V'\Y!T%A3,E#;PNGUB?)% M3>*%%^Z4N%WJR9K<$_ORZ7)[=2CH@ER?-R6X2A@_W1=3N'<,MV)6R&L4%E9Q MBUF9E7&+J/5[0U$_L"PX#FP.]'ZO8#/I@YPSRQF.+$@]$WN[-PZ>L XXWW-; M,#0$?02U[_*MC3DV$9M]1>TIS32*7G^_DB? =T=PP4H.A#DF5N20N]&%&]K) M_=HCUN.GO^],"[&RW/T^GP!7[1QB_:^$T37SZ_:.,7;?RB M;3,;\XLV?M%6,0KY15OUWBI^T7:*#EE^T7825P_\HHU?M)T.M_.+-G[1QB_: M^$4;OVCC%VVMY1)^T7:"%VW5WYQMOINCSWW$XFCWQ@R3_"[>#-^B'K0[YD#[ MC99:@D\7F)C'OGO"I1[1O9RQ6!I+'XT"=KN6NEECF>O>B-ZXT1*[9X!&CQ;Y M8745IKZ-5UC"Q+.(0U/8EUJ[[VYBSB_HCN&";M"6ZP#:4_0KX[WK5=ZC:^&W M6FVZO>&W6L=PJU5ZZ5AG]&R$S8YIZ2X2A()OA''[HJ-RPYP565*9B7X\/MQ) MYYI\)I^KFYOQ-(;#NLW0TJ!??Y\2$Z.B''M$CH\5"FVC(_-BGO?/U'-1F!'# M+R\@ZS\7XL*6 ;8'PK*RT/ORZIUR([C3CR7Q3/QO#M7"U4X_I>O%>ZPI"L\3<+@ MUG/-R/>Q:F#Z=N BN!NA-^=,DL\4Z9T0N3;[X=OCU3O!(J8],9P ?_PN!!\@=JP'KOK!2U+SWRSZ]7[87A%W>IAM;KZCU M]X.I"-(OUQ>/UT(.:'/(!^<8RU4FQ:GCAB?_(:S:Y^(2+ZZ73D'!@K%Q=72; M%8'>4,X\VP#&6&IT2R_G:KF3J_'Z+0?'-G7[5E1AKJJ#:DT7?USW8[U&1&81MA.-\,! MO/QM@+PB9MD9$)FX[^4?-_3*7GR=(V9RF=$N8^.%]JKP\@8FKSA32S7X5*57E_/F^K4!,8Y"8N2<.^KGT;:WN]Y7[@,F5R) MPK'?*&N))Y_+2#W+B\!HJ8V'=D_=^.;GE&F ,D7W=%%TUJTW[*MB?K&-9[P( MM-L:_<7US(8%_Z&URVKTD8,I(:W3'5OA23AFJI0].AK2 7/GX'$]@VN )TB9 M VB U=V\;[\;7G^3S!XZRB:>;&D4BI-LW)F^T<2VBIY+V'VE)3Q'MH-\&R1M MW2DH26MW."ELRV#U0+%AIF,$@3VRL?]BD+2?!=N!W7W2_77FC3"?,=,2^^'N MV_PO;(=M4#\V34-<'L-9V!\ $+M=+=8R.G/'>B[ W.GY5F?!,J>I6]YGBI6X ML7'<,Y*"0>.XA#@C,VX%/+%=>Q)-XE&G++0%$/-*6#8F^SXD_@0O>UF[R D\ MP[KLLO["J:[=Y+M)"&TY*Y\)7-06%8FB>NS K0.K.XP?AWDJP1FYL" MG=TP@=EX\0F=]URX6\(Z^8Z5*6A/U!0JL!TGL*-O4+HZMLL:F *&[ UK! 3; M0:9@K.FQEJ:/Q($!7GK"9^+"W Y]]L)"!.(,M+%H#,6I-/C&33EON/T&^VG1 M>!IY(L+NIS"&FS32_:OA1H8_$Z1>W#<^O:N)PR)Y*:'GC7:GOF%2=9#BUK(9 M=[KSYNQLC'FK]K$!^WK1A'K1U]J+? I"GBT'.'B.@+=M*]4D>\.@F_;PHME[ M7)H8-N(8>"/IH8MUAAGL$^2O ' +4LDT@-F3KMI&0'$1LW-2K'BG-$#,+\FD M8&WS["UG9G*\_O;WR[MT#%PTC?MQ&\Y'AK%'1-B-"Y-.:.S; PLJ>?+B _LH M$M]Y* T/I>&A-#R4AH?2M 1U/)2&A]*T$/*F_)H\E.9(XS!X*$WG2"@-US/;!/GA!/^AM4L>M,%#:3I%%1Y*P_4,K@%VGC*=#*6I^/9N MI7I$)C;G ?%Y-_H6$.J87%_%8FT5B>^!_<&U'5"5_(B\$]Z7GB=/M0I5@9V6 M*E>Q;8[M "5*\NQR6_V."E:>;Z*UA4*JGZ@TCI2A@TB.'*"(UU*-@VZZV7GG3]8*N3PCYT MG.26.>]4(\ S2<^6'F69PM>#?6^*'-T(;JT'-PEBP-9JDI\[8DO M:@M>PA>1@]HO/,\J]"41U;SLWKJR>[L[\VST(.2NA(DOTTBF8>G:>XV">WEW M^_CMR]/-[6?AXO9*N'OZR_6#1P>CA'%#*_W>^ZU&!K MOB\I/+3'%@V7HSD)H2=XON"3B6&[+$EAY/DF$:S(QY=IW@?5*(HTEVIJS.@I!=LL#5%/H!0WW*1_'?SN$Y/@ M(G_HT[=AU[&L)]8++QA37+ L#MRL"$TR.CR1Y(0A$)FRVW801)BAQC*NQO8+ M'-68_/&#>"Y+\S$-..&,%T+[Z)%Y_SQ%%"QC%N"W^(U'!T-G;X^^:!''QO<0 MA'A\P$R"!V( $4>@21B.\._(\$'B)%DZ:Z@!"HY'U058&D[HO=H!5900E@PQ M4Z@RDO7 \_$E,"[-CD4=4F6.O2!Z_A<:D=A<&TYS R4=RUMS;%")+#N<">25 M9MG@VCYZF(AD3!$2PTF3'Y.[@B2-; TO9+8Q@D$78Q&6@D.^$Y/VE(2]X +& MZ>)#8DR2$6-"]N+$L;D0]@*;:8[PW.7U74^X]TF _49""N_E)_CJ;>QA_MID MZG@SAM4EV8],E]XQL.VFV&.1X+>S.5Y=1/$DZ"\[\,H">J1O4/8,)1U<9@-1ZTFJG/271YZ)29X6#N="_B72'ID;E[?8TQ2&U"K3[!;+(@!O M,.R)_4$6O(7,6I*65 ;,,=(?R(@1_,QP\H,L,Y&)&7O/A+!$6<,T_8BEYH)L MN@+TLI7$I\?QL_!VY60]X2DT.SNE]N)3"^1TY"/G4:F*0[&V#U^)A<923P # M\YR^$=.55;>G[=[C U"8)Q+_(-+Q?Y"E0:^ORVQ+ 7-,V=GO@$2DS/_BPWQT MGV1YA(X'AR:]@,1W&)<*A83'2RXR?]S.*WA)&3E<734"AB79@NA,* MJ9P3$B:G9[!XC?YLXMB.0ZQ,KF1^LSE/RV#<4L0-J'Q.=PZX0&S!6=;];,F, M^ASAA\>GN\O_$>[NGV[ 7F1F1U2_BEQCCF.;NO56'K282NJJ>NR]84A^3AZI MCG.7,M H-_Y.\/*?6!OYLSE08OU^+21[H'F/4+&F>:Y8*&"SU+B-Z,'JC5K M&4P%JXHQFJ-;S7V/P4[S33N(+6+ZM2^\G\..UCG%7&$_:Z6;JF3[RZ3E9!F, MW44AK=M!78VKBK9>T/U\R&:8-;5CE'J*3CU"^Z'B()TI*V",?;/J^C4UQ3SO M*S40H*)-6U];R\^Q(5-6.M62NE)F82?<=KG\TNL_:THO\CH^@3GK+-*OD]MOW(>+F;<5#A@+4?S3X-"^E'I^7[FU-A&#?%<*]1*M1Y2=."$ M6C)]5CWF3?+9FM2H2H>LA=QS6'J\@048>: M**7HFF_JZ@ NS(<#7575_N$ +LJ>ZE!2E.%!$5R,:X=#257*POO)\PD<-2SQ MT)P]^09(7!-Y_8L7!!_)"'Y_,KY7P<*R**;0FW/B"N$MS,%J.H>A>7B+,G!? M.BBX1?E7DOM2:7A7L[1N7 SW\WRL=%T!TRHR[+(%F%OG*PU<40[5^H/^GK!1 MA6KL.:".!I@\$LYNO9!@BHCC!9'?5)#)L65[; ]\*7^!.6@@!:3N-5S_[=O- MT]]SK".'Q>$<46C?4O9,.G020]+8)WKQL_YB_S@#'M-QC4E[B-!+N66R08PK MZ0-)9"'H^+WAD.4>2)K:Z^MB'*C:$[(!B>L3AMPJ)VKVRP)$ !QM#S>=/"%=D1'Q,WTG;O32JLI>T>2#V M-&EU$I DS-8.X%"(7XWP]?&6#("7^JVUB/QGXGV#%D)\+%P%K?[(26IJ!DW;)F!&6&@/(>B9QY/#Q M!^WFXN%4%#9#T?I([%1VA9^0'7,X7(Q?)<)P4VSVNM#QK;'9BV2+5,3Z/+9\ MTS+R!),+Q0+)D_CW*H/)A7D@^4E&D2\'B^](!EP1JC&E&$XWL]2#!Z.$P@4R M1."Y62(-59%^83*^,$#K/Q'$W[EQSIL\3\!8@UP#F/0%-LJ+$:920"1)Z0V5 MP8X4D*2Y%^9(.23 MEMQX!N\D!X8__[=\*E2@12;1KXYQLJN"LPD]?J#%'DI M$)E$D],@UUPEFR,*=8C8&7UJFACF6E@$Q*ZS2*Y(79B]I5#$F#9.H<"T22.( M$YB#YK*+V\$Y^"&5[/#[QU3<]D.95##4R!X"@1/@6@/S_$4")X"P5,@ M> I$@3=K2H%0>IJD]71Y[WY$/ 6BFN >K08"5+1I>0H$CR/O8!PY3X'@K-M1 MUN4I$*T)NC_4=N!8[-RAP+,.FK9&&MUT)YMWD-=7!"L8XE62"BV75TGB5P1M=BP=Q=+K/VM* M+Y)?$7#6[:3$Y5<$O$I2EZG!JR3Q^PI>)>ED;RL:J9+D'-MMQ:;\3Y;6]!9[ M@L\2/RP"P[I=Q8T\0NR 'AF.X-@CFI&T*:-DWI###@3Q7!FP9-YS31)FQ/"7 M$GG79R>M1T>N$E5Y*R:L:51/DZ;H +2\59"6GFM;K$K2F:BG:C^PU]+E'VYN M/[W[55:UOJPK@TP?^RV3+5>!H+U*,(',)V/B!H"W&]?T)@1K;MR2\&Z4K_2+ MT ZAUF#)A[WB3 M?]XG^;N7A\?3@4'*@Z6K]F&I89"V[;HG+/D2^;.6[;L#@K4-6Q<6:Q!E./>& M;=VXE\;4#@VG/7AK!8#;,/B .: NL:X-'X_QH#VH.RQD6[G.-*,);:!LA%VK69DD#>3#+&X-V;I"A+I02CO;W<0]*(.X,&MPX5I) M&OQ]W";PR;L;P7FXK,LN(%93$ _.%#&_5I8M&(<%5_> JH$%E52?&H2LH,K2 M !.44!$:@*[00;R\]5K+K]6O[*[MN:9JBF2/(Q1L7;HE3+5$7GR'@CEUGO##VT2L'JF(2#NUG--]L>^ M$$FRK/3U5 G=G/.M5M-^#F_< -@22W!],DQR,<%26EO@2HZ1Z\CW+B9 ;M.@ MQ46#$(>X]/QI#H&HB/A/NL[V>CA6RZB&!#@KO#=FZ$B]W(G%2J"5!_I@,$A7 M5UT'Q7;FO<)*2_GX/C?LOS(_H0P:X":4IJ<_&*!S<73]/:3UQ9*Y M%NN01?1W*AM98]LZ+D J6+83H<_WD9CX'&R#Z^^F$\%<"#X>&5%HX"%^-TH. MNGOB4WFUAO-S%0K>(#^'(#0T*;5%*P&OL35OKS^\:.!A_)V?_DW<=EXO90,6!_:'JZ0<71H >$%@BK"!9]Z;GTEA[. M"3@VO#VP)&NB-E24(\32W!)E*T^AZFD?1$FR)HM]^9@0E1R824'@3!^<>7<< MT$/P;%PUV38A2M3Z0U'O*J+6'$TEQ;2DZ%V6TUL0PN7T5O14*J=5$-,#]0BQ MQ.7T+D35(Z<'>A]$=D4"T[>G M!1JYY;>I%T7ZX3G76I0H1U"%-P,+*3,K-BZUOY+R14.2\,%1Y.,:=[TP/,]C M]:;6W 2BTI758RL^_N6;&R /$NN+-S]I?[V*"!:0, M0[, *R[PKQ\8_NQ@"Z;W98L]K*5X.[W@Q,-ON,8++5+_Q9[8(;&2U7Z"A=!: M^X'P1GRR(# 6,S?@!Z1Z^(89[0)(R7 0 MQ%U:<4H]81\#M 8P?5FJ_&B[WW!RB^?R1E?L%OC6+6SQ3/PBL19CL>EO:)< MJ>HCL+AGHAB\RZN]=(P :!*;+'?^ P8+LQH!=Z.%OG-I8%+1QUEBVL0/!A40 M=Z['Q6/G1H0BZJJ8ZK]63VXX'^#@?0SII3)L5?@!8%@G5PKR=@KJ>] 7AESJA-K+&DR-KC&A8ER MY]LOMHM17,\AF*QH9]Z-Z!_&["LZ;"YV#[=M;[E]Q1SJ9[7)<9:M_4U M?3IWMLP6ZT+S%JTVKZG+INX..??\6]54MYI5>^FYJM-PW$(X+7/BK[/B4U4" MY9T3^$\SZZOA53]5"ER6CT@58]CKC]I[ILKOV'FZB:RROG<'W91)7PFAVJGQ MR"QR$&H(SKKD2_HI_W: <:+(T#OJQ&1(NC''S9C35%BW-RI<'Z@&>JT(5P]8 MY9*B!,*#P4F[?T"$"[:]:+ZL>B]GHHP]E\NBVB_#T(? ,W]A4P;E+HO<'AJ] MSIZ0)QE0B/M0PWTHU.5ZF#KCTD.GU#*G8:X-T;WMWG5$^P/$]%"([F'7KJ-X MTFLB?O7MUHRH0G>X^Z)6C.)] (,__6R.>;7WP[<+IV]_T-XZ'KF.R1H_Q$EM MND9TAJ\()]W;A[6\M[.EZ5NB7%+BNPDH_>MN9KJRB[I6HD@U#C@3U:)N5*&H M=TF=*(R.E;;M?KGN?3IYKS%%DY#(I/!X,W#C5>"V!J%3GH[&'Z-/QF"5E(\+ M;6TL"6: @&)]61.H9*^"S U-Y_ 6:=2/ 7%3J%3ZWMQSI9(L0+[]_<)-#K@] MP!S7GGYB4"]LWQ35 6N'FSRPNP,=%/'DB@1,I3&H>1-EP+K';;1GM:O?W:CO[[.R_ &?[@ -G$NW?M_Y5:T6JB0=M(>P-Z?9%S0IWZOBEP2!?L MP+NE=S?SH@#TJ0]TUG WL^A.J?!E1M:!,>B/.CHSE,>D;BH4"-4]4Z&]&P%V M5IS/3=NG2_7+?_ MJ"&"OQ&>PV)>;J-A2L/@TW=,C=3>^>6Z=SC.J&L3JIG>VU]MB[O6TSBPLJ!N M!)F*"P)_-V3ZW7-@&+Q[]+3X*0UW0TA5BQ)DP$G^0KPMU2 @WO @Q"/[1BL> M&8]P-<6Y3;=T=X@M0NV5YZW*J,6Q#67>%8*Q)X!SF*,0X-Y)%8 5,]%-S3,0 MS< DIE/->5F:9YU/])#%NI5LHVZUU$AO!>^+E32)Q#?\DU8$B:\"U,\!T9(H- MQEONS&_IWB ;F[YTUO@>;]1G.4IU1:'"I&GG6,Z+-]R*)N1DK!/L85_S[VXS M_>!S4:JS= M73*T?_ EJQ.O%3.C,FZ@S.&A*LPEC(4EIVSIH(2Z'DW_XSXH=:L: EH2-ZC= MX0WN=5NR1!6Y(CAKP&GX6#CI;H<]X[1IG4#SKFF=C,?!J4!4Y*_3V81\'(#6 MA-M?<0N41:LW.L12I0J%[ ,MH]L8M-8Y<(?5>B1A<:()B]),^!PW5L.%>@%. MGTPWFF)U E_'2QW.LO?:$\4GV5(-QZ>H-5/3WPK0L];<<=&E;X>P-,]KMUZ=L[/D6]X\FGN.8BX"_ M8>K3JV06G,!7;U-?DXGI')F.?0^@A=XB>11I0(];*Y-U>HMOIVP*-(")C47( MWL'K8]]NL5^QLJ05FJ*_\+*V=.'F (XC!I?#@D$8G?V MG ?LDB_9C3.7Q_C!."9*CF.:XC#Q'Z%5@%!C<'A[=GMQRZ[. MV?7-A]L/EW=G=Q=7ER70HH]^:G5_)OY)?;6H"MPIBYFU '-SOCC]BS%HYW+R M?N:]FW%FPEZD(";NQL@U(\N62<&!Y]C8ILMB4]LUW8EM.@1/@'6FR17.O"G[ M_6'B^>P3MY#[6^S"G1RS'[%9G$!JU.FT3V68-/[&.,6^2-H#-(CV\T]L9G[% M9F#<90N?+TPPNYCM$K"^!;!PMK3#&?TM! E!MO!M ',!TH[=SL^L4$-C+S,:@ASU/: #?P/=S$G>BSQU"@B/; M=/N<8CD!P1-Z[!P>A>4Z^A<]>H9" D32""EWP^\C1PQS>_0?_ 8'24I2L0_? MX*AQ[SG#X+,=8"7H8R#P&A7"F1=PYD>(-\[BQP,+,"8@FTS ?A7PJ>>%V,*- M678P<;P 9'W 7'P$Z0:DI.:*2+=L;F :)R3KY(1TJ?!D@+U!JP,]>-8!Q1O9E@@0D5 MJ_Z3^!Y?I69EHJW?&O&/'U=4'5)$5EU7P:Z"9P0A0U2NQ%K9;MP045#V%J63 M(&U;-,.D!Y'&+;6&WL)VD2=@V'G<#**58EG30K )B);8]0"K'9"2Y;FPG^%= ML;>!VS"ZC#_H+S$7ECC GG2BAR.;FK:/TC= 92Z4T^=Q5$(,F!>(!8\+,.#] MR!%'A2>_-T!#-B=?[GTX?2W4 MDCW_#3;S#'E:&<,/-GXXDR7Q@;:H\=M@B:BM8K*/'O(BV1&^2RC8L4HV+M+O M'QNMIZJF92A3)F8KXEAT'&J[6G1C58O$:('N/6FJX0*)S:J>!EL8Q1"&G2P& M.D0 N ;PA5A>.Z1?.:5%*GE%@@?V8DC/X^[[H3_LMSJ&$>^ETEL=+=0] M)$(03:?VQ,;PV\(+;-S@0AS&TD:H"XF(.69G!$7&%&$*4Z :6WK^%R*&:,T# M*HB8;8("-F&0'WK#;LOHG+1 CBBX@A$)3-7W8#8YLYH#*'I+!:'4ZW59_ M=$(@F5(B(10BU4?(5> =$VAS+R02_.6;-OP>1&.L]1"B#+:\:!RBBF7Z-+47 M@0PKVH(9*USAU(/YTBH4D$L[6G!*GT\=D*=$45B7 'N LFF$3A:"@E,BBVH2 MC$>4AQ?Y)GP'.<_JI":6GYL/BK[(#T)+ MQ:,V"F&GR4/!#H ,4GT.'YZ_6(_%C6)Z&WM]@[H@U0C@E 4HYKB@YF1F<[FW M?.%;8B XEZ'HVHS,*_/:2+'%W>>I3B924* Q(W555':EKE.PP\PQ, 7"9 +P MH*R2\0(R@X#XH=MNM]KM-@*G]^1A2>X+PZX\QRF;3W]2M_U:,,P]IR-?69I^ M1$JUR(&C_=H9C%J#P: E^UB#,!(["J@L6OR0G9%ENX!@ *&,:))8YJI[-I'8 M%46M4 ^: .&$&H0R2XA36VQQV40;'_M'!.+2$",;QP3#W:I$#SC_ BLCIL(Q MD4XD:STTA4P'K,CH?@9S((%Q-W]QO268(3-!!?5HW*T[@5DJ:%2/F!3?![&E MU4S'[%=O"2SBMU("=(,4A,C Z'X@7&],5G&Z U$5D7UEYC* M8:WQ_S2B^CUJN1029)6""#Q"(I#%#-J^MHYD#HJE9/>12=>DN91R=.+#3^FC M7NB]. ?0@*>/>5P?,B@ 7F(E83W$5),T >H0E23,&> 0! 2ZA\^458#1YG# MYE?3=FB)/%?Z;\2""1:#LRQ$FP?D!W";!7/C/L Y86&EJA\/D>8YP(,@(#X# MA"TXDPEL6$M80)0V7[GC+4A:X-?>?(Z%9$!,_B\^2V"I4+0!M?$)3)%F@3PR MD$4US2(1W(F_?,T'OI9)"A*9SBXW3!ZZA@,8MD1P![OJK>--OE3RG%=RA)<_ M3*JXS#=YRV,W>'E_[YH['?,!;+?\2/OV17=V]J7=Q^9%=7_UV\>[BPVW3'>P[T2*MAZ5P>SQEL);5C.WQZ]A3+KQ_ M4S2_I9(/DBO7"'^*R#_YY8.#6*HRY2TR98J%TG<0Y8=K6J2PX\FU!(7$>3@" MM8\,Z3$<][:)V>@M5*[,W^T@=NN).(\)BJUC+O'0A6$7GCCW?M(?9Q_GXU_Q MR8]P>)MNZCF:^);:A=R2BL^9['"++WS^Y\J@8S!X)8R":]?@1 PU2$4T:L6> M01T-- 8?]7ARDK_U)B:[,4-\X?PW,+U!*0(%'LA/P9Z0#C7QNJ(D*!6@O 2F MB/4(BB NH!E,[93#!73<.:Q/N!I'0;7XJ?+CT]]1ZP(1,Z1DK$K+3KCV/==# M#X!P[K](Q09AH*2BVMJFY5&85UN^6ZQ]BJ7$8/];B3MHU.NT&%UM3,=_SV[? MX6^I$+!T2DQM'XPV*390RJ"&G?+2Q0XD!4^T$.(9Y4&0J/1:S)HMI%)/?D]' M 16L;<\9C=X2P4M%,PV9CT1A4CL+3TX*?V*\/ J#*D(#8W/3*W()HE?LG+A MZ4FHXB!$2&GJ2)(HMUS6N-FG$H&2=3*]2+V#87 >^SGA%_(GX/]=>$/GR93( M(WO:%I42QP_$ ^?QHF;NM+<>_ \-8Q$O"^0/+. A/3F&G2BUSM@/2\:LP3108S T(]3BNB(ZCTR,"GL@1RP[3H"R2X M'"(#MU[V@H3<)@54=!1Z_G];\&:&>* 3+%,L;5! M7*AX%@5N]3@*G>D^6E!'L',C^$-7:&ZN/NO*C SW4=",)-C*.'J,K"!Y*,<, M3:5L@0)S]9EI1$"G2$"TD8$ YVU]C*%Y4L\,+BEA=6L(^3]0&5"8SV<87(3Q,)8L M\)\CS^NFEM*'S"!.*KAW;67;E))02/D5.?FR3YJD]EQR87K_AKE$UR ;J6;) MBQK4) PPY#D1D5^5];5 VW FK$O:T%$H3$P+*QK@7HL?3408I2YA'38]?!XH MPW0I.X 2)T+* MYL+(_S&[14,TAM5Y2,@A(4(:BJ0X*>G)JDS,Y"0-@-+&K&C"]73!>"&.V:4G M!Z=33*6;D9)-OO>Y:7&5-J&8@RGFT,@NSQN=J%+]%8L0*%T4.91/3%2SZ6S% M'$KX3E&5,G:TUH[C+6G' MTAXC70(T!GEQ(]FQ2NA,X[U+*TQ"0&6LK-[; $UMHNX'8?91AD1*!-J;ITK* MBLR0)++HB2NKB2T2D-R,E#AS9=A_737O)(8D-YEE[(6A-R^Z_8DS'@F)A(\[ M5IJXZ(7D?A9YDE2*@L$*7EP!!^@!9'/__JKSJCIHJ73I6J![OFBM)KXTEWE. MF=Q81P(2V!C'?77->I_$CQ/(U+QO'1-$),W.R!(D&-#:S<4F$W2QP>OAP2= MG=&>J5.5E;.NU/CWXQ\[[5ZKTQVU.OW^3R5NRO='K]-T M(=3E^]?EUVVE1D >+"5X2@TQ7!F#G+@TR%#DL6\<87<@FDH!H]4=[8D&=;#O MOY,;8=E$R@3IW\H" (MD(:N(I-3!-62KKLVV"Y*]"-W6T!BV1IU!J??*S/>\ M\'EL09@)W7L^AO,ADGZ V!2W7ZK2&[6'KI-M])KS5:?6&)ZWNH-<@ MWMI.2ETG3HC8O?1DV,IH=8:=5KO?>29L53<^AQ991>IS7 Z;J7ZJ3._$PK"S M9#75MK)NLTG%WE[EJ3:RS@#M8;]UTJZLU&\+Z',EYQGMX7[)^"A2.P=2 M]35"*9Q9PE.)/72_N]4^:>'U^V%U3\'+MEDE9+_;:W5[>R:DVCCT45T)T[I0 ME+H0F=+L:^9?NEC%XHJ:TE%"$NT5:_ UO* MDYS:LMD./RH2RE*4VEX;CMV<1F][#7N+$S7KX"PI(NN(-PRVB#=0W=54K9M: M0&P$;I>K97SJ0JW.>$K5L[L8[OHB!!4)7C)"L&5XJSI:+V0J2Z;O@9D/$ Q\ M0CQ\@&#@"W5>>.>PO/,(NMTVU-Q%77V9<1\S'BCCH)N;<7"9Y!7+Y@GR6H[1 M?IV[:1H1@E^I36?Q?Q]=-IL+Z#W M$[3,9ZG,B=9%YF'A[_2?-OQ&?M;4DX ?G]DZG1PD72N&LM1_AL%>TU4+R;>I M#/321&2K5-Q4ZJZ.E/S=R?6(5S%J -:1=_]45SN"*VEME^&\'L?8[!^UC=6: M&Q PJ,/%5&NR>:7!ZDSS/PO9UCZ^9T,!O2KU/@GPXN%\\5*]>*F:XD_Y;CPX M_573[QEX<%:=4M^3)9^/>WZ";#,M^>(4[)2)'Q?O]6-%MV$&6R]?!G\'!F?W M=35[$TW-7GL'4S//TDP9F5KR7/4T*)5)]?L?[Z[>"%$)+\>"LF07[[*-K<4$ M:TV&C;_]G#W_5M"M]7IN#G0CC7:E.C<_-G35^DIOAJ[[."NKO 2)@^#@Y#,Z M1UVC!@ [!0#^[>=O8]^QW^"_\.?_ U!+ P04 " Z-&Q/4B&I+S,/ "U MFP $0 '9Y8V\M,C Q.3 Y,S N>'-D[1UK<]NX\7,[T__ :J;3=*:R)#MQ M8E]\'=NR4TW]T%E*E^?7?!A_B$2-DYJI7RP9& W>6^ M .PN0.CCOQ8SVWBB0C+NG#4Z!^V&01V36\R9G#4^#YKG@\M>KV'\Z\>__-F M?Q__VFP:UXS:UJG1Y6:SYXSY#\8=F=%3XQ-UJ" N%S\87XCM80N_9C85QB6? MS6WJ4NCPGW1JO#OHC*C1;):@^X4Z%A>?'WH1W:GKSD];K>?GYP.'/Y%G+A[E M@B![<6'=OMMN]T^+H=^RZ09(9\ESC/\BMAMX>C_LGO[W[]X-''Z=/7B_>CGQZ__7LYF9K6PW_8 MI?>%?S@^O/K%[/N/_"C-*9T1 VSOR+-&3)W/1P=<3%J'[7:G]?/MS4#!-7S MTX7-G,<\\,[)R4E+]8:@&.9(ESAF MYR(X0X M\+N6WYD 9;F@QSXH"T$MFH*3U#R8\*<6=+30!YKM3O.H$X)[LCDA9!ZAC(D< M*=)!1SZ*X#:5N3BJ)P=)"C<+#XWYH$UW.<][0-25@^9PQ_%F^?JW7-%"O!8 M-0&*"F9&>.N1D@@@90%[84\.=SA"(X2GI^=']7DN MJ 0R"ND&&@+$ *0 ":0V/;L:SHJ57)2@(=3XQC:X(#9.*H,II:[TE9YLTFOY M$%2+:S0SR+0<\_]NI&C?2) -FFU$68'-TG M^_6&.-K,$,:;Q$-VUS"1[N3]&$,U0:?4D>R)WG 9C L]B-X\;W7F61$V^-A( MD#:0]G[DQ UT/QZXW'R<7*2,5@ND-]:Z4H=!.#J]$#G7. 8_43Y1)#Y%*$R^6Y98+T%.IG9PB=K M1'3_:<0I[Q-AL-/5-X^Y01 9?-9K^3"M91]K9Q4XF$(FV<2*IH4I#.0O<<YX[H!J51@ 64@4=>@ ],I_FU9^C)2J MHB6([; %'.G9J C0[[T[I>)\(JB?SH2#2U=-J(LFTZG6;31HC?,,GL+OZU>7B%=+V0XS&>M:\_AD=]Z)%K]Q,ANKC[K5:LLR2F&4JH>CMDDUKR]=G]L;SRRQQVR1: M]*K/)+4^[EZK!06:Q!#0@NCUGDEDBRHY>TLD,J"X_O,Z]%K/)+ )$GM5YVR# M=JE+F"WOB$ E/='"_=(,H-X4Y?9/C3NPYINU9U.HYERO1[L==9GLNM>ZHBR=J^E2H"2C0=HE$XG6?I_>5JKN] M"!%P%QP@ O[\\RD83QLABP9SC!B3"!NP:0"?_E&C.17^W!RYXNXZ8#R;R9\7 MM!!Z(^LWF_<308$=F@-O-B-B>3_.T7W6*'IPK86.,F6!I(6PGJ9HXSC*-][> M9&MMD',&=D-E(@MB -O/O??.R!V_ !S+&T-=DZ&W"]! M),;KZY'3NT!^.22U>,8?GCPWGI._K-*R M7X*KVC8VBB\\R1PJ98 ILT:L9/AJE/5>D2D"5?&*Y'01\A*2D+D>M/>;M=8- ME_D5P(L=IA1)O:=DRU;5/&454ZR@]AZ24\[-7Q0*^O0VRQ2]PA+O?CI/*3T> M3\T"JQT/\<'ES%2"E)OHTS1 M26.C@/#>1$7;)@4Q;DE@O:&RATD*MU+V,]XZ0\6&S+F4WLQW[,\R5<^5$'7: MQ'QL2G,*U*0_ /J"F1 "W'*+VLD0Y0]ZF-91WF:/M10Y2G*,QW@SD+E4V5AM M6O@,#GP&@_G "%@T%(_[R4%W.#M_@JB"H+=]IMRE/;R]GRE*'N@N,EL%#+W= M,C6J-0>^]Y8K<0@\WVJEH?46RY28B@^)[XU5=,RA<%QI0/1FR7E[)7'T86^) M?$LD]KFSZL\QS#H,O9WRWG")V2F]LYUGP_\CR^$?#!L?Z-A0=XF=XH509PW) M\/*X1M V%71\UD!C-L-[FGX#T0X6,SL$0=*:N\24W=/:"!X"B%;(?$C 92ZB)\ZWX'/ B5JO(;)-1E5%!A1J?T=9;Y#^JPJ)([6B MD"F'_4ZBQ@^2O*; ,'2J"IP<;=])WF[TD+BXP4UHK=55:,'W]'5I'T%P+ES# MR=R]IKOIS[^C\(:;BI0&!;\U0[PF-C4[A\VCSL%"6BM.JS"Q4D,U)D*\#9C0 MWC>8QX4L0L(/S15V60:TMQ<6J$$]/Q>Q16U7ABTOY"9[+^#F["A:&_!3XDK$ M,JX2Q[SS$=%73M!7.L6**RWU?RVCAB^*6YHK(9,YX0 M>!M5]3&4P(R^O<1_T_=TEG+=$,EW6[RY\V4<;#J$LGRL&3_!%9PJ4,9K.W\[ M-TUOYJFD\'R&NX:_J^?=4;",)JYV'3_TD MN#Q!7@ELK8@Q#6F3#@+"KR2$G=(2SS=BC>&I@ME0R, M OQ8P#R%4-U5?,<,EM>WL22F@.SS#Q,E7N(ID"@%LJV"J7VWGI3 >=<3>"Y= M\:1NQ+[FXH(38?DEXZ!:>$WQM1%?Y$V1URK#\L+W_K="&VI_0VZJCO78%?01 M%UPJPJ\@=I<):KI3AKTFQLM?[-ZF?NB&-5U"1;H2*'KXJUO<.\DB0^R&9:B'#K MGL6_<<]%4?"'9KY2U >D14^@I F]6E!A,DGQ2$64/=7+0GF[!+,E3)7SX+W' M/T+_<@/I52 D>XX? ;Z*#;X[&]67K?\!0X1"UF^+JIQLO3DVT $D06,*S/AK MZM5BSGP17MJPTM!? 8@ M,#S-9&"W*?*V!K5WWFQ$!9C'DRZ?41%E''D=&Z83#-QZ0L4K<-L7%#(WB]\@0_5QN#Q.DY3U2JT[.77,R3O)> MJUV6._Y$OC#\U53[O;PLEN=9"U,Y_;/GJPWR59+VH MLW:NP\+)D/<]84XA)HLM64D9RH'6+E&7CN [AHJ7'(:E<'%?KN>XO%"P2ABU MRQ?-F7YE*\;RL%C$JDBU2PG!/SP!5GUUV='RFCGX957038I7&KIVN?K4I>)7 M L,'GNFEC)3?5SO/UW@T!4A-*;&""N4M<8B?S=VP&?[85E*22ABURS>D8H9W MOZ16FW1K[7Q^P6/D/,[V.9]IKYQ5/JE#U(Z5^Y2 S;>@ :N?^:@%KH#.A M!6.PN+MVSE=!*)8M9VI:3KNV%J1V"6+K2>%"LSW<%BR*6[@2=L.B:6S/*EO& M60M5NQQ8E;P,SNYGZY69GMKY362*ZU;WLL"U2W5+($T8/O/AE'N2.-: XN\N M4>K YZOQ&)R?/='SN6#VO4/SX-)STFN1JUTS,>ZN<,M66S4M"[QU4H'**PFF M@:]=MG/X:JGU,']0:OIKYWVUOZ2KB7:WK/89>S>!I<.3@K[:>?[L2&IZH,P; MGG;V_*[:.0[*((A'["Z3KF CS\4R6DZQI!BJ=CDRBP-;X'RB#V2J(M4N9=&, MV5,W0\#R5WZ2S4>I7<*K('J/'X-)17 ZB-KYO^/A\8AT8I)IKYW7D",(EU+U MHYR.VKE]X, (IJ-4R/1.?D%?[3P'X3G)I"%Y'?5S&Y@=IHQ\?XAWU,YM_!VO M,DEK:?#:)1M,N7!QXTV]*E 0<*X#JEV*R&FF(EVER>^JG>-;XGAC8N(9B.R< M6-19.]?A9ES^%MWV\!E78&:&*>JLG>LN-[VP# KA$I['CMX=/ >: IB.IIA2 ML"3X%,JT\2M9+IXQDR+5XYV!I%_-CRK^R C_\% M4$L#!!0 ( #HT;$^Z84QWY0\ !*[ 5 =GEC;RTR,#$Y,#DS,%]C M86PN>&ULU5UM;]LX$OY^P/T'7A9WZ +GV$[2[B;;WB*)DR) -O;&Z?;NOBP4 MB8Z)RJ)+2DY\O_Y(2G+T0E&4;8G,8M&7E#-Z9AYR9O@BZN.O+PL?K""A" >? M#H:'@P, Q=[*'CZ=/!EVCN?7M[<' :.H'G^#B GPX"?/#KO_[Z%\#^^_BW M7@]<(^A[9V"$W=Y-,,._@#MG <_ 9QA XH28_ +^A]P\8>)A\N;_9Z)V'X?*LWW]^?CX,\,IYQN0;/72Q MGKHICH@+-[K^^,_E&!P-AJ>#T^,!& Y^![\?@]'UW>'+C!DRAA,#A[_^%L&3AC1S0,'+S\/!B>#P>!#+/[11\&W,_[+HT,A M8/0$].R%HD\'&3.?CP\Q>>H?#0;#_K]_NYVZ<[AP>BC@-+GP()7B6F1RP]/3 MT[[XU[1IJ>7+(_'39QSW4S@;S>Q?D:)]!@E%9U3 N\6N$XI>5OL84-F"_ZV7 M-NOQ'_6&1[WCX>$+]0Y2YPL/$NS#>S@#_'?6639/7:U=3!;00Z[CLTZRZ/,& M?492M(!!>!YX5T&(PC5GC"P$8&:$T#@G@OP/2"\?GGIW.(0QI'31IXY:P3!S"G#"'(6_3")A4@%LCT>0UD U?.66FQ_^)CV M!0I%E&=)_!*+(<6"I<9HU!#=)\Z 1CY_ GO6F&5,ZH'6R^X/Z3WT M68#W6&8/UP_$8_6ERVPG6CU1VGB/XR-ZI/![Q)YPM=+ALJI] M1QEJ+YFJO8RE?.P#STV[(<^K:"?3ZL&LEMASUM5TFZQMYSE8D^%ME.T['^M! ME;5M/3=K>E%'N*68K8=0(=+J/&,$0P?Y],XA_-&KVKJU@8J.(F6/KRIYD0_% MQ'>! S&?9"'G)G#]R(/>37#I^&[D"[#CV0CY$4O==S#D4^,))*)S)$;L%'!; M0=).W&Y*NXYL.TA[TVBQ<,AZ/)-@: );2Y$!&QJM1^VF=<_9-M/?I]&2Z>29 MRO&S:V:9%)64S \XSKZ:#.[]09WG^:9#;4>UG=N7(>,'3\E?^0-97]%DH)&2MK&/EV*A M82?HGA!6 M(P9/OV$/^KHCOUL8G:Q3-NT#6ZCJ9AVSN2'-=;6_SMG4BJ9Z6II3;^'\>N&6 ML.9FA648C:!KZE)9XKY&B%OV]YP$? EAP.:IJ1YNS!X.)+ ?LHC!>YC-P?6Y\=,,,G3GV 59TEF#GT4!THBVGMRG&6?=XL^]$.:_D1T ME-Y@F)PK^2'Y\9\L*S PEQ'A4\#T ;[S"'WQV#^3=H5F?7. ^=8ZC^[L-UZP MK!Q?Q/OPD@W1-8N8X@A2M2&:XD4#,UWIG+@ $P^23P?#]#D.<7,=J'S()VG1 MI[SR%L.3,;](Y6<$+U3^3GR+MS$ERPM#<0">(7J:AP*]01Z3)3%Z#UW(L#_Z M\ Z&]?U0*:7'VI%1UG3LMHZLFX#OR6&R9EBKRA_@@+6Q2?L9]+.PN7JQ8PEQ7K_Y;N,GCE= M=99J)%_A(V46-R9D(VV7D8(?K(O F5!SQZ92=3&WHKFQA-B4++49MG*T MY&]FL+)7[.3<6*;@!"J[48L8RX[:_$"S%LYKCDJQ7*REXM9<>TJ[)NK#=8CR4S$QA9)M4*#+;U MO%OD/"(?A0C6SUID;2U8JTB.36BO4A3;FXY?U114+%+(#>ZD9"81WZ,*(8$T MS.XD5!?+U1*F U2]WVM-L'109T\390!S0WV'4C1#T*L=+HV4F([*VF-H"]=T M/K!$[M ;44E3TTM%6PVEG)G6C:$X@<>(FR3).CD]JMZ;'REZ#K"3M^PHUV-, M*J''U0=+N%(8;1U+HP@^X$+\K>-)):/'U$_FF:HWW#JN\JL7J:7K^G%5(Z?' MV<_F.=-S@'6\9=_*S[]O6^9*UM;LYMH,,N]Z E?-X0%I8].3NFKGEW?0JDRU MKD=EWHFI.]!1:FEZMJ=-2)61UK'Q0%@XBLA:AP]96]-S-FU&J@V5<-(S2\H] M/\<70._*(0'+SO1;?C*)(F#JRIF=ZVJ3I.\*Z@96!*@KKW&T\-X&+%^). MGCL8CF MV2%T^8N[N1/IQ]N=2 ?OH#> 9R&@%7:^+T%_)4E2B'[ MWU/6*ULI,QU#)7252M&M?61=-KS$E)54GS'V1"B%9(5<2*PL4(!K&KT4F%BM6?37E30<)70Z;^<,Z.C=FODZ@ M->)&MK$U@ZUL08$J6=RWAFM+9T#/V47O'[UJK+S *S8Q'21GJJ@PL:6EE M<:%C5'W_M*V.S5EUOG*0+ZX-QIF=]615E]]%ZFIV01U%5G52?3#P:(Q\L]1[LUBRX*A[>*=.BU7C=6M^M_%<31KI?LM#__,ON0V" M]UH;!'Q_(*OU'\X2TU_ J_+<5D%'NR"R#\CD;/N@;1M7!(0F2_8\^&TG#!.; MD//.Z%VLX\OH-@GUG!4X*[&!IXS6VCILR4YOJ?QI2-";3"K99=?Q+/-&9=V[ MR#5R%B2.W>C35'WQ2+)74-'>]('$ MG=E2.\(ZWE@0Y\=AX0C&O]\$Y;O+5 MK.M*FCR'NS&D3)]FW0%-&G]Z(IJR_ M:L1,'U!L@52)6]X"F_E+TYH06I0T_=I;"YS*G?,6:"U^@-D"MY7[X)OU)Q38HM7@UJY"<+ M64[N=_[*.B4_1XC REL*%?N9#718NJ>@H+:XD=G88?;-XRJ<<(T")W!WZ]]2'69O&74A M]"A_$29["FT$']6WC"JD+.W#"OK*-Y'6.L6ZH)P'O4R&8?XSHKJ,5DE;NF6V M+;-J)UG',#>]\ V9>Q:5"7)9!TV^,9/_0:;E!!*$O7*1F+SG=O7BSIW@"=ZS MSGXUFT'5^9RN<9B.)V;\7MZK;YJ8K3S>:+,S57'$MF 0VS>>96T>!SMY=^/' M$:)+3!W_,\'1DDFPO[OB&XT1])()#0X4M8\-V$R?&+"BG]M Q.[!J+V# E:0 MM,7*@75775#$BJ@)@90Y)G]6(G<:\B?^:4C63WQ,(P+97X0D/_V8EVWW\"9Z M"M",_8Q-1^/])^;D"?;Y,=**4YP_%W%G=(!7)>!52ZL62*O5'.#3(F A DJ% M?"OPQ)684ES#01%7TK9=PO6^M2Y'/"Q1'VL#&W7_!%F%'7[FM'#_30[V41%V M\7JC=CPM_[:U'.)QR;-"6AR[ O(#9:V 5GR,6@[\I @\HT%\\+:@HV7TU5^@ MEL-_7X:?JA#HA1*0U=*J 54?GY:#_U $GX@#(0_R"MIV_.NGFN5@2^FN(-/N M6(P>*?P>L<==K:H[0SFS;<1 *FRI7Y=T M969<8L$5'+G(H,5OUK)PS5(D0$4@ PVWC9! M!QB\^';&):L4!<*-W[O,1'H=1ST7-M!ALB;TIGREBJSS6U JOH]+-4+>'E[" M"96<,+FIUAA8?RWJ<4U%H6-MQU>DBE(B,^ZGT7+IBZF4XV"=SD^KGQ4]4=PN*R> MJ.DM3[VO$^.F9EFZEU;Q,1_=KI81L,^(CC[)U%57+)'3PG>9#%R;&79?/NO9GDFH%Q%% :0TD:1E#\D=4YIL-G%,/K^F$%(55.I$:UR7EF"O M#71]5I[N-O/9:W'VVLJ(K^*%!;T15)HIIZL2G0^.^,'98I)/T[[RQ[-.IV2N M-%].C"@4BF+:ERKLF(VB7>.E6+A7FE6:[2K,2O1U-Q[ERTEZG:Z\FEVYL-1] MC)8;EN&/U7G1(G9W?'PALW) 6M?L,>]%6,GY37 MQ*L0( ,"6F>=1[$-J=6!3DHS9>6VI(%> MI-JJU#.Q-/>MV;HT8&35=J:>@:7:K7I[TPR!KPO&>@9)]LISB\YF;*"27/E3\JMU M@^;X@_4)^YBBD-!?K:_(B_AOR*7K86J=D?F3AT/,_I!\^(-U_&KX@*W!0*/= MK]AW"/UR=[5L=Q:&3Q_V][]___[*)\_H.Z'?@EO'J9,D'.4O+P[.#@Z.#AXDU3_S7/];Q_X?QY0@"U&CQ]\> GMSFFR\E]7BK8CJ#=^_?[\?_S4KNE'R MY8%ZV3=>[V=PEBVSOSKALD*^\/%^\L=\45?1= YTX'X(8DD^$QN%<8#U\]1(X>QE/L;(I\? =GEK\_UF_6G[U>6$3.L>.:R./ M]:?Y/B^PS_B,YM@/3WSGP@_=<,')I?,8,!,B;G%&\?3C'J\_R/H2_^S?=.J& MBRIA(P88^^BXC!+%)P[9) MQ&8-__&6>)RBW-V P_X$NVP^=0 M-H'J:4M=K3E\K/6Y&\:S/%O$ST@\I-ADJ3$:-:HVB=,/(H]_@7UKQ%9,>O)( M<;(\E0,MK]L82M[N)A0Q)BS.76E*,OJ-:I+F\E.M7JBL'"#XR-Z M"/!?$?O"Q;,.E[+R':U0C:Q4[:U8RL].^-JT'?)B$^VLM'HPY34:7G4UU28J MV_D:K,EPG<::7H_UH(K*MKXV:VI1IW)+<[8>0D655L\9YSA$KA?<(,H__5RZ M;ZW01$?/_B2 M_#O_(.LKF@Q4:J1M[*.GV-"P%71Q&ZWOU2O/A-6::1U_3HTG01#-$RU^"=8V M=FQ[?.HA^]L@L&>LM2#1]BUE>T3_\9HXV-,=^=W"Z,1.6;4/U&BJ&SMF=4&J MM]6^G;.J%%7;:>E,74/YY95;PEHX%6["J 1=LRV5)(C:F3"BPGDP$N^&S,F" MNS4Q,Q^[?HNGS0^LQ\+N/%+B'T'.QERWF #_DCLU[R=@^1_0VM@9;7R M_T2^8R5-6(4VVD0O=CLJP#UD&)=.(.S??!DGGNOP5=!*ZUM) ]8O7WP4.2[[ MRW]WB%MLZ2D(\;J>$-8OA;9;%DK/@ZD@UY%*KE5[%IE:A18MWF1W=.G[.A6D M.]:2C@N7;_6_T!,)?K56C1?D3*7,Y/2(71#.X[Z/A JGKGC*F:+@(9YWHF#P MB-#3/M^K[&,O#++?Q+N7P<$P=7;\6_KK^R5@IE%\Q?ZYY-1##]B+OWV?%A:5 MW0< ?9)W&%+ 3LNM0U[UJA.:@4_G;]X<$*BT?8R?/C7D@C@<@F6$IL'GS $S\^ M-[ZX.GU-7*U1#H7;W#+.BE1(^%+)+*#/*%%K6,_3S;.,($GQ1HG9W,J7L:)4 M.-$10$;.X<'.LW,_%,C0%$'9MG;;N7!;!F,A922^-DMB[OKY.CWOR0C<*'K? M.'?%@Z>$%_4H(>68FY[L-DTQ/#SG_I;]$5.*G3.I9GFY]6(M#(GFU"H%+-5I M6TH]UU-J6NQ>-%>"5&H>L'3B-[LL3RA&04076K.&H/"]:,Z#0D8);.DT;I:2 M$\>)=8>\6^3&MSM/;HB\,G*4U>Z/X--4+H",L".SA-UQ.[R/G0M$?==_#,J8 M$I>_/X9/D0*YC)MCPX/)MJ-Y%%]?Q==O!8O0E6^3.2X=6+I-W+^!SV U862D MOC%+:M[R58P*$IWTU\O>OS=#4P5[C! RS'-][*X0C*(PCM=GDX*"BO6B\)D0 M(I9NY9K='L?=X"H((K:1C"CW.,;4)4X>_-G[8E&^T8_*DL!X;D-%ZI+;A4;R>2]#1O]@[QA@?596O$R3-R MO3A\G^0NWU++!(\)MN5,5VP(/,UUY-&Y2/MM?TU4!N1;-VYIF[FM"IYH;[0] MT7A#5MQ2E]Z0\E18!3'>2Q'%[(>X)H==K-NJ+Z!65JP"['?KL'-M M6*M&K%4K;0H@S)U5P/M^'6]L-O<:UX\79*E9O$[-. M1JX"[J-UW+D68O?YM3;:!:^1I:N _G@3?=9$##YNQ,JWTB;^TOQ=!>QOUK&G MU:VXOE5LH&6U"_)[%;!N+')K=5H=AK)\7P6$F^O9LIJ5U3.V!"N7XN'&TE:R M%%N_9/]J.\2@0B*PO$2'&ZMBJ41):RW+H\@85H"_L486]AH=@16F$RO W%@4 MDRH=X:N70ZP@P.::J;\7Z4A*8?JQ@A ;"VA2I2L6M'*0%0!OK)FRG4I'(JB2 ME!6 ;RR8A9H=H:V2JJR 7N^<:/V2MF8MF^OCJ_KX*J#Q54$F>X#M5X_D>=_! M;L(0^\Q7]Y_Q(_*2@%Q) !4KM5$(:+B4"*I4]UUJ.0$D#;)A18HE.HYZ M4NB-2!#*U+I56%/+>@49KU19]^T$)$FN_2XB2D[FF/*#PI7_C)-KXC-"GY01 M'&75.H_HD/5?4A&SM-N;]/)D73?$MY,?Y-U>LP&XK-60 M ^:&\!P_L#'-YV0N[R6R\IZIC M'2^1@DI3"C)82?(]?N]L9<@LU[=RV'C9%)W%X"7)!Y\P36[SEM=(_>51?WD$ M]/*H@>0+;"0Y? RXSWB,;3XUL0%U\9(,F$NF$WZ='87I8,ZR2F3#^'0A;D!M MP6SUH[!MGQWH&]IY1XR8/WM?9F8KKVG&7MH%B3K=9E.'X,RL[9$/V< *KX-T M>@>9>\OFUD.^\N)16-90JD/M4;:>(4&$O^G)6&;<2Z,6)^0VHO8,!5@GQV1L M-RNO:2HY8ATB=,61\M(P,>S8QZ8(=GX)SHC_C&GHLET!.ZL377[T&S"5;K$. M316E:OSZOBS191+KF\,VT2:L4ANFLC+6X:RZ8-*5QK#I/4NEFG/1704 WZ)% M'.%2=B]8I153MX55::XKFM3""/',H;T!*[/B-]+\_=#0%*!MV&A03(W=4-=6 M3JVGDPMV274 ;>]WWIL.?R;3H2Q4\W21_XO:$EBE#=B&O>K:@&:GR^,L,\Z( MRIJQQ=70NYPXX,:T[1B";#!K@<4?PNO>S 91,22JN-^WY('51TSI1DQMXQS5 M1TRULPKT$5,_2\14U[;S)B*F6C&0]Q%3!B.FS+I@]A%3?<14I= A:$M7^WQ# MCICJGV[5?KK5K$MU_W0KY)FS?[I5DT'(,'TI M8-[V-!R$M;MT*3F"%%Z:<[M*_LG7[EOJVGBH2YFBB1UCL$P2F.80+L,*;BH# MCYC+Q$H<[)*G*DI8U6]G)ZBM* [,8]B9AX)@-$VW5"-ZYS[.PIN(:VDT77E0 MG2'/P\[I(G-93@LJ3M1;-@R^!S0AGZQ+F'WC3BC9Q0NFMAO@>,):_G$ICF+D MUVIN-^G7DDI&NMEG\8IKU033N>X*S@W$TGR.Z&$T% MGI]+]'F'S]<;2=B+#I\\0W[<)(\D%_N"]AZ@O0

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�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end XML 25 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Consulting and Other Agreements (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended

Apr. 20, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2017

Stock option cash $ 401,440 $ 492,125

Number of common stock issued for fees 1,113,936

Fountainhead [Member] | 2018 Stock Option Plan [Member]

Value of stock options grant 0 216,582

Fountainhead Consulting Agreement [Member] | Fountainhead [Member]

Number of common stock issued for fees, value $ 337,500

Number of common stock issued for fees 1,607,142

Fountainhead Consulting Agreement [Member] | March 2017 and Effective April 1, 2017 [Member]

Payment of fees $ 450,000

Stock option cash $ 5,000

Common stock exercise price $ 0.21

Consulting Agreement [Member] | Fountainhead [Member]

Number of common stock issued for fees, value $ 562,500 $ 225,000

Number of common stock issued for fees 1,669,056

X

- Definition
Value of stock options grant.
+ References
No definition available.
+ Details

Name: VYCO_StockIssuedDuringPeriodValueStockOptionsGranted

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for fees classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_FountainheadMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=VYCO_TwoThousandEighteenStockOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=VYCO_FountainheadConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=VYCO_MarchTwoThousandSeventeenandEffectiveAprilOneTwoThousandSeventeenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=VYCO_ConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 27 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Net loss $ (209,609) $ (152,179) $ (575,211) $ (897,399)

Working capital deficiency (473,129) (473,129)

Related party liabilities 1,223,589 1,223,589

EuroAmerican Investment Corp. [Member]

Term note 300,000 300,000

Accrued interest $ 268,666 $ 268,666

Maturity date Dec. 31, 2019

EuroAmerican Investment Corp. [Member] | Extended Maturity [Member]

Maturity date Nov. 30, 2020

X

- Definition
Working capital deficiency.
+ References
No definition available.
+ Details

Name: VYCO_WorkingCapitalDeficit

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=VYCO_EuroAmericanInvestmentCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LoanRestructuringModificationAxis=us-gaap_ExtendedMaturityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting, Geographical Information (Tables)
9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of Business Segments Information

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment

Three Months Ended September 30, Nine Months Ended September 30,

2019 2018 2019 2018

Revenue:

Vycor Medical $ 301,053 $ 399,450 $ 988,786 $ 930,553

NovaVision $ 45,255 $ 56,763 $ 138,078 $ 152,426

$ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit

Vycor Medical $ 273,146 $ 357,674 $ 895,484 $ 821,240

NovaVision $ 41,635 $ 51,739 $ 124,746 $ 138,609

$ 314,781 $ 409,413 $ 1,020,230 $ 959,849

September 30, 2019 December 31, 2018

Total Assets:

Vycor Medical $ 1,022,449 $ 981,553

NovaVision 63,276 62,224

Total Assets $ 1,085,725 $ 1,043,777

Summary of Geographic Information

The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.

Three Months Ended September 30, Nine Months Ended September 30,

2019 2018 2019 2018

Revenue:

United States $ 320,477 $ 425,800 $ 1,051,237 $ 1,002,923

Europe $ 25,831 $ 30,413 $ 75,627 $ 80,056

$ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit

United States $ 291,536 $ 382,006 $ 953,861 $ 889,190

Europe $ 23,245 $ 27,407 $ 66,369 $ 70,659

$ 314,781 $ 409,413 $ 1,020,230 $ 959,849

September 30, 2019 December 31, 2018

Total Assets:

United States $ 1,051,776 $ 1,010,067

Europe 33,949 33,710

Total Assets $ 1,085,725 $ 1,043,777

X

- Definition
Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Consulting and Other Agreements
9 Months Ended

Sep. 30, 2019

Consulting And Other Agreements

Consulting and Other Agreements

9. CONSULTING AND OTHER AGREEMENTS

The following agreements were entered into or remained in force during the period ended September 30, 2019:

Consulting Agreement with Fountainhead*

In March 2017 and effective April 1, 2017, the Company amended the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees of $450,000 are payable to Fountainhead, with an option to receive $5,000 per month in cash and the remainder payable in Company Common Stock issued at the higher of $0.21 and the average price for the 30 days prior to issuance, and deliverable at the end of each fiscal quarter. The Consulting Agreement also contains provisions for Fountainhead to receive a higher proportion of its fees in cash subject to certain future liquidity events and Board approval. Under the terms of the Amended Agreement, Fountainhead provides the executive management team of the Company, including the positions of CEO, President and CFO, whose employment agreements with the Company stipulate they receive no remuneration from the Company.

During the nine months ended September 30, 2019, under the terms of the Amended Agreement, Fountainhead received total fees of $337,500, which were paid through the issuance of 1,607,142 shares of Company Common Stock. During the nine months ended September 30, 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued as at December 31, 2017.

During the nine months ended September 30, 2019 and 2018, options pursuant to the Vycor Medical, Inc. 2018 Stock Option Plan with a value of $0 and $216,582, respectively, were granted to Fountainhead with performance vesting conditions. The performance conditions of the options granted during 2018 were not met and these options were cancelled.

X

- References
No definition available.
+ Details

Name: VYCO_ConsultingAndOtherAgreementsAbstract

Namespace Prefix: VYCO_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Consulting and other agreements [Text Block]
+ References
No definition available.
+ Details

Name: VYCO_ConsultingAndOtherAgreementsTextBlock

Namespace Prefix: VYCO_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting, Geographical Information
9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Segment Reporting, Geographical Information

5. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

(a) Business segments

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment

Three Months Ended September 30, Nine Months Ended September 30,

2019 2018 2019 2018

Revenue:

Vycor Medical $ 301,053 $ 399,450 $ 988,786 $ 930,553

NovaVision $ 45,255 $ 56,763 $ 138,078 $ 152,426

$ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit

Vycor Medical $ 273,146 $ 357,674 $ 895,484 $ 821,240

NovaVision $ 41,635 $ 51,739 $ 124,746 $ 138,609

$ 314,781 $ 409,413 $ 1,020,230 $ 959,849

September 30, 2019 December 31, 2018

Total Assets:

Vycor Medical $ 1,022,449 $ 981,553

NovaVision 63,276 62,224

Total Assets $ 1,085,725 $ 1,043,777

(b) Geographic information

The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.

Three Months Ended September 30, Nine Months Ended September 30,

2019 2018 2019 2018

Revenue:

United States $ 320,477 $ 425,800 $ 1,051,237 $ 1,002,923

Europe $ 25,831 $ 30,413 $ 75,627 $ 80,056

$ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit

United States $ 291,536 $ 382,006 $ 953,861 $ 889,190

Europe $ 23,245 $ 27,407 $ 66,369 $ 70,659

$ 314,781 $ 409,413 $ 1,020,230 $ 959,849

September 30, 2019 December 31, 2018

Total Assets:

United States $ 1,051,776 $ 1,010,067

Europe 33,949 33,710

Total Assets $ 1,085,725 $ 1,043,777

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

The Company adopted Accounting Standards Codification 842, Leases (“ASC 842”) in the first quarter of 2019. As a result the Company updated its significant accounting policies for leases below. Refer to Note 4 for additional information related to the Company’s lease arrangements and the impact of the adoption of ASC 842 on the Company’s unaudited consolidated financial statements.

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Leases

Leases

The Company has one leased buildings in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.

The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Net Loss Per Share

Net Loss Per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

September 30, September 30,

2019 2018

Stock options outstanding 700,000 1,380,000

Warrants to purchase common stock 3,717,826 3,717,826

Debentures convertible into common stock 2,707,933 2,479,364

Preferred shares convertible into common stock 1,272,052 1,272,052

Directors Deferred Compensation Plan 1,075,908 685,107

Total 9,473,719 9,534,349

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

Leases [Abstract]

Operating Lease Assets Current portion $ 43,586

Operating Lease Assets 43,586

Operating Lease Liabilities Current portion 43,586

Operating Lease Liabilities $ 43,586

X

- Definition
Operating Lease Assets Current portion.
+ References
No definition available.
+ Details

Name: VYCO_OperatingLeaseRightOfUseAssetCurrent

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 34 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Equity (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended

Apr. 20, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2017

Number of common stock issued for fees 1,113,936

Warrants to purchase common stock 3,111,560

Weighted-average remaining contractual life of outstanding warrants 4 months 9 days

Weighted-average remaining contractual life of outstanding options 1 year 8 months 16 days

Fountainhead [Member] | Fountainhead Consulting Agreement [Member]

Number of common stock issued for fees 1,607,142

Number of common stock issued for fees, value $ 337,500

Fountainhead [Member] | Consulting Agreement [Member]

Number of common stock issued for fees 1,669,056

Number of common stock issued for fees, value $ 562,500 $ 225,000

Robert Anderson [Member] | Consultancy [Member]

Number of common stock issued for fees 5,000

Number of common stock issued for fees, value $ 940

Non Employee Directors [Member] | Directors Deferred Compensation Plan [Member]

Shares issued for services 299,997 174,580

Value of shares issued for services $ 63,000 $ 63,000

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_FountainheadMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=VYCO_FountainheadConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=VYCO_ConsultingAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_RobertAndersonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=VYCO_ConsultancyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=VYCO_NonemployeeDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=VYCO_DirectorsDeferredCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Statement [Abstract]

Revenue $ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Cost of Goods Sold 31,527 46,800 106,634 123,130

Gross Profit 314,781 409,413 1,020,230 959,849

Operating expenses:

Depreciation and Amortization 15,115 42,994 45,011 128,326

Selling, general and administrative 491,339 499,143 1,497,016 1,684,445

Total Operating expenses 506,454 542,137 1,542,027 1,812,771

Operating loss (191,673) (132,724) (521,797) (852,922)

Other income (expense)

Interest expense: Other (12,109) (12,280) (36,074) (36,505)

Interest expense: Related Party (5,315) (5,924) (15,331) (6,570)

Loss on foreign currency exchange (512) (1,251) (2,009) (1,402)

Total Other Income (expense) (17,936) (19,455) (53,414) (44,477)

Loss Before Credit for Income Taxes (209,609) (152,179) (575,211) (897,399)

Credit for income taxes

Net Loss (209,609) (152,179) (575,211) (897,399)

Preferred stock dividends (162,185) (162,185) (324,370) (324,370)

Net Loss available to common shareholders (371,794) (314,364) (899,581) (1,221,769)

Comprehensive Loss

Foreign Currency Translation Adjustment 7 810 2 33,515

Comprehensive Loss $ (371,787) $ (313,554) $ (899,579) $ (1,188,254)

Net Loss Per Share

Basic and diluted $ (0.02) $ (0.01) $ (0.04) $ (0.06)

Weighted Average Number of Shares Outstanding - Basic and Diluted 24,222,946 22,221,266 23,689,516 21,258,184

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense incurred on a debt or other obligation to related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 36 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Significant Accounting Policies
2. SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.

Recent Accounting Pronouncements

The Company adopted Accounting Standards Codification 842, Leases (“ASC 842”) in the first quarter of 2019. As a result the Company updated its significant accounting policies for leases below. Refer to Note 4 for additional information related to the Company’s lease arrangements and the impact of the adoption of ASC 842 on the Company’s unaudited consolidated financial statements.

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that, other than as disclosed above, such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Leases

The Company has one leased buildings in Boca Raton, Florida that is classified as operating lease right-of use (“ROU”) assets and operating lease liabilities in the Company’s unaudited consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. Minimum lease payments include only the fixed lease component of the agreement. Operating lease expense is recognized on a straight-line basis over the lease term and is included in cost of Selling, General and Administrative expenses.

The standard was effective for us beginning January 1, 2019. The Company elected the available practical expedients on adoption. The adoption had a material impact on our unaudited consolidated balance sheets, but did not have a material impact on our unaudited consolidated statements of comprehensive loss. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

September 30, September 30,

2019 2018

Stock options outstanding 700,000 1,380,000

Warrants to purchase common stock 3,717,826 3,717,826

Debentures convertible into common stock 2,707,933 2,479,364

Preferred shares convertible into common stock 1,272,052 1,272,052

Directors Deferred Compensation Plan 1,075,908 685,107

Total 9,473,719 9,534,349

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R40.htm IDEA: XBRL DOCUMENT v3.19.3

Share-Based Compensation - Schedule of Assumptions Used in Calculations of Black-Scholes Option Pricing Model (Details) - $ / shares
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Risk-free interest rates 0.00%

Expected life 0 years

Expected dividends 0.00% 0.00%

Expected volatility 0.00%

Vycor Common Stock fair value

Minimum [Member]

Risk-free interest rates 1.72%

Expected life 1 year 6 months

Expected volatility 102.00%

Vycor Common Stock fair value $ 0.20

Maximum [Member]

Risk-free interest rates 2.41%

Expected life 4 years

Expected volatility 107.00%

Vycor Common Stock fair value $ 0.49

X

- Definition
Common stock fair value of company.
+ References
No definition available.
+ Details

Name: VYCO_CommonStockFairValueOfCompany

Namespace Prefix: VYCO_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R44.htm IDEA: XBRL DOCUMENT v3.19.3

Concentration (Details Narrative) - Purchase [Member]
9 Months Ended

Sep. 30, 2019

Manufacturer One [Member]

Concentration risk, percentage 10.00%

Manufacturer Two [Member]

Concentration risk, percentage 10.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_MajorCustomersAxis=VYCO_ManufacturerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=VYCO_PurchaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=VYCO_ManufacturerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.19.3

Notes Payable (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2019

Jan. 31, 2018

EuroAmerican Investment Corp. [Member]

Note extended maturity date description Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019.

Debt maturity date extended Dec. 31, 2019

Debt conversion shares issued 2,707,933

Offering exercisable term 3 years

EuroAmerican Investment Corp. [Member]

Note payable other $ 300,000

Conversion price $ 0.21

EuroAmerican Investment Corp. [Member] | Stock Warrants [Member]

Warrant to purchase common stock 2,308,405

Warrant exercise price $ 0.27

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term notes payable classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_OtherNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=VYCO_EuroAmericanInvestmentCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_EuroAmericanInvestmentCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Share-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of Assumptions Used in Calculations of Black-Scholes Option Pricing Model

The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2019 and 2018:

Nine Months Ended September 30,

2019 2018

Risk-free interest rates - % 1.72-2.41 %

Expected life - 1.5-4.0 years

Expected dividends - % 0 %

Expected volatility - % 102-107 %

Vycor Common Stock fair value $ - $ 0.20-0.49

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Notes Payable (Tables)
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Summary of Notes Payable

Related Party Notes Payable consists of:

September 30, 2019 December 31, 2018

On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $30,000. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. The note was extended for another twelve months on its due date to June 25, 2020 or on demand by the Payee $ 30,000 $ 30,000

In March 2019 and between March 2018 and July 2018 the Company issued various promissory notes to Fountainhead Capital Management Limited for $180,873. The notes bear interest at 10% per annum and are payable on the earlier of one year or five days following the delivery of written demand for payment by the Payee. Five notes were extended for another twelve months on their due dates which will be due between March and July 2020 or on demand by the Payee. 180,873 163,000

Total Related Party Notes Payable $ 210,873 $ 193,000

Other Notes Payable

Other Notes Payable consists of:

September 30, 2019 December 31, 2018

On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011, and has been extended on a number of occasions. On March 19, 2019, the note was extended to December 31, 2019. See further note below. $ 300,000 $ 300,000

Insurance policy finance agreements. 51,058 25,814

Total Notes Payable: $ 351,058 $ 325,814

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Notes Payable - Summary of Notes Payable (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Total Related Party Notes Payable $ 210,873 $ 193,000

Total Other Notes Payable 351,058 325,814

Peter Zachariou [Member]

Total Related Party Notes Payable 30,000 30,000

Fountainhead Capital Management Limited [Member]

Total Related Party Notes Payable 180,873 163,000

Insurance Policy Finance Agreements [Member]

Total Other Notes Payable 51,058 25,814

EuroAmerican Investment Corp. [Member]

Total Other Notes Payable $ 300,000 $ 300,000

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=VYCO_PeterZachariouMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=VYCO_FountainheadCapitalManagementLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=VYCO_InsurancePolicyFinanceAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=VYCO_EuroAmericanInvestmentCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R34.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting, Geographical Information - Schedule of Business Segments Information (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Revenue $ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit 314,781 409,413 1,020,230 959,849

Total Assets 1,085,725 1,085,725 $ 1,043,777

Vycor Medical [Member]

Revenue 301,053 399,450 988,786 930,553

Gross Profit 273,146 357,674 895,484 821,240

Total Assets 1,022,449 1,022,449 981,553

NovaVision [Member]

Revenue 45,255 56,763 138,078 152,426

Gross Profit 41,635 $ 51,739 124,746 $ 138,609

Total Assets $ 63,276 $ 63,276 $ 62,224

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=VYCO_VycorMedicalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=VYCO_NovaVisionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 R38.htm IDEA: XBRL DOCUMENT v3.19.3

Equity - Schedule of Stock Options (Details)
9 Months Ended

Sep. 30, 2019

$ / shares

shares

Equity [Abstract]

Number of shares Options Outstanding, Beginning Balance | shares 1,380,000

Number of shares Options, Granted | shares

Number of shares Options, Exercised | shares

Number of shares Options, Cancelled or expired | shares (680,000)

Number of shares Options Outstanding, Ending Balance | shares 700,000

Weighted average exercise price per share Options, Outstanding, Beginning Balance | $ / shares $ 0.53

Weighted average exercise price per share Options, Granted | $ / shares

Weighted average exercise price per share Options, Exercised | $ / shares

Weighted average exercise price per share Options, Cancelled or expired | $ / shares (0.79)

Weighted average exercise price per share Options, Outstanding, Ending balance | $ / shares $ 0.28

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 46 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Concentration
9 Months Ended

Sep. 30, 2019

Risks and Uncertainties [Abstract]

Concentration
11. CONCENTRATION

Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals.

Sales Concentration

Three months ended Nine months ended

September 30, September 30,

2019 2018 2019 2018

Number of customers over 10% 1 1 1 3

Percentage of sales 11 % 25 % 10 % 10%, 11 % and 11 %

Accounts Receivable Concentration

At September 30, At December 31,

2019 2018

Number of customers over 10% 1 2

Percentage of accounts receivable 48 % 13% and 40 %

We have two sub-contract manufacturers who both represent over 10% of purchased on an annual basis.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Share-Based Compensation
9 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

7. SHARE-BASED COMPENSATION

Stock Option Plan

Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option-vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.

For the nine months ended September 30, 2019 and 2018, the Company recognized share-based compensation of $0 and $4,871 respectively, for employee stock options.

Stock appreciation rights may be granted either on a stand-alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2019 there were no awards of any stock appreciation rights.

Non-Employee Stock Compensation

The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

Aggregate stock-based compensation for stock and warrants granted to non-employees for the nine months ended September 30, 2019 and 2018 was $401,440 and $487,254. The expense related to stock not issued during the periods ended September 30, 2019 and 2018 comprise: $63,000, respectively for both periods, related to stock granted but not issued to directors under the Directors Deferred Compensation Plan. As of September 30, 2019, there was $0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

During the nine months ended September 30, 2019 and 2018, options with a value of $0 and $216,582, respectively, were granted to Fountainhead with performance vesting conditions, (see Note 9). The performance conditions of the options granted during 2018 were not met and these options were cancelled.

Stock-based Compensation Valuation Methodology

Stock-based compensation resulting from the issuance of Common Stock is calculated by reference to the valuation of the Stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the expected life of the option or warrant, and the risk-free rate is based on the U.S. Treasury Constant Maturity rate.

The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2019 and 2018:

Nine Months Ended September 30,

2019 2018

Risk-free interest rates - % 1.72-2.41 %

Expected life - 1.5-4.0 years

Expected dividends - % 0 %

Expected volatility - % 102-107 %

Vycor Common Stock fair value $ - $ 0.20-0.49

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R2.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Balance Sheets (Unaudited) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Current Assets

Cash $ 98,502 $ 86,481

Accounts receivable 214,807 257,468

Inventory 226,618 203,122

Prepaid expenses and other current assets 116,046 82,575

Total Current Assets 655,973 629,646

Fixed assets, net 353,746 372,641

Intangible and Other assets:

Patents, net of accumulated amortization 26,320 35,303

Website, net of accumulated amortization 187

Other Assets - Long Term 6,100 6,000

Operating lease right-of-use assets 43,586

Total Intangible and Other assets 76,006 41,490

TOTAL ASSETS 1,085,725 1,043,777

Current Liabilities

Accounts payable 198,219 92,955

Accrued interest: Other 268,666 232,765

Accrued interest: Related party 39,606 24,274

Accrued liabilities - Other 267,573 295,056

Accrued liabilities - Related Party 973,110 648,740

Notes payable: Other 351,058 325,814

Notes payable: Related Party 210,873 193,000

Current operating lease 43,586

Total Current Liabilities 2,352,691 1,812,604

STOCKHOLDERS' DEFICIENCY

Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2019 and December 31, 2018 respectively 27 27

Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2019 and December 31, 2018, 24,856,170 and 23,244,028 shares issued and 24,752,836 and 23,140,694 outstanding at September 30, 2019 and December 31, 2018 respectively 2,486 2,324

Additional Paid-in Capital 28,173,146 27,771,868

Treasury Stock (103,334 shares of Common Stock as at September 30, 2019 and December 31, 2018 respectively, at cost) (1,033) (1,033)

Accumulated Deficit (29,569,267) (28,669,686)

Accumulated Other Comprehensive Income (Loss) 127,675 127,673

Total Stockholders' Deficiency (1,266,966) (768,827)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY $ 1,085,725 $ 1,043,777

X

- Definition
Accrued interest other
+ References
No definition available.
+ Details

Name: VYCO_AccruedInterestOther

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued interest related party.
+ References
No definition available.
+ Details

Name: VYCO_AccruedInterestRelatedParty

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For an unclassified balance sheet, the accumulated amortization, as of the reporting date, representing the periodic patents.
+ References
No definition available.
+ Details

Name: VYCO_AccumulatedAmortizationNetPatent

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an unclassified balance sheet, the accumulated amortization, as of the reporting date, representing the periodic website.
+ References
No definition available.
+ Details

Name: VYCO_AccumulatedAmortizationNetWebsite

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all intangible asset and other assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: VYCO_IntangibleAndOtherAssetTotal

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: VYCO_IntangibleAndOtherAssetsAbstract

Namespace Prefix: VYCO_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 49 R6.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statement of Cash Flows (Unaudited) - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Cash flows from operating activities:

Net loss $ (575,211) $ (897,399)

Adjustments to reconcile net loss to cash provided by (used in) operating activities:

Amortization of intangible assets 8,983 37,748

Depreciation of fixed assets 43,376 98,455

Inventory provision 9,418 3,139

Stock based compensation 401,440 492,125

Changes in assets and liabilities:

Accounts receivable 42,661 (134,732)

Inventory (32,914) (7,565)

Prepaid expenses 58,714 (21,913)

Security Deposits 3,169

Accrued interest - Related Party 15,332 6,570

Accrued interest Other 35,901 35,901

Accounts payable 105,205 (45,575)

Accrued liabilities Other (27,483) 143,945

Cash provided by /(used in) operating activities 85,422 (286,132)

Cash flows from investing activities:

Purchase of fixed assets (25,057) (56,604)

Cash used in investing activities (25,057) (56,604)

Cash flows from financing activities:

Proceeds from Notes Payable - Related Party 17,873 193,000

Proceeds from and (repayments of) Notes Payable - Other (66,941) 28,473

Cash provided by/(used in) financing activities (49,068) 221,473

Effect of exchange rate changes on cash 724 5,180

Net increase (decrease) in cash 12,021 (116,083)

Cash at beginning of period 86,481 206,213

Cash at end of period 98,502 90,130

Supplemental Disclosures of Cash Flow Information:

Cash paid for interest 0 0

Cash paid for income tax 0 0

Non-Cash Transactions:

Common stock issued to related party for payment of accrued liabilities $ 0 $ 225,000

X

- Definition
Increase decrease accrued interest other.
+ References
No definition available.
+ Details

Name: VYCO_IncreaseDecreaseAccruedInterestOther

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in security deposits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInSecurityDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586
+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Share-Based Compensation (Details Narrative) - USD ($)
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Non-employee [Member]

Share-based compensation $ 401,440 $ 487,254

Total unrecognized compensation costs 0

Directors [Member] | Directors Deferred Compensation Plan [Member]

Stock granted but not issued 63,000 63,000

Fountainhead [Member] | 2018 Stock Option Plan [Member]

Value of stock options grant 0 216,582

Employee Stock Options [Member]

Share-based compensation $ 0 $ 4,871

X

- Definition
Stock granted but not issued.
+ References
No definition available.
+ Details

Name: VYCO_StockGrantedButNotIssued

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of stock options grant.
+ References
No definition available.
+ Details

Name: VYCO_StockIssuedDuringPeriodValueStockOptionsGranted

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_NonemployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_DirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=VYCO_DirectorsDeferredCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=VYCO_FountainheadMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=VYCO_TwoThousandEighteenStockOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=VYCO_EmployeeStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)
1 Months Ended 5 Months Ended 9 Months Ended

Mar. 19, 2019

Jun. 25, 2018

Mar. 25, 2011

Mar. 31, 2019

Jul. 31, 2018

Sep. 30, 2019

EuroAmerican Investment Corp. [Member]

Notes interest rate 16.00%

Debt due date description Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019.

EuroAmerican Investment Corp. [Member] | Extended Maturity [Member]

Debt due date Dec. 31, 2019

Term Note [Member] | EuroAmerican Investment Corp. [Member]

Value of notes issued $ 300,000

Peter Zachariou [Member]

Value of notes issued $ 30,000

Notes interest rate 10.00%

Debt due date Jun. 25, 2020

Fountainhead Capital Management Limited [Member]

Value of notes issued $ 180,873 $ 180,873

Notes interest rate 10.00% 10.00%

Debt due date description Five notes were extended for another twelve months on their due dates which will be due between March and July 2020

X

- Definition
Date the original debt was scheduled to mature, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value of notes issued in noncash investing and financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=VYCO_EuroAmericanInvestmentCorpMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LoanRestructuringModificationAxis=us-gaap_ExtendedMaturityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=VYCO_TermNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=VYCO_PeterZachariouMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=VYCO_FountainheadCapitalManagementLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Segment Reporting, Geographical Information - Summary of Geographic Information (Details) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Revenue $ 346,308 $ 456,213 $ 1,126,864 $ 1,082,979

Gross Profit 314,781 409,413 1,020,230 959,849

Total Assets 1,085,725 1,085,725 $ 1,043,777

United States [Member]

Revenue 320,477 425,800 1,051,237 1,002,923

Gross Profit 291,536 382,006 953,861 889,190

Total Assets 1,051,776 1,051,776 1,010,067

Europe [Member]

Revenue 25,831 30,413 75,627 80,056

Gross Profit 23,245 $ 27,407 66,369 $ 70,659

Total Assets $ 33,949 $ 33,949 $ 33,710

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=srt_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions
9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Related Party Transactions

10. RELATED PARTY TRANSACTIONS

Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at September 30, 2019, 56% of the Company’s Common Stock and 70% of the Company’s Preferred D Stock. Adrian Liddell, Chairman, is a consultant for Fountainhead.

During the nine months ended September 30, 2019, under the terms of the Consulting Agreement referred to in note 9, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500. During the nine months ended September 30, 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued as at December 31, 2017.

During the nine months ended September 30, 2019 and 2018, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,037 was in respect of Fountainhead and $83,386 was in respect of Peter Zachariou.

During the nine months ended September 30, 2019 and 2018 the Company issued unsecured loan notes to Fountainhead for a total of $17,873 and $133,000, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary. During the nine months ended September 30, 2019 and 2018 the Company issued unsecured loan notes to Peter Zachariou for a total of $0 and $30,000, respectively. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary. (See Note 3)

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Equity
9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Equity

6. EQUITY

Common Stock and Stock Grants

During January to September 2019 and 2018, the Company granted 299,997 and 174,580 shares, respectively, of Common Stock (valued at $63,000 during each period) to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15^th following the termination of their services as a director. As of September 30, 2019 these shares have yet to be issued.

During January to September 2019, under the terms of the Consulting Agreement referred to in note 9, the Company issued 1,607,142 shares of Common Stock to Fountainhead for fees of $337,500. During January to September 2018, under the terms of the Consulting Agreement, the Company issued 1,669,056 shares of Common Stock to Fountainhead for fees of $562,500 of which $225,000 had been accrued at December 31, 2017.

During the period ended September 30, 2019 the Company issued 5,000 shares of Common Stock to Robert Anderson for fees of $940 for consultancy.

On April 20, 2018, the Company issued an aggregate of 1,113,936 shares of Company Common Stock on the cashless exercise of an aggregate of Warrants to purchase 3,111,560 shares of Common Stock.

Warrants and Options

The details of the outstanding warrants and options are as follows:

STOCK WARRANTS:

Weighted

average

Number of

shares
exercise price
per share

Outstanding at December 31, 2018 3,717,826 $ 0.27

Granted - -

Exercised - -

Cancelled or expired - -

Outstanding at September 30, 2019 3,717,826 $ 0.27

STOCK OPTIONS:

Weighted

average

Number of

shares
exercise price
per share

Outstanding at December 31, 2018 1,380,000 $ 0.53

Granted - -

Exercised - -

Cancelled or expired (680,000 ) (0.79 )

Outstanding at September 30, 2019 700,000 $ 0.28

As of September 30, 2019, the weighted-average remaining contractual life of outstanding warrants and options is 0.36 and 1.71 years, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R3.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares

Sep. 30, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 270,307 270,307

Preferred stock, shares outstanding 270,307 270,307

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 55,000,000 55,000,000

Common stock, shares issued 24,856,170 23,244,028

Common stock, shares outstanding 24,752,836 23,140,694

Treasury stock, shares 103,334 103,334

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 56 R7.htm IDEA: XBRL DOCUMENT v3.19.3

Basis of Presentation
9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2018 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

The unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2019 and 2018, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2019 and 2018 are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Ability to continue as a Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $575,211 for the nine months ended September 30, 2019 and has not generated sufficient positive cash flows from operations. As of September 30, 2019 the Company had a working capital deficiency of $473,129, excluding related party liabilities of $1,223,589. As a result these conditions, among others, raise substantial doubt regarding our ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

The Company is executing on a plan to achieve revenue growth and a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”), together with accrued interest of $268,666, which has a maturity date of December 31, 2019, having been extended on a number of occasions from its initial due date of June 11, 2011. The Company will seek an extension to the note, although it is not known whether the note will be extended or the terms of any extension. However, the Company believes it may not have sufficient cash to meet its various cash needs through November 30, 2020 unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Fountainhead, the Company’s largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case. The Company may consider seeking additional equity or debt funding, although there is no assurance that this would be available on acceptable terms or at all. If adequate funds are not available, the Company may have to delay or curtail development or commercialization of products, or cease some of its operations.

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies (Details Narrative)
9 Months Ended

Sep. 30, 2012

EUR (€)

Sep. 30, 2019

USD ($)

Sep. 30, 2018

USD ($)

Rent expense | $ $ 5,700

Lease termination date Sep. 30, 2020

Trade tax | € € 630,000

Trade tax reduced | € 75,000

Interest expenses | € € 12,000

Germany [Member]

Rent expense | $ $ 73,925 $ 74,784

Germany [Member] | Short-Term Lease Agreement [Member]

Rent expense | $ $ 2,200

X

- Definition
Sales and excise tax payable reduction current and noncurrent.
+ References
No definition available.
+ Details

Name: VYCO_SalesAndExciseTaxPayableReductionCurrentAndNoncurrent

Namespace Prefix: VYCO_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=country_DE

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=VYCO_ShortTermLeaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R45.htm IDEA: XBRL DOCUMENT v3.19.3

Concentration - Schedule of Concentration (Details) - Number
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Sales Revenue [Member]

Number of customers over 10% 1 1 1 3

Sales Revenue [Member] | Customer One [Member]

Concentration risk, percentage 11.00% 25.00% 10.00% 10.00%

Sales Revenue [Member] | Customer Two [Member]

Concentration risk, percentage 11.00%

Sales Revenue [Member] | Customer Three [Member]

Concentration risk, percentage 11.00%

Accounts Receivable [Member]

Number of customers over 10% 1 2

Accounts Receivable [Member] | Customer One [Member]

Concentration risk, percentage 48.00% 13.00%

Accounts Receivable [Member] | Customer Two [Member]

Concentration risk, percentage 40.00%

X

- Definition
Number of customers.
+ References
No definition available.
+ Details

Name: VYCO_NumberOfCustomers

Namespace Prefix: VYCO_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=VYCO_CustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=VYCO_CustomerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_MajorCustomersAxis=VYCO_CustomerThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Equity (Tables)
9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Schedule of Stock Warrants

STOCK WARRANTS:

Weighted

average

Number of

shares
exercise price
per share

Outstanding at December 31, 2018 3,717,826 $ 0.27

Granted - -

Exercised - -

Cancelled or expired - -

Outstanding at September 30, 2019 3,717,826 $ 0.27

Schedule of Stock Options

STOCK OPTIONS:

Weighted

average

Number of

shares
exercise price
per share

Outstanding at December 31, 2018 1,380,000 $ 0.53

Granted - -

Exercised - -

Cancelled or expired (680,000 ) (0.79 )

Outstanding at September 30, 2019 700,000 $ 0.28

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Schedule of Common Stock Not Included in Calculation of Diluted Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

September 30, September 30,

2019 2018

Stock options outstanding 700,000 1,380,000

Warrants to purchase common stock 3,717,826 3,717,826

Debentures convertible into common stock 2,707,933 2,479,364

Preferred shares convertible into common stock 1,272,052 1,272,052

Directors Deferred Compensation Plan 1,075,908 685,107

Total 9,473,719 9,534,349

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Details) - shares
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Potential shares of common stock that are not included in the calculation of diluted net loss per share 9,473,719 9,534,349

Stock Options Outstanding [Member]

Potential shares of common stock that are not included in the calculation of diluted net loss per share 700,000 1,380,000

Warrants to Purchase Common Stock [Member]

Potential shares of common stock that are not included in the calculation of diluted net loss per share 3,717,826 3,717,826

Debentures Convertible into Common Stock [Member]

Potential shares of common stock that are not included in the calculation of diluted net loss per share 2,707,933 2,479,364

Preferred Shares Convertible into Common Stock [Member]

Potential shares of common stock that are not included in the calculation of diluted net loss per share 1,272,052 1,272,052

Directors Deferred Compensation Plan [Member]

Potential shares of common stock that are not included in the calculation of diluted net loss per share 1,075,908 685,107

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=VYCO_StockOptionPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=VYCO_WarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=VYCO_DebenturesConvertibleIntoCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=VYCO_PreferredSharesConvertibleToCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Equity - Schedule of Stock Warrants (Details)	9 Months Ended
Equity - Schedule of Stock Warrants (Details)	Sep. 30, 2019 $ / shares shares
Equity [Abstract]
Number of shares Warrants Outstanding, Beginning Balance \| shares	3,717,826
Number of shares Warrants, Granted \| shares
Number of shares Warrants, Exercised \| shares
Number of shares Warrants, Cancelled or expired \| shares
Number of shares Warrants Outstanding, Ending Balance \| shares	3,717,826
Weighted average exercise price per share Warrants, Outstanding, Beginning Balance \| $ / shares	$ 0.27
Weighted average exercise price per share Warrants, Granted \| $ / shares
Weighted average exercise price per share Warrants, Exercised \| $ / shares
Weighted average exercise price per share Warrants, Cancelled or expired \| $ / shares
Weighted average exercise price per share Warrants, Outstanding, Ending balance \| $ / shares	$ 0.27

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Basis of Presentation (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss	$ (209,609)	$ (152,179)	$ (575,211)	$ (897,399)
Working capital deficiency	(473,129)		(473,129)
Related party liabilities	1,223,589		1,223,589
EuroAmerican Investment Corp. [Member]
Term note	300,000		300,000
Accrued interest	$ 268,666		$ 268,666
Maturity date			Dec. 31, 2019
EuroAmerican Investment Corp. [Member] \| Extended Maturity [Member]
Maturity date			Nov. 30, 2020

Lease - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
Leases [Abstract]
Operating Lease Assets Current portion	$ 43,586
Operating Lease Assets	43,586
Operating Lease Liabilities Current portion	43,586
Operating Lease Liabilities	$ 43,586

Equity (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
Equity (Details Narrative) - USD ($)	Apr. 20, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017
Number of common stock issued for fees	1,113,936
Warrants to purchase common stock	3,111,560
Weighted-average remaining contractual life of outstanding warrants		4 months 9 days
Weighted-average remaining contractual life of outstanding options		1 year 8 months 16 days
Fountainhead [Member] \| Fountainhead Consulting Agreement [Member]
Number of common stock issued for fees		1,607,142
Number of common stock issued for fees, value		$ 337,500
Fountainhead [Member] \| Consulting Agreement [Member]
Number of common stock issued for fees			1,669,056
Number of common stock issued for fees, value			$ 562,500	$ 225,000
Robert Anderson [Member] \| Consultancy [Member]
Number of common stock issued for fees		5,000
Number of common stock issued for fees, value		$ 940
Non Employee Directors [Member] \| Directors Deferred Compensation Plan [Member]
Shares issued for services		299,997	174,580
Value of shares issued for services		$ 63,000	$ 63,000

Concentration (Details Narrative) - Purchase [Member]	9 Months Ended
Concentration (Details Narrative) - Purchase [Member]	Sep. 30, 2019
Manufacturer One [Member]
Concentration risk, percentage	10.00%
Manufacturer Two [Member]
Concentration risk, percentage	10.00%

Notes Payable (Details Narrative) - USD ($)	9 Months Ended
Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2019	Jan. 31, 2018
EuroAmerican Investment Corp. [Member]
Note extended maturity date description	Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019.
Debt maturity date extended	Dec. 31, 2019
Debt conversion shares issued	2,707,933
Offering exercisable term	3 years
EuroAmerican Investment Corp. [Member]
Note payable other		$ 300,000
Conversion price		$ 0.21
EuroAmerican Investment Corp. [Member] \| Stock Warrants [Member]
Warrant to purchase common stock		2,308,405
Warrant exercise price		$ 0.27

Notes Payable - Summary of Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total Related Party Notes Payable	$ 210,873	$ 193,000
Total Other Notes Payable	351,058	325,814
Peter Zachariou [Member]
Total Related Party Notes Payable	30,000	30,000
Fountainhead Capital Management Limited [Member]
Total Related Party Notes Payable	180,873	163,000
Insurance Policy Finance Agreements [Member]
Total Other Notes Payable	51,058	25,814
EuroAmerican Investment Corp. [Member]
Total Other Notes Payable	$ 300,000	$ 300,000

Equity - Schedule of Stock Options (Details)	9 Months Ended
Equity - Schedule of Stock Options (Details)	Sep. 30, 2019 $ / shares shares
Equity [Abstract]
Number of shares Options Outstanding, Beginning Balance \| shares	1,380,000
Number of shares Options, Granted \| shares
Number of shares Options, Exercised \| shares
Number of shares Options, Cancelled or expired \| shares	(680,000)
Number of shares Options Outstanding, Ending Balance \| shares	700,000
Weighted average exercise price per share Options, Outstanding, Beginning Balance \| $ / shares	$ 0.53
Weighted average exercise price per share Options, Granted \| $ / shares
Weighted average exercise price per share Options, Exercised \| $ / shares
Weighted average exercise price per share Options, Cancelled or expired \| $ / shares	(0.79)
Weighted average exercise price per share Options, Outstanding, Ending balance \| $ / shares	$ 0.28

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 98,502	$ 86,481
Accounts receivable	214,807	257,468
Inventory	226,618	203,122
Prepaid expenses and other current assets	116,046	82,575
Total Current Assets	655,973	629,646
Fixed assets, net	353,746	372,641
Intangible and Other assets:
Patents, net of accumulated amortization	26,320	35,303
Website, net of accumulated amortization		187
Other Assets - Long Term	6,100	6,000
Operating lease right-of-use assets	43,586
Total Intangible and Other assets	76,006	41,490
TOTAL ASSETS	1,085,725	1,043,777
Current Liabilities
Accounts payable	198,219	92,955
Accrued interest: Other	268,666	232,765
Accrued interest: Related party	39,606	24,274
Accrued liabilities - Other	267,573	295,056
Accrued liabilities - Related Party	973,110	648,740
Notes payable: Other	351,058	325,814
Notes payable: Related Party	210,873	193,000
Current operating lease	43,586
Total Current Liabilities	2,352,691	1,812,604
STOCKHOLDERS' DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at September 30, 2019 and December 31, 2018 respectively	27	27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at September 30, 2019 and December 31, 2018, 24,856,170 and 23,244,028 shares issued and 24,752,836 and 23,140,694 outstanding at September 30, 2019 and December 31, 2018 respectively	2,486	2,324
Additional Paid-in Capital	28,173,146	27,771,868
Treasury Stock (103,334 shares of Common Stock as at September 30, 2019 and December 31, 2018 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(29,569,267)	(28,669,686)
Accumulated Other Comprehensive Income (Loss)	127,675	127,673
Total Stockholders' Deficiency	(1,266,966)	(768,827)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$ 1,085,725	$ 1,043,777

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (575,211)	$ (897,399)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Amortization of intangible assets	8,983	37,748
Depreciation of fixed assets	43,376	98,455
Inventory provision	9,418	3,139
Stock based compensation	401,440	492,125
Changes in assets and liabilities:
Accounts receivable	42,661	(134,732)
Inventory	(32,914)	(7,565)
Prepaid expenses	58,714	(21,913)
Security Deposits		3,169
Accrued interest - Related Party	15,332	6,570
Accrued interest Other	35,901	35,901
Accounts payable	105,205	(45,575)
Accrued liabilities Other	(27,483)	143,945
Cash provided by /(used in) operating activities	85,422	(286,132)
Cash flows from investing activities:
Purchase of fixed assets	(25,057)	(56,604)
Cash used in investing activities	(25,057)	(56,604)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party	17,873	193,000
Proceeds from and (repayments of) Notes Payable - Other	(66,941)	28,473
Cash provided by/(used in) financing activities	(49,068)	221,473
Effect of exchange rate changes on cash	724	5,180
Net increase (decrease) in cash	12,021	(116,083)
Cash at beginning of period	86,481	206,213
Cash at end of period	98,502	90,130
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	0	0
Cash paid for income tax	0	0
Non-Cash Transactions:
Common stock issued to related party for payment of accrued liabilities	$ 0	$ 225,000

Share-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
Share-Based Compensation (Details Narrative) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Non-employee [Member]
Share-based compensation	$ 401,440	$ 487,254
Total unrecognized compensation costs	0
Directors [Member] \| Directors Deferred Compensation Plan [Member]
Stock granted but not issued	63,000	63,000
Fountainhead [Member] \| 2018 Stock Option Plan [Member]
Value of stock options grant	0	216,582
Employee Stock Options [Member]
Share-based compensation	$ 0	$ 4,871

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)				1 Months Ended	5 Months Ended	9 Months Ended
	Mar. 19, 2019	Jun. 25, 2018	Mar. 25, 2011	Mar. 31, 2019	Jul. 31, 2018	Sep. 30, 2019
EuroAmerican Investment Corp. [Member]
Notes interest rate			16.00%
Debt due date description						Under the Amendment, the Note was extended until December 31, 2018 and was further extended until December 31, 2019.
EuroAmerican Investment Corp. [Member] \| Extended Maturity [Member]
Debt due date	Dec. 31, 2019
Term Note [Member] \| EuroAmerican Investment Corp. [Member]
Value of notes issued			$ 300,000
Peter Zachariou [Member]
Value of notes issued		$ 30,000
Notes interest rate		10.00%
Debt due date		Jun. 25, 2020
Fountainhead Capital Management Limited [Member]
Value of notes issued				$ 180,873	$ 180,873
Notes interest rate				10.00%	10.00%
Debt due date description					Five notes were extended for another twelve months on their due dates which will be due between March and July 2020

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	270,307	270,307
Preferred stock, shares outstanding	270,307	270,307
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	55,000,000	55,000,000
Common stock, shares issued	24,856,170	23,244,028
Common stock, shares outstanding	24,752,836	23,140,694
Treasury stock, shares	103,334	103,334

Commitments and Contingencies (Details Narrative)		9 Months Ended
Commitments and Contingencies (Details Narrative)	Sep. 30, 2012 EUR (€)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)
Rent expense \| $		$ 5,700
Lease termination date		Sep. 30, 2020
Trade tax \| €	€ 630,000
Trade tax reduced \| €	75,000
Interest expenses \| €	€ 12,000
Germany [Member]
Rent expense \| $		$ 73,925	$ 74,784
Germany [Member] \| Short-Term Lease Agreement [Member]
Rent expense \| $		$ 2,200

Significant Accounting Policies - Schedule of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Potential shares of common stock that are not included in the calculation of diluted net loss per share	9,473,719	9,534,349
Stock Options Outstanding [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	700,000	1,380,000
Warrants to Purchase Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	3,717,826	3,717,826
Debentures Convertible into Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	2,707,933	2,479,364
Preferred Shares Convertible into Common Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,272,052	1,272,052
Directors Deferred Compensation Plan [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,075,908	685,107